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Although South Africa has the largest antiretroviral therapy (ART) program 
worldwide, data on key outcomes like mortality and loss to follow-up (LTF) are 
limited. A few cohorts have published patient outcomes but there is no national 
reporting on ART scale-up and its impact on the health of HIV-infected individuals. 
Yet such monitoring of outcomes is vital to inform and improve service delivery. 
The International epidemiologic Databases to Evaluate AIDS Southern Africa 
collaboration (IeDEA-SA) was established in 2005 to collect and analyze individual-
level data from the larger cohorts of individuals on ART in Southern Africa. Using 
routine, anonymized data from the South African sites, this thesis aims to describe 
how the program has evolved over 10 years and to assess its effectiveness. 
 
Five quantitative analyses were performed using descriptive statistics and survival 
analysis methods. The studies used patient-level data on adult patients starting ART 
to describe characteristics and to explore outcomes and temporal changes in 
outcomes over time. Patient numbers ranged from 19,481 (limited to cohorts with 
civil identification numbers) to 83,576 adults, followed for up to 214,400 person-
years. The results are presented as four published papers and one submitted for 
publication.  
 
The thesis describes a rapid, massive scale-up of services. Despite improvements in 
baseline immunologic status, late diagnosis and ART initiation especially in men are 
a challenge. Over five years, 12-month mortality drops and 12-month LTF increases, 
suggesting that LTF is a greater challenge to program effectiveness than mortality. 
Excluding early deaths after TFO/LTF, mortality risk compared with retained 
patients is similar among TFOs and higher among LTF. Censoring TFOs did not bias 
mortality estimates due to the lower incidence of TFO and subsequent death 
compared with LTF. Mortality increases with age at ART initiation, but the effect of 
age is modified by baseline immunologic status. The proportions of patients ≥50 
years old enrolling and remaining in care each year increases. Men have higher 
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mortality on ART than women and this is only partly explained by more advanced 
HIV disease at ART initiation, differential LTF and subsequent mortality, and 
differences in responses to treatment. Observed gender differences in mortality on 
ART may be best explained by background differences in mortality between men 
and women unrelated to HIV/AIDS or ART.   
 
The thesis concludes that the major challenges to program effectiveness are 
programmatic and not clinical. They include the earlier initiation of patients, 
especially men and patients ≥50 years old, and the need for good monitoring 
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Chapter 1: Introduction 
 
 
1.1 Introduction and background 
1.1.1 Epidemiology of HIV/AIDS  
In 2013, an estimated 35 million people were living with HIV worldwide. According 
to the 2013 UNAIDS Global Report, 70% of new infections occurred in Sub-Saharan 
Africa (SSA), home to nearly 25 million individuals infected with human 
immunodeficiency virus (HIV), 58% of whom are female(1). South Africa remains the 
epicenter of the epidemic with 12.2% adult prevalence and 6.4 million people living 
with HIV in 2012(2). The overall prevalence masks large differences between and 
within provinces as well as differences by age, gender, race and urban vs. rural 
location. The scale of the HIV epidemic in South Africa has had a huge impact on 
both individual and population health. The burden of opportunistic infections has 
grown and HIV has been responsible for increased morbidity and mortality and 
decreased life expectancy(3). 
 
1.1.2 Antiretroviral therapy (ART) 
Antiretroviral drugs were available in Europe and North America in mono- or dual-
therapy regimens from the late 1980s. In 1996, at the 11th International Conference 
on Acquired Immunodeficiency Syndrome (AIDS) in Vancouver, researchers 
announced that a combination of three antiretroviral (ARV) drugs (‘triple therapy’) 
delayed the onset of AIDS(4). Triple therapy was introduced into clinical practice in 
developed countries and resulted in declining morbidity and mortality(5), but only 
for those who could afford the prohibitive expense. At an estimated cost of 
US$10,000-15,000 per person per year in the late 1990s(6), it seemed unlikely that 




1.1.2 Individualized ART  
In developed countries, patients are prescribed highly individualized care. In 
Switzerland, for example, patients are prescribed ART selected from 36 different 
regimens(7). The choice of treatment regimens may impact on patient outcomes 
and on the effectiveness of an ART program. High levels of adherence to ART are 
required to ensure virologic suppression, some studies suggesting up to 90% for 
protease-inhibitor-based drugs and at least 95% for non-nucleoside-based 
treatment(8).  
 
First-line regimens need to be simple and manageable for patients to stay on 
lifelong therapy and to avoid unnecessary and costly switching or substitution of 
drugs. In the early years, treatment regimens were complex with heavy pill burdens. 
For example, in an early study on adherence patients with a low pill burden took 
<10 pills/day while those with a high burden took more than 15 pills/day(9).  Short- 
and long-term adverse drug reactions were frequent, serious and sometimes life-
threatening. Such complex regimens and serious side effects increase the likelihood 
that patients will be non-adherent, fail therapy and require either drug switches 
(swapping one or two drugs due to intolerance) or drug substitution (swapping the 
entire regimen as virologic replication was not suppressed). In addition to the 
implications for patients, increased drug switching and substitution have major cost 
implications. Second- and third-line ART are far more expensive than first-line and it 
is important to prolong the durability of first-line ART as far as possible(8). 
 
1.1.3 The public-health approach to ART  
In contrast with the highly individualized approach to ART in most developed 
countries, South Africa and many other resource-constrained countries have 
adopted a public-health approach following recommendations from the World 
Health Organization. South African activists and health care workers were centrally 
involved in helping to drive down the exorbitant cost of treatment. In 2013, the 
average cost of first-line ART for low- and middle-income countries was US$115 per 
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patient per year, and $330 for second-line treatment(6), and the cost continues to 
drop.  
 
Such huge reductions in cost paved the way for the provision of public sector ART in 
developing countries. However there was recognition that highly individualized ART 
was not feasible in resource-constrained settings. In September 2002, the World 
Health Organization (WHO) published guidelines for a public-health approach to 
offering ART in resource-constrained settings with standardized drug regimens, 
clinical decision-making and patient monitoring(10).  Regimens are chosen on the 
basis of cost and ease of administration and may include antiretroviral drugs which 
are no longer used in developed countries. This thesis highlights some successes 
and challenges in applying the public-health approach in the South African national 
program. 
 
1.2 ART in South Africa  
1.2.1 Background: a history of inequality 
In addition to HIV, South Africa faces numerous other major public-health 
challenges. It has one of the most serious TB epidemics in the world, with over 50% 
of new TB cases being in patients co-infected with HIV and growing epidemics of 
multidrug-resistant and extensively drug-resistant TB(3). These overlapping 
epidemics are compounded by a high burden of non-communicable disease, injury 
and violence-related deaths and mental health disorders, placing enormous strain 
on a beleaguered health system. Indeed, South Africa’s health burden per capita is 
reportedly the highest of any middle-income country worldwide(11).  
 
To some degree, the roots of the public-health challenges facing the country – 
including the scope of the HIV epidemic – may lie in the violent and divisive history 
of South Africa(12). Health inequities are evident in racial and gender differences in 
rates of mortality and disease, reflecting differential access to services and health. 
In addition, huge inequities persist in health outcomes between and within 
provinces. Historically, funding for health services was extremely uneven and 
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focused primarily on tertiary care. Primary-level services were underdeveloped and 
there was little funding for the former Bantustans, poorly-resourced areas of land 
to which black South Africans were assigned according to their ethnic identity(13). 
At the time of the first democratic elections in 1994, there were 14 separate health 
departments. Since then, the health system has restructured with the focus on 
delivery through primary health care. Despite good policies and the existence of 
many excellent facilities, it is argued that implementation of the system has been 
poor, largely due to failures in leadership and weak management(14). Levels of 
socio-economic inequality have continued to increase despite government’s 
commitment to reducing poverty. Indeed in 2013 the Organization for Economic Co-
operation and Development (OECD) stated that ‘no progress toward income 
equality has been made since the end of apartheid’(15).  
 
1.2.2 South Africa’s response to the HIV epidemic 
The first documented cases of HIV in South Africa were two white homosexual flight 
stewards(16). Over the next few years, HIV remained concentrated largely within 
the gay community, paralleling the epidemic in developed countries. During this 
time, the apartheid government failed to address HIV prevention beyond a number 
of unsuccessful advertising campaigns. From the early 1990s, the country has faced 
a more generalized epidemic with heterosexual transmission the dominant route of 
transmission(17). In 1993, the National AIDS Convention of South Africa (NACOSA) 
was established. NACOSA was an extremely inclusive body with representatives 
from government as well as a wide range of HIV/AIDS activists, unions, business 
groupings, health workers, religious groups and others. The explicit intention of 
NACOSA was to formulate a National AIDS Plan (NAP) for urgent implementation 
following the election of a democratic government. Despite the NAP being adopted 
and prioritized as a lead project, high-level political support was not forthcoming. 
The newly-formed HIV/AIDS and STD directorate was located within the 
Department of Health (DoH) and not within the President’s Office, as intended. The 
DoH was dogged by a series of widely-publicized debacles including government 
support for a controversial anti-AIDS play and a supposed cure for AIDS as well as 
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government’s refusal to fund treatment to prevent mother-to-child transmission of 
HIV(3).  
 
1.2.3 Delays & denialism 
In 1998, the struggle for public sector ART in South Africa began in earnest, strongly 
opposed by the Minister of Health (MoH) at the time, Nkosazana Dlamini-Zuma. She 
argued that ART was toxic and that drug companies were trying to persuade 
Africans into buying expensive medication unnecessarily. Following the election of 
President Mbeki and his appointment of Manto Tshabalala-Msimang as MoH in 
1999, the situation worsened. In conflict with the country’s stated HIV/AIDS policy, 
President Mbeki openly stated that HIV did not cause AIDS and the new MoH did 
not contradict him. Mbeki established an ‘advisory panel’ of dissident scientists who 
supported this controversial position in the face of the overwhelming body of 
expertise within and outside the country. While Mandela could be criticized for 
delaying implementation and not prioritizing HIV/AIDS during his presidency, it is 
estimated that Mbeki’s era was responsible for the unnecessary loss of over 
330,000 lives(18).  
 
In addition to Mbeki’s opposition to ART, others raised high-level concerns about 
the capacity of health systems in developing countries to provide ART. In 2001, for 
instance, the USAID Administrator Andrew Natsios said that ‘Africans don’t know 
what Western time is. You have to take these [AIDS] drugs a certain number of 
hours each day, or they don’t work. Many people in Africa have never seen a clock 
or a watch their entire lives … They know morning, they know noon, they know 
evening, they know the darkness at night’(19). Indeed Natsios later argued that the 
newly-established Global Fund to fight AIDS, TB & Malaria should focus on 
prevention and include little if any funding for treatment. Even among individuals 
committed to the provision of ART in developing countries, there were concerns 
about possible ‘antiretroviral anarchy’ including the development of resistance and 




Fortunately a group of committed health care practitioners supported by Médecins 
sans Frontières and the Treatment Action Campaign found creative ways of 
circumventing official channels to offer lifesaving ART. A number of pilot projects 
tested the feasibility and logistics of offering public sector ART(21) while activists 
brought court actions to force government to provide widespread access to ART. In 
2002 the Constitutional Court ruled in favor of the Treatment Action Campaign, 
forcing government to provide treatment to prevent mother-to-child transmission 
(MTCT) of HIV(22). In 2003, the South African cabinet eventually ordered Minister 
Tshabalala-Msimang to initiate a national ART program(23). In April 2004, 
government officially launched the national ART program, one of the largest, most 
intensely-funded health care programs in South Africa and the largest ART program 
worldwide.  
 
By the end of 2012, an estimated 2.1 million individuals had initiated therapy in 
South Africa, saving more than 2.7 million life-years and preventing hundreds of 
thousands of new HIV infections(24). HIV-positive individuals starting ART with 
CD4+ cell counts over 200 cells/µL had near-normal life expectancy(25). By any 
standard this is an extraordinary achievement, but even more so when it has been 
implemented against a backdrop of high-level political opposition to ART.  
 
1.2.4 Monitoring 
Unfortunately the expansion of ART services has not been matched by the ability to 
monitor and report on service delivery and data on key program outcomes such as 
mortality, LTF and retention are limited. The cascade or continuum of HIV care 
includes linkage from HIV testing to enrollment into pre-ART care, enrollment onto 
ART when eligible, adherence to ART and retention in long term treatment(26). 
Monitoring of these stages provides insight into where patients are being lost to 
care and/or non-adherent to treatment. A few cohorts have published patient 
outcomes(21,27-29). These analyses provide insights into the performance of 
specific programs but the generalizability of findings may be limited.  There is still 
no national reporting of key indicators of ART scale-up and its impact on the health 
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of HIV-infected individuals. Yet monitoring of program outcomes is vital to inform 
and improve service delivery.  Planning for current and future ART services is 
dependent on accurate data on enrollment and retention. Information is also 
needed on those groups of eligible patients who are not currently in care. Mortality 
is a crude indicator of how patient management and understanding how mortality 
risk differs between groups facilitates targeted prevention and testing campaigns. 
Differentiating between patients truly lost to care vs. those lost to monitoring 
informs strategies to trace these patients and ensure that they are re-engaged in 
care. The ability to do so ensures a more accurate estimate of program retention, 
increasingly regarded as the most important measure of effectiveness.  
  
Given these key indicators, this thesis makes two significant contributions towards 
our understandings of the response to the epidemic. Firstly, it uses routinely 
collected data from the IeDEA-SA collaboration to provide the first – if partial – 
picture of the evolution and effectiveness of the national program. Secondly, it 
identifies key gaps in the existing program which could be addressed to improve its 
performance. The 2007-2011 National Strategic Plan on HIV/AIDS identified the lack 
of a monitoring and evaluation (M&E) operational plan as a major concern(30). This 
thesis aims to address part of the existing gap in monitoring and evaluating the 
national ART program. 
 
1.2.5 South African ART guidelines 
Since 2004, South Africa has issued three sets of ART guidelines, each time 
expanding the criteria for eligibility(31-33). In  2004, patients were eligible for ART if 
they had a CD4+ cell count ≤200 cells/µL or were classified WHO stage IV(31). From 
2004-2008, first-line ART in South Africa consisted of two nucleoside reverse 
transcriptase inhibitors (NRTI) and one non-NRTI (NNRTI). Tolerability was poor, 
with frequent side effects including peripheral neuropathy, lipodystrophy, lactic 
acidosis, hepatotoxicity, neutropenia and anemia(34). In 2009, after four years 
providing ART in a busy clinic in Johannesburg, Sanne et al commented that “High 
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rates of single drug substitution suggest that the public-health approach to HAART 
could be further improved by the use of a more durable first-line regimen”(35).  
 
In 2010, in response to concerns about d4T, WHO issued revised guidelines which 
recommended replacing d4T with tenofovir (TDF), a drug with a better safety 
profile.  From April 2010, despite concerns about the six-fold higher cost, South 
Africa started initiating new patients on TDF(32). Eligibility was extended to include 
pregnant women and people co-infected with TB with CD4+ cell counts ≤350 
cells/µL, and all individuals in WHO stage IV or with drug-resistant TB, regardless of 
immunologic status. Since then a study comparing public-health and individual 
approaches to ART has reported similar virologic responses but a far lower rate of 
drug switching for TDF than for AZT or d4T, both of which had far higher rates of 
total substitution(7). Simplifying first-line regimen is an important step in improving 
adherence and retaining patients on ART. In 2012 the Minister of Health announced 
the tender for a triple fixed-dose combination (FDC) tablet of TDF, FTC and EFV 
which is cheaper and simpler than the previous regimen and will be used in the 
initiation of an estimated 90% of new patients(36).  
 
In the most recent change to ART guidelines, Minister of Health Aaron Motsoaledi 
has announced that from January 2015, eligibility will be extended to patients with 
a CD4+ cell count <500 cells/µL(37). Raising the threshold of eligibility has major 
implications for service delivery, increasing the number of individuals eligible for 
ART. For example, raising the CD4+ cell count from 200 to 350 cells/µL was 
estimated to create a backlog of 1 million patients(38). This thesis highlights existing 
challenges in the ART program that will be compounded by such increases in patient 
load unless they are addressed. 
 
1.3 Problem statement and rationale 
South Africa has the largest antiretroviral treatment program worldwide, which has 
enrolled over 2 million individuals on ART since 2004. While there have been 
9 
 
reports from individual cohorts and two provinces, there has been little 
consolidated monitoring or reporting of ART outcomes at a national level. After ten 
years of ART, there is a need to evaluate the program in order to plan and deliver 
future services efficiently and equitably.  
 
1.4 Aim and objectives  
The aim of this thesis is to review the evolution and effectiveness of the South 
African national antiretroviral therapy (ART) program using data from the IeDEA-
Southern Africa collaboration. The thesis uses individual patient-level data to 
describe the baseline characteristics of a large sub-set of adults who have started 
ART nationally, and to explore patient outcomes over time in the context of a rapid 
and massive scale-up of services.  
 
Specific objectives include: 
1. To characterize adults accessing public sector ART in South Africa over five 
years of enrollment;  
2. To investigate temporal changes in mortality, loss-to-follow-up (LTF) and 
overall program retention over five years;  
3. To explore mortality among patients transferred and lost from these ART 
services compared with mortality among patients retained; 
4. To explore the impact on ART outcomes of age at enrollment; 
5. To explore gender differences in adult survival on ART. 
 
1.5 The IeDEA-Southern Africa Collaboration 
1.5.1 Background to IeDEA 
The International Epidemiologic Databases to Evaluate AIDS collaboration 
(www.iedea.org) is an international research network that was established by the 
National Institute of Allergy and Infectious Diseases (NIAID) of the US National 
Institutes for Health (NIH) in 2005. IeDEA evolved from the work of previous historic 
collaborations such as the Antiretroviral Therapy in Low Income Countries (ART-
LINC), the Antiretroviral Therapy Cohort Collaboration (ART-CC) and others. 
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Participating sites within the collaboration collect and provide patient-level data. 
These data are analyzed by researchers in the data centers, site investigators and 
others to address research questions that cannot be answered in single cohorts or 
with small patient numbers. 
 
1.5.2 IeDEA-Southern Africa 
IeDEA-SA (www.iedeasa.org), the Southern African Collaboration, is one of seven 
regional centers, with administrative and scientific oversight at data centers at the 
Universities of Cape Town and Bern. The University of Cape Town has primary 
responsibility for managing data and relationships with South African sites, while 
the University of Bern liaises with sites in other Southern African countries. The 
broad aims of the collaboration are to conduct epidemiologic, clinical and health 
services research to inform and improve the delivery of ART in the region. IeDEA-SA 
successfully re-competed for funding in 2011 and is funded until 2016. The African 
networks of IeDEA-SA have been previously described(39).  
 
During the course of this thesis, the regional collaboration has evolved. New cohorts 
have joined and where possible, their data has been included in subsequent 
analyses. By December 2013, the IeDEA-SA database included data on 476,067 
adults on ART and 72,474 HIV-positive patients not on ART in Zimbabwe, Malawi, 
Mozambique, South Africa, Zambia and Lesotho. In its second cycle of funding, 
IeDEA-SA focuses on long-term issues including the effectiveness and outcomes of 
ART over time, long-term and temporal trends in regimen durability and important 
co-morbidities of HIV infection.  
 
The collaboration has relied on data routinely collected in ART services, which 
entails a balance between quantity and quality. On the one hand, routine data are 
likely to be more generalizable than data from closely monitored research sites. On 
the other hand, the sheer volume of patients and the caseload result in missing 
laboratory and other values for key variables. For instance, although some cohorts 
were included in earlier analyses, missing data and data quality issues sometimes 
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precluded them from later analyses. However IeDEA-SA has successfully enhanced 
routine data through, for example, linking HIV cohort data with the National 
Population Register to improve mortality ascertainment and using appropriate 
statistical methods to minimize the impact of missing data and LTF and mortality 
estimates.  
 
1.5.3 Data center management 
I have managed the South African data center since 2007. In this capacity I have had 
primary responsibility for independently managing the organizational aspects of the 
data center including relationships with sites and management of the complex 
scientific process that has been developed to govern analyses of shared datasets, 
collaborative writing committees and authorship processes. I participate in the 
IeDEA-SA Executive Committee which has scientific oversight over the collaboration.  
 
Patient data are transferred anonymously from participating sites to the data 
centers using the IeDEA-SA data transfer protocol (DTP) which was developed 
within the UCT data center in consultation with other staff and investigators. Based 
on the HIV Cohorts Data Exchange Protocol (HICDEP) used by the large European 
network EuroCoord, the DTP provides the structure and format for the collaborative 
IeDEA-SA and for data imports from sites to the database. After transfer, data from 
different sites are merged into a single IeDEA-SA Microsoft SQL Server database 
stored securely at each data center, with access restricted to data managers. I was 
involved in revising the HICDEP format for resource-constrained settings. The DTP 
has now been accepted as the South African Data Exchange Standard for all data 
transfers between HIV monitoring programs nationally.  
 
All analyses included in this thesis used data from the South African cohorts of the 
IeDEA-SA combined dataset. Figure 1.1 shows the location of current and historical 
cohorts. Tables were extracted via open database connectivity download to STATA 
(versions 12-13, College Station, Texas). I undertook all data management including 
merging data from different tables, checking quality and data cleaning in discussion 
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with participating sites. Data management and analysis in Chapter 4 were done by a 
co-author, Ms A Grimsrud.  
 
Figure 1.1.  Location of adult IeDEA-SA cohorts in South Africa 
 
 
1.5.4 Publication process 
I was responsible for formulating and managing an explicit process to access and 
analyze the data (Appendix A). Briefly this process consists of the proposal of a 
regional or multiregional concept sheet which describes the analysis and specifies 
the required variables. The concept sheet is circulated to the data centers and to all 
site investigators, who decide whether to participate in the analysis. Once the 
analysis results are available, sites may not withdraw their data. In the event where 
any data are shared between the data centers and any third party, a data sharing 
agreement is completed.  For each of the analyses in this thesis, I developed, 
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The IeDEA-SA (first known as the Observational Antiretroviral Studies in Southern 
Africa [OASIS] study has ethical approval from the UCT Health Sciences Faculty 
Research Ethics Committee (HREC REF: 084/2006, Appendix B), renewed annually. 
In addition, each cohort has ethical approval from their respective institutional body 
to contribute data to the collaboration.  
 
1.6 Meta-analysis of individual patient-level data 
The approach used in these analyses can be thought of as individual patient-level 
meta-analysis. The use of individual-level data differentiates this approach from 
study-level meta-analysis which combines aggregate-level data from a range of 
studies to provide a summary estimate(40). A body of literature addresses the 
comparative benefits and disadvantages of individual patient-level meta-analysis. 
Compared with meta-analysis of observational studies in the literature, Stewart et 
al(41) argue that a meta-analysis of individual patient data provides the least biased 
way of addressing questions that have not been answered by clinical trials. As the 
length of survival is of great importance in most chronic diseases, using individual 
survival times to estimate the overall relative benefit of a treatment is a particular 
advantage. Meta-analysis of individual level observational studies can also detect 
small effects which may not be evident in smaller sample sizes, notably in genetic 
epidemiology(42), or with limited follow-up.  
 
The results from meta-analysis of individual-level observational studies may also be 
more directly relevant and applicable than results from trials(43). Clinical trials 
often exclude whole groups such as women or older individuals, or apply such strict 
eligibility criteria that their subjects differ from patients accessing public sector 
health services. On the other hand, the absence of randomization in observational 
studies may increase confounding, bias or both. Even when analyses have adjusted 
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for potential confounding, there may be residual confounding and increasing the 
sample size of an analysis may produce very precise but invalid estimates.  
 
1.7 Conceptual framework of thesis 
The provision of ART is not a single intervention. Individuals with HIV must pass 
through a care continuum to ensure optimal health outcomes. McNairy and El-
Sadr(26) have identified four key steps in the HIV continuum (or cascade) of care: 1) 
HIV testing and linkage to HIV care, 2) engagement in pre-ART care with counseling, 
support and monitoring, 3) initiation of treatment as soon as ART-eligible and being 
retained in care, and 4) ensuring continued adherence and virologic suppression, 
with patients lost to care at each point(44,45). Pre-ART care plays an important role 
in ensuring good outcomes on ART, maintaining patient wellness and ensuring that 
patients start ART as soon as it is indicated. However most national HIV programs 
do not report retention during pre-ART care and services that collect data during 
the pre-ART phase report high levels of disruption of care(46). As the participating 
cohorts in IeDEA-SA do not generally collect pre-ART data, the first two steps are 
beyond the scope of this thesis, which focuses on outcomes after enrollment on 
ART. 
 
1.8 Overview and structure of thesis   
This Chapter introduces the topic of HIV/AIDS and antiretroviral therapy programs 
in resource-constrained settings. It includes the thesis problem statement, rationale 
aims and objectives. As the analyses were based on data from the IeDEA-Southern 
Africa Collaboration, the chapter also includes a description of the regional network 
and its processes for data center management and publication of papers. 
 
Chapter 2 provides the background to the thesis in a comprehensive review of the 
literature on adult enrollment and outcomes on ART in South Africa published from 
2000-2013. The review includes patient numbers and characteristics at ART 
initiation and gives a sense of the pace and magnitude of the national ART program 
scale-up. It identifies gaps in the literature which are subsequently addressed in the 
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empirical parts of the thesis. These include men’s access to and outcomes on ART, 
mortality among patients transferred and LTF from ART, and the impact of age on 
ART enrollment and outcomes.  
 
Chapters 3-7 present the empirical studies included in the dissertation. These map 
to the objectives, exploring and discussing the key research questions and findings. 
Broadly, the studies reflect the temporal nature of the ART program and of the 
thesis.  Chapters 3 and 4 set the scene, describing the baseline characteristics and 
outcomes of adults starting ART and how these change over five years of 
enrollment. Chapter 3 relates to the first objective of the thesis and characterizes 
patients accessing public sector ART. It describes the characteristics at ART initiation 
of 20% of children and 10% of adults who started public sector ART nationally. It 
finds some improvement in these characteristics over five years of ART initiation, 
although many patients still start treatment with advanced HIV disease. The chapter 
highlights areas for further research including the impact of gender and age at 
enrollment on ART outcomes and is the motivation for much of the empirical 
section of the thesis. Chapter 3 highlights the challenge of missing data and finds 
that with scale-up, data on key variables including laboratory measurements are 
less complete. The chapter concludes by arguing for the establishment of sentinel 
surveillance sites to facilitate the collection of good quality data without unduly 
burdening staff at ART sites.  
 
Chapter 4 addresses the second objective of the thesis, documenting strong 
temporal trends in mortality and LTF. With each successive year of enrollment and 
with duration on ART, mortality decreases but LTF increases and poses the major 
challenge to program effectiveness. The impact of baseline immunologic status, 
gender and age on outcomes are reported, for detailed exploration in later 
chapters. The chapter highlights the difficulty of long-term chronic care and the 
need to better understand the context-specific meaning of LTF. At the time of 
publication, this was the first report on outcomes from multiple cohorts in the 
world’s largest ART program. To our knowledge it was the largest analysis of 
individuals starting ART at the time of writing.  
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Chapter 5 explores mortality after TFO and LTF in an attempt to minimize possible 
bias in mortality ascertainment, addressing objective 3. As the ART program 
continues to expand, it is increasingly important to transfer patients between 
facilities without resulting in poorer outcomes. However, due to inadequate 
monitoring systems little is known about the outcomes of patients after TFO or LTF 
in South Africa. Restricted to patients with ID numbers, this analysis traces the vital 
status of patients after TFO/LTF and finds that compared with patients retained, the 
mortality risk is similar among TFOs and three times higher in patients LTF. Thus 
censoring TFOs at the date of transfer may not bias mortality estimates but cohort 
analyses should correct mortality estimates for LTF to avoid bias, particularly where 
LTF rates are high. 
 
Chapters 6 and 7 provide evidence on how age at ART initiation and gender impact 
on enrollment and ART outcomes. Chapter 6 explores the impact of aging in ART 
programs (Objective 4). Age is frequently reported as an explanatory variable but its 
specific impact is little understood. In a context of high HIV prevalence and good 
ART coverage, the proportion of older individuals living with HIV is set to increase 
dramatically yet there are few empirical data from South African sites to inform 
planning. Chapter 6 finds that increasing proportions of patients over 50 years of 
age are starting treatment and being retained in care each successive year, and that 
their outcomes are generally poorer than younger patients. There is a need to 
provide services tailored to older individuals with HIV and to extend epidemiologic 
measures beyond 50 years of age.  
 
Chapter 7 addresses the explanations that are frequently cited in the literature for 
men’s poorer survival than women on ART (Objective 5). During the analysis and 
writing of Chapters 2 & 3, it became clear that disproportionately more women 
than men were accessing ART. Concurrently, African cohorts had started reporting 
poorer outcomes among men than women on ART. Differential outcomes on ART 
were frequently attributed to men’s poorer ‘health-seeking behavior’ resulting in 
later HIV diagnosis and initiation of ART. In addition it was suggested that men 
might be less adherent to ART and more likely lost to care. This paper assessed 
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whether the evidence supported these explanations and found that only delays in 
ART initiation explained any of the gender difference in mortality. Indeed, the 
gender difference in mortality among HIV-negative individuals was less than among 
HIV-positive people on ART. This was a new and important finding, highlighting the 
fact that people with HIV do not die of HIV-related causes only. Further, the paper 
focused attention on a broader issue of major public-health relevance - the 
invisibility of men’s health(47-51).  
 
Chapter 8 summarizes the empirical findings of the thesis and considers the public-
health implications of the thesis. It concludes that the major challenges to the 
success of the ART problem are not related to clinical management or treatment 
adherence, but relate to the way in which the health system is structured and the 
ART program was implemented. The chapter makes recommendations for targeted, 
evidence-based prevention and intervention efforts to increase equitable 
enrollment and improve ART outcomes in the transition to a chronic care program.  
 
1.8.1 Context of thesis 
This thesis began in 2009 as an evaluation of the adult ART services in South Africa, 
explicitly focusing on program outcomes (Chapters 3-5). As it became clear that age 
and gender, two key socio-demographic variables, also impacted on ART outcomes, 
these became the subject of further detailed analyses (Chapters 6 and 7). My 
research thus forms part of, and contributes to the evolution of, the literature 





Chapter 2: Literature Review 
 
2.1 Background 
At the time when this thesis was initiated, there was a paucity of evidence on ART in 
developing countries. Given the fairly recent introduction of public sector ART, this 
was not surprising. As yet there is still no reporting at a national level on mortality, 
LTF or retention on ART in South Africa. Using empirical evidence, the thesis aims to 
describe and evaluate the effectiveness of South African ART program. The 
literature review contextualizes the thesis.  
 
The review provides a clear picture of how the priorities of the program have 
changed over time as the epidemic response matured. The initial priority was to 
prove that it was feasible to enroll and retain patients on ART in a resource-
constrained setting. Papers from two pilot projects describe intensive patient 
preparedness and follow-up and short-term outcomes comparable with those from 
developed countries. Later studies describe massive, rapid increases in enrollment 
in urban and rural settings nationwide from 2004 onwards. Following these are 
reports of longer-term outcomes including later mortality, immunologic and 
virologic response in the context of differential mortality ascertainment in large ART 
programs in developing countries. Important gaps in the literature include the 
outcomes of patients transferred out (TFO) and LTF compared with patients 
retained in care, and the impact of gender and age on ART outcomes, each the 
subject of a chapter in the thesis.  
 
2.2 Aim and objectives 
The objectives of this literature review are to review and discuss the published 
literature on adult characteristics at ART initiation and outcomes on treatment in 
South Africa from 2000-2013. Given that gender/sex and age are two of the basic 
determinants of population health, the review also explores published literature on 
their effect on outcomes on antiretroviral therapy in South Africa. The review 
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focuses on public sector programs but includes other studies reporting outcomes 
for example in the private sector. Specifically the review explores: 
 The number and characteristics of adults initiating ART and temporal 
changes in these characteristics. 
 Mortality and LTF among adults starting ART. 
 Mortality among patients TFO and LTF compared with those retained at the 
ART enrollment site. 
 Gender differences in enrollment and outcomes on ART. 
 The impact of age on ART outcomes.  
 
2.3 Search strategy 
The Medline bibliographic database was searched using the PubMed interface 
(National Library of Medicine, Bethesda, MD). The following search strategy was 
used: “((antiretroviral therapy OR antiretroviral treatment) AND (South Africa) AND 
(mortality OR survival))”. In additional searches the following terms were added: 
(loss to follow-up OR loss OR retention) AND (transfers) AND (sex OR gender) AND 
(aging OR ageing). 
 
The inclusion criteria for the literature review were: 
 The review included studies published in English between 2000 and 2013 
that reported patient characteristics at ART initiation and/or outcomes 
(mortality, loss to follow-up and/or retention) of adults 16 years or older in 
South Africa. 
 
The exclusion criteria for the review were: 
 The review excluded articles from countries outside South Africa unless they 
were methodological. 
 Studies undertaken prior to 2000 were excluded. 
 Studies which included individuals who were HIV-positive but not on ART 
were not included.  
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 Clinical trials were excluded, as were studies that focused exclusively on the 
choice of treatment regimens and/or cost effectiveness. 
 
Studies which included individuals not on ART were not included. In cases where 
there was more than one report from a cohort, the study containing the most 
detailed data and longest follow-up period was generally selected for inclusion in 
the tables. Short- and long-term outcomes were included for the two pilot projects 
and two other large cohorts, Free State Province and Themba Lethu clinic. 
  
2.4     Results 
2.4.1     Overview of included studies 
2.4.1.1   Number of studies included 
The search strategy generated over 600 studies, twenty-six of which fulfilled the 
eligibility criteria and are reviewed in detail below (Tables 1.1-1.3). These include 
short- and long-term reports from two pilot sites (Gugulethu and Khayelitsha, Cape 
Town) as well as individual cohorts, the IeDEA-SA and other multi-cohort 
collaborations (with some cohorts contributing data to different analyses), two 
provinces (Free State and Western Cape) and two health and socio-demographic 
surveillance system (SDSS) sites in Limpopo and KwaZulu Natal. 
 
2.4.1.2 Characteristics of included studies 
The characteristics of the eligible studies published between 2000 and 2013 are 
summarized in Table 1.1. Early reports from the pilot projects in Khayelitsha and 
Gugulethu, Cape Town include small numbers of patients and are clearly intended 
to support advocacy for a national ART program(28,52). They include minute details 
of patient selection, preparedness training, staffing, regimens, cost-effectiveness 
etc. The first paper from the IeDEA-SA collaboration describes changes in baseline 
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Table 2.1.  Characteristics of studies included in the literature review and characteristics of patients at enrollment onto ART in South Africa. 
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Pilot project in a primary care clinic 
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Coetzee et al, 2004(28) 
 
 






Urban township, Cape Town 
First pilot project in 3 primary care clinics 
 























Nachega et al, 2006(56) Aid for AIDS Countrywide 
Private sector disease management program 
(DMP) 
1999-2004 6,288 61 149 37 
Johnson & McLeod, 
2007(57) 
N/A DMPs, workplace (administered by DMPs) and 
community treatment programs countrywide 
2001-2006 67,600 NR NR NR 
Barth et al, 2008(58) Elandsdoorn Medical 
Center 
Rural Mpumalanga 
ART administered by general practitioners in a 
primary care clinic 
2003-2006 609 71 67 (1-466) 35 










Free State province 
13 clinics, 4 treatment sites and 3 combined 
sites located in all districts 
 
Free State 



























Boulle et al, 2008(21) Western Cape  Western Cape Province 
43 sites, mainly in primary care settings 
(includes Gugulethu, Khayelitsha) 
2001-2006 14,123 70 NR NR 
Cornell et al, 2009(60-
64) 
IeDEA-SA Multi-cohort collaboration, sites in Western 
Cape, Gauteng, Free State & KwaZulu Natal 
2002-2007 
 
45,383 68 102 (44-164) 35 (30-41) 
22 
 













Fox et al, 2012(66) 
Themba Lethu Helen Joseph Hospital, Johannesburg 
Public sector ART program based at Themba 
Lethu clinic 





















2004-05:  35 
2008-09:  37 
Bassett et al, 2010(67) McCord & St Mary’s 
Hospital 
Durban & Mariannhill, KwaZulu Natal 















Charalambous, 2010(68) Aurum workplace 
program 
Countrywide 
Anglo American-funded ART program providing 
free treatment and care for employees in 70 
rural and urban sites 
2002-2005 3,270 5 158 41 (36-47) 
Russell, 2010(69) Aurum community  Countrywide 
Multi-clinic community and GP program 
2005-2006 1,350 60 83 (27-147) 36 
Barth et al, 2011(58) Ndlovu Medical 
Center 
Rural Limpopo NR 735 66 NR NR 
Boyles, 2011(70) Madwaleni Rural Eastern Cape 2005-2009 1,803 68 123 (55-184) 32 (27-39) 
Klausner et al, 2011(71) PEPFAR-supported 
ART sites 
Countrywide 
ART programs supported by PEPFAR funding 
2005-2009 631,985 65 NR NR 
Fatti, 2012(72) Kheth ‘Impilo Multicenter cohort, 57 public sector clinics 2004-2010 66,953 70 127 35 
Lim, 2012(73) Platinum miners Rustenburg, Northwest 
Workplace program 
2003-2010 2,078 0 162 (89-240) 32 
Fox, 2012(66) Themba Lethu, 
Johannesburg 
Helen Joseph Hospital, Johannesburg 
Seven year experience 









Faith-based NGO providing community HIV care 
in 71 sites in rural, urban, peri-urban, squatter 
and mining communities.   








Imkhanyakude rural district, Northern KwaZulu 
Natal 
Longitudinal demographic surveillance system 







71 129 (67-182) 34 (28-42) 
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characteristics and patient numbers over five years in eight large adult cohorts(64). 
Three subsequent studies report on early mortality as well as long-term outcomes 
up to seven years on ART in a context of rapid scale-up(53-55). Other studies 
reporting longer-term outcomes include the IeDEA-SA collaboration of sites in 
Western Cape, Gauteng, Free State and KwaZulu Natal(61), some of which also 
report on outcomes as individual cohorts. In addition, the review includes two 
studies from Themba Lethu, a public sector ART program based at a tertiary hospital 
in Johannesburg reporting shorter and long-term outcomes(35,66).    
 
Four studies reported the outcomes of private sector ART. One was a report from 
Aid for AIDS, a private sector disease management program (DMP)(56). A more 
comprehensive study reported on private sector ART including 13 DMPs and 10 
community treatment programs(57). One study describes two workplace programs, 
one in mines with numerous sites(76) and the other among male platinum miners in 
the Northwest province(73). Two large community programs are included: the 
Southern African Catholic Bishops’ Conference ART program(74), a network of 
community-based treatment sites in a wide range of settings, and the Aurum 
community program, which offers care and treatment delivered largely by general 
practitioners(69). Bridging the gap between public and private sector ART, one 
study reports on patients at two partly government-subsidized hospitals in KwaZulu 
Natal(67).  
 
Six papers provide insight into ART delivery in under-resourced and often extremely 
poor rural areas. Two studies are from demographic and health surveillance sites in 
Mpumalanga(77) and KwaZulu Natal(75). Others are reports from rural cohorts in 
Limpopo(58,65), Mpumalanga(78) and the Eastern Cape(70).   
 
The review identified two provinces which have been able to report at a provincial 
level on enrollment and outcomes on ART. The Free State provided an early report 
on the effectiveness of public sector ART(29) and a subsequent report after four 
years of scale-up and a large increase in enrollment(59). Free State data were also 
included in the first IeDEA-SA collaborative paper. The Western Cape reported on 
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43 sites, mainly in primary care settings, including data from Khayelitsha and 
Gugulethu.  Other large studies were from ART sites receiving PEPFAR funding(71) 
and the Kheth ‘Impilo multicenter cohort including 57 public sector clinics(79).  
 
2.4.1.3 Enrollment dates and number of adults initiated on ART 
Before 2004, access to ART was largely through private sector programs. Aid for 
AIDS, the single largest DMP, started enrolling patients in 1999(56). By mid-2005, 
nearly 70,000 individuals had started ART through disease management programs, 
workplace and community treatment programs. Expansion was rapid in these 
programs, on average 32% growth in a single year and twice as fast in community 
programs(57). 
 
Initiation onto public sector ART started slowly with small numbers of patients in 
Khayelitsha and Gugulethu in Cape Town. The Khayelitsha program was established 
in 2001 by MSF and the provincial government, and Gugulethu began providing ART 
in September 2002 with donor funding for 150 patients. In a context of high-level 
opposition to ART, these cohorts were trying to prove that it was feasible to offer 
ART in resource-constrained settings. Both sites reported small numbers initially 
and a huge increase in enrollment from 2004 onwards. 
 
After the public ART program was formally launched in 2004, numerous sites 
reported a trend of rapid and sustained increase in enrollment. For example 
enrollment at Themba Lethu, Johannesburg, increased annually and by 2010 nearly 
14,000 patients had initiated treatment(66). Similarly in eight South African sites of 
the IeDEA-Southern Africa collaboration, ART initiation increased 11-fold between 
2003-2007, mostly in 2006-2007(61). The Western Cape enrolled around 1,000 
patients/month, with over 16,000 patients having started ART in 43 mainly primary 
care sites(21). Reports from the PEPFAR-funded sites in South Africa provide 
additional insight into the scale of ART initiation and expansion(71). From 2005-
2009, the rate of ART initiation in these sites increased nearly four-fold. By 
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September 2009, an estimated 631,985 patients were still on ART in these facilities, 
an 18-fold increase from 2005.  
 
2.4.1.4 Gender and baseline immunologic status  
Two notable features of the literature are the consistent gender distribution and 
improving immunologic status at enrollment over time. Almost all of the cohorts 
were predominantly female. The exceptions were workplace programs in mines 
with male employees(68,73) and a study in hospitals which charged a user fee for 
services, which might have restricted women’s access to ART(67). All studies 
reported a similar temporal pattern in baseline CD4+ cell count: extremely low in 
the first year of ART enrollment and increasing with calendar year of enrollment. 
Predictably the lowest median CD4 count was in Khayelitsha, the oldest cohort, with 
a range from 43-131 cells/µL over different calendar years(55). Similar temporal 
patterns were also reported by the Free State Province, IeDEA-SA and two public 
sector clinics(29,54,61,66). Generally patients in private sector programs(56) started 
treatment at higher median CD4+ cell counts than those entering public sector ART.  
 
2.4.1.5 Age at ART initiation 
There was little variability in age among patients starting ART, the majority being 
34-35 years of age in urban and rural sites. Patients were slightly younger in a rural 
site in the Eastern Cape(70) and a platinum mine in Northwest and slightly older in a 
workplace program, median age 41 years(73). There was no clear temporal pattern 
of increasing or decreasing baseline age. Themba Lethu cohort reported that 
patients were enrolling at younger ages over time, with a median age of 27 years in 
those enrolling 2009-2010. In contrast, in the IeDEA-SA analysis (which included 
Themba Lethu data), there was a trend towards increasing age at enrollment(61). 
 
2.4.1.6 Pace of ART scale-up 
Despite increasing enrollment, there were concerns about delays in initiating ART 
among patients who were eligible. Two years after eligibility in the Free State, 68% 
of patients had started ART and 26% had died prior to initiation(80). Similar 
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concerns were highlighted in a study in Durban hospitals, where only 39% of ART-
eligible patients started treatment within 12 months(67).  
 
2.4.1.7 Estimation of ART need and coverage 
Estimation of ART need and coverage presents many challenges, particularly in the 
light of changing guidelines on ART. In the first place, estimates (including those of 
UNAIDS) regularly refer to the number of people on ART instead of the number who 
have started ART. In reality we are unable to report at a national level the number 
of individuals who are still on treatment, having not died or been LTF. The issue is 
further complicated as coverage is a cross-sectional measure, defined as the 
number of people receiving ART at a particular time divided by the number of 
people eligible to receive ART at the same point, including patients already 
receiving treatment(81). This measure may be too sensitive to ART eligibility criteria 
and annual enrollment. For example, in 2012 South Africa was one of ten African 
countries that reported reaching over 80% of adults eligible for ART, based on 2010 
WHO guidelines. However new guidelines issued in 2013 once again increased the 
number of people in need(82). In an alternative longitudinal measure of program 
performance proposed, the denominator is the number of people becoming eligible 
for treatment in the same year based on the current ART guidelines(81). 
 
2.4.1.8 Conclusion 
In summary, this review found evidence of a sustained increase in enrollment in 
many single and multi-site urban and rural cohorts across the country since 2004. 
The improving baseline immunologic status suggests improved coverage. Men’s 
disproportionately lower access to ART is a clear gap that needs urgent attention. 
Waiting times remain a challenge. 
 
2.4.2  Mortality in ART programs  
This literature points to three distinct phases in mortality in ART programs in South 
Africa: undocumented pre-treatment deaths, early (within the first three to four 
months on ART) and late mortality (after four months). Although outside the scope 
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of this literature review, mortality prior to ART initiation is extremely high, reflecting 
the high burden of untreated HIV in the community. For example, in Gugulethu 
mortality pre-treatment was 36/100 person-years(83). Despite increased access to 
ART, many patients still start ART with advanced HIV infection resulting in elevated 
mortality in the first three or four months on treatment. After a few months on 
ART, patients stabilize and mortality drops steeply. Both calendar year of 
enrollment and duration on ART impact on mortality. Mortality is high among LTF 
patients, and correction via linkage to the National Population Register (detailed 
below, section 2.5.3) almost doubles mortality estimates. A body of literature 
addresses the underlying issue of mortality ascertainment in large cohorts of 
patients, particularly in developing countries. 
  
2.4.2.1 Mortality during early ART 
Mortality rates were extremely high during the first few months on ART (Table 1.2). 
Reporting on the first two years on ART, 71% of deaths in the Khayelitsha pilot site 
took place in the first three months on treatment(28) and in the Gugulethu pilot 
site, the rate for early mortality was 19/100 person-years (pyrs)(53).  Even higher 
rates were reported by the Aurum community program delivered by community-
based general practitioners(69), the large urban Themba Lethu clinic(66) and a rural 
program(65). There was some evidence to suggest that as the program matured, 
rates of early mortality dropped. For example in the Western Cape, mortality at six 
months on ART dropped from 13% in 2001 to 7% in 2006(21).  
 
2.4.2.2 Mortality during later ART 
Once patients were stable on ART, mortality dropped dramatically. After the initial 
peak in the first few months on ART, mortality rates were far lower and ranged 
from 3/100 pyrs in Gugulethu(53) to 9/100 pyrs in a workplace program(76). With 
successive years of enrollment too, mortality dropped(61). Evidence that ART was 
impacting on overall mortality was reported from Agincourt, Limpopo, where an all-
cause mortality rate of 8/1,000 pyrs resulted from a higher rate of 13/1,000 pyrs 
before ART followed by a sharp decrease in mortality after 2004(77). Duration on 
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 Table 2.2.  Studies reporting mortality on ART in South Africa, 2000-2013. 









71% of mortality (0-3 months) 
86% survival at 24 months 
 









19/100 pyrs: early deaths (0-4 months) 
3/100 pyrs: later deaths (>4 months) 
 
11% after seven years 
Nachega, 2006(56) Aid for AIDS 1999-2004 4% crude 
Fairall, 2008(29) Free State  2004-2005 aHR 0.14, 95% CI 0.11-0.18: ART vs. no ART 
Boulle, 2008(21) Western Cape  2001-2006 13%: 0-6 months, 2001 
7%:   0-6 months, 2005 
Barth, 2008(78) Elandsdoorn medical center 2003-2006 19%, especially in first few months 
MacPherson, 2009(65) Acornhoek 2005-2007 20/100 pyrs: 0-6 months 
8/100 pyrs:   6-12 months 
3/100 pyrs:   12-24 months 
Cornell, 2010(61) IeDEA-SA  2002-2007 9%: 12-months, 2002-03 cohort 
6%: 12-months, 2007 cohort 
Russell, 2010(69) Aurum community 2005-2006 24/100 pyrs:  0-3 months 
13/100 pyrs:  3-9 months 
6/100 pyrs:    >9 months 
Charalambous, 2010(68) Aurum workplace  2004-2007 9/100 pyrs: overall 
4 vs. 11/100 pyrs: unadjusted, IPT vs. no IPT 
Barth, 2011(58) Ndlovu Medical Center NR 23%, mostly 0-3 months 
Boyles, 2011(70) Madwaleni 2005-2009 11% 
Fatti, 2012(72) Kheth ‘Impilo 2004-2010 aHR: 0.65, 95% CI 0.59-0.72: adherence support vs. none 
Fox, 2012(66) Themba Lethu 2004-2010 24/100 pyrs:   month 1 
5/100 pyrs:     month 12 
4/100 pyrs:     overall 
Ahonkhai, 2012(74) SACBC  2004-2008 10%: 12 months on ART 
11%-7%:  early deaths, 2004-08 
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ART influenced mortality in the Aurum community program, where the mortality 
rate dropped from 13/100 pyrs for patients three to nine months on ART to 6/100 
pyrs for patients who had been on treatment for over nine months(69). Mortality 
corrected via linkage to the National Population Register was generally about twice 
observed mortality recorded by sites. For example, Gugulethu and the SACBC 
network reported approximately 10% uncorrected mortality(54,74) while 
Khayelitsha reported corrected mortality of 21% after five years of ART(55).  
 
Interestingly, estimates from two rural sites(58,78) were close to corrected 
mortality, suggesting that in rural areas mortality ascertainment may be better than 
in large, highly mobile urban sites. The lowest mortality was reported by Aid for 
AIDS (56), one of the first private sector programs to enroll patients.  
 
2.4.2.3 Mortality estimation  
Numerous studies over the past ten years have addressed the complex issue of 
mortality estimation, particularly in developing countries(84-88). Many countries 
with rapidly expanding ART programs lack functioning vital registration systems. 
Reliable ascertainment of death is difficult under these circumstances, particularly 
as LTF is often high in these programs. In contrast, South Africa’s National 
Population Register reportedly captured 94% of deaths in the period 2007-
2011(89). Through linkage of their databases to this Register, some of the IeDEA-SA 
sites are able to report mortality corrected for deaths previously misclassified as 
LTF, TFO or alive.  
 
High mortality among patients LTF has been well documented, particularly in 
programs with high levels of LTF(84). In the past few years, a number of studies 
from outside South Africa and within have attempted to correct for mortality 
among LTF patients using different approaches. Using a sampling-based approach in 
Uganda, the cumulative mortality incidence at one year increased from 2% to 
8%(88). Studies in South Africa used patients’ civil identification (ID) numbers to link 
to the National Population Register and ascertain the vital status of LTF 
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patients(55,63,75,90,91). After linkage, for example, mortality on ART in Themba 
Lethu cohort more than doubled from 4% to 11%(90). In Khayelitsha, correction for 
mortality reversed the direction of LTF, which was then found to have increased 
over time(91). In five ART programs in sub-Saharan Africa, crude estimates of 
mortality at one year increased from 6-11%, while estimates adjusted for excess 
mortality in patients LTF ranged from 10-17%(84). On the basis of this multi-cohort 
study, Egger et al developed a nomogram to correct mortality estimates in sub-
Saharan Africa for LTF(92). The nomogram provides a correction factor based on the 
proportion of patients LTF and the estimated ratio of mortality between patients 
LTF and retained and is a simple method to correct potential bias in mortality 
estimates. 
 
2.4.2.4  Conclusion 
The literature describes an evolution in mortality outcomes in ART programs. The 
first few months of extremely early mortality are followed by a decrease and 
stabilizing of mortality rates. There was some suggestion that mortality rates 
decrease with each successive year of enrollment. Overall, uncorrected mortality is 
about 10% and correction for mortality in LTF patients generally doubles this 
estimate, with uncorrected estimates from rural areas approximating corrected 
mortality.  
 
2.4.3 Loss to follow-up and program retention  
This review found that LTF increases with each successive year of enrollment and 
with duration on ART. LTF poses a challenge to ART program effectiveness. Once 
patients leave care they are at increased risk of morbidity and mortality, generally 
within the first few months after being LTF(84,93). Even if they re-engage in care at 
a later stage, their outcomes are generally worse than those who are retained(94). 
Given the magnitude of LTF, there is a growing body of research on different 
methodological approaches to ascertaining mortality among LTF with a view to 
standardizing a definition to improve evaluation within and between 
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Table 2.3.  Studies reporting loss to follow-up and retained on ART in South Africa, 2000-2013. 
Study Cohort name Definition of LTF  LTF rate/percentage Percentage retained   
Boulle, 2008(21) Western Cape  90 days without a clinical visit 0.4%: 6-month, 2002  
5%:    6- month, 2005  
76%: 4 years on ART  
Boulle, 2010(55) Khayelitsha 6 months without a clinic visit 23% (95% CI 20-27) 65% uncorrected, 65% uncorrected,  
80%: 5 years corrected 
Cornell, 2010(61) IeDEA-SA No contact with clinic >6 months before 
database closure 
1%:  12- month, 2003 
13%: 12- month, 2006   
29%: 36 month cumulative  
80%: 2 years 
64%: 3 years 
Boyles, 2011(70) Madwaleni  No patient contact >6 months before 
study end 
11%: 48 month 82%: 4 years 
Nglazi, 2011(54) Gugulethu No clinic visit for ≥12 weeks & not died or 
transferred 
19% overall 60%: 7 years 
Fatti, 2012(72) Kheth ‘Impilo  No clinic visit for ≥180 days 13 vs. 17%, adherence support  vs. none, 
5 years on ART 
79 vs. 74%: adherence support  vs. none 
Ahonkai, 2012(74) Southern African Catholic 
Bishops Conference 
No follow-up visits 30-400 days after ART 
initiation 
20%: enrolled 2004 
14%: enrolled 2008 
60%: 1 year 
 
Fox, 2012(66) Themba Lethu  ≥3 months late for a scheduled visit 
Mortality among LTF corrected  
4%: 2004/05, lost in 1 year 
12%: 2009/10, lost in 1 year 
76%: 1 year 
38%: 7 years 
Mutevedzi, 2013(75) Africa Center 
Demographic Information 
System (Hlabisa) 
180 days since last visit. Disengagement 
defined as LTF adjusted for mortality. 
12% LTF 
10% disengaged  
61%: 5 years 
32 
 
programs(84,87,88,90-92,95,96). Some later studies correct for mortality among 
LTF while others report crude LTF estimates, generally inflated due to misclassified 
deaths. In contrast with LTF, retention on ART has not received much attention to 
date. Although retention in ART programs in SSA was the subject of two systematic 
reviews, most South African studies include retention as a secondary outcome only. 
This review found estimates of long-term retention in large urban and rural ART 
programs ranging from 60-80% up to seven years of ART. Retention was higher in a 
rural cohort and in a study which compared retention with adherence support 
versus none. 
 
2.4.3.1  Definitions of loss to follow-up 
Although cohorts routinely report on LTF, the variability in definition is notable.  A 
number of studies have attempted to identify the most efficient definition of LTF. 
Chi and colleagues used an empirical approach and found the best-performing LTF 
definition was ≥60 days after a missed visit(97). Within the South African cohorts, a 
variation in the definition of LTF impacted on the estimated proportions of LTF. The 
LTF definition currently used by IeDEA-SA analyses was found to be the most 
conservative definition(98), minimizing misclassification. In general retention was 
defined as the total number of patients who initiated ART minus the total number 
of patients lost to the program (Figure 2.1). Some studies treated TFO patients as 





Figure 2.1.  Definition of retention. 
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2.4.3.2 Estimates of loss to follow-up and retention 
Most studies reported on the proportion of patients LTF and/or retained on ART, 
often at different time points and by calendar year of enrollment. The lowest 
reported LTF was in rural cohorts(70,75). In the Eastern Cape, for example, only 11% 
of their cohort was LTF after four years on ART and a similar proportion in Hlabisa. 
The Hlabisa cohort corrected for mortality among LTF, differentiating between LTF 
and disengagement (LTF corrected for death). In contrast the highest proportions 
LTF were reported in the IeDEA-SA collaboration(61), possibly as the study used the 
most conservative definition of LTF(98) and did not correct mortality for LTF. While 
it is possible that the challenges of retaining patients may be less in rural than urban 
areas, it is also plausible that rural sites are better able to ascertain deaths, and 
hence may not overestimate LTF. Two studies which reported mid-range estimates 
were both from sites offering some form of adherence support, which may have 
increased the probability of remaining in care(72,75). Estimates from these studies 
are in line with the weighted average from a systematic review in SSA(99).  
 
There were strong temporal trends in LTF which increased with successive year of 
enrollment and with duration on ART. The first study to identify this trend was from 
the Western Cape, which reported that six-month LTF increased from 0.4-5% in 
patients enrolled in 2002 and 2005(21). Temporal trends in LTF were explored in 
detail in the IeDEA-SA analysis, which documented 12-month LTF increasing 
annually from 1-13% between patients enrolled in 2003 and 2006(61). Subsequently 
Themba Lethu reported a similar trend, with LTF three times higher among patients 
enrolled in 2009-2010 compared with those enrolled in 2004-2005(66). These 
results suggest that as a program increases in size, LTF may become an increasing 
challenge to effectiveness. 
 
Not all cohorts demonstrated this phenomenon, however. The SACBC study 
reported the opposite trend, with lower LTF among patients enrolled in 2008 
compared with 2004. This study explored one year outcomes in a large community 
program differentiating between LTF (liberally defined as 30-400 days without a 
34 
 
visit) and interrupted laboratory monitoring (ILM), where a patient may have been 
missing laboratory measures for an extended period but returned to care within the 
window period. If they had excluded patients with ILM, the LTF proportion would 
have increased from 17 to 28%, highlighting the difficulty of comparing outcomes 
across programs without standardizing a definition of LTF. The program also used 
the existing care network between the church and communities to identify 
treatment defaulters and support return to care, suggesting a different dynamic 
from that operating in public sector programs.  
 
While measures of LTF provide insight into programmatic challenges, some suggest 
that retention is the best metric for evaluating long-term effectiveness as it includes 
all losses to program(21,99). Two systematic reviews highlight the challenge of 
retaining patients in large, rapidly expanding African programs(99,100).  The first 
review included studies from 2000-2007 with limited follow-up and caused 
widespread concern when it reported the weighted average retention after 24 
months in African ART programs was 62%(100), with individual estimates reporting 
24-month follow-up ranging from 46-85%. A subsequent update reported 72% 
retention after 36 months, declining to 65% after adjusting for variable follow-up 
time(99). In this literature review a number of sites reported similar proportions 
retained for durations of ART up to five years(54,61,75). Estimates from the IeDEA-
SA and Gugulethu cohorts may have been higher if they had been able to correct for 
misclassified mortality. Such correction increased retention estimates in the 
Khayelitsha cohort from 65-80% at five years(55). It is notable that this corrected 
estimate was similar to the retention reported by the rural Madwaleni cohort, 
which had the highest proportion of patients retained(70), suggesting that rural 
cohorts may be better than urban cohorts at ascertainment of vital status and 
retention of patients. 
 
2.4.3.3 Conclusion 
Generally there was strong evidence that LTF increases with each successive year of 
enrollment and with duration on ART. Over time LTF has emerged as a greater 
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challenge to program effectiveness than mortality but lack of a standardized 
measure makes it difficult to compare between programs. Community-based and 
rural programs utilizing existing networks may be better equipped to retain patients 
in care than public sector programs. 
 
2.4.4 Virologic responses and adherence to ART 
In order for ART to be effective HIV must be suppressed below detectable levels, 
referred to as viral suppression. The level at which viral load can be detected has 
decreased with improvements in laboratory assays from 400 cells/µL to 50 cells/µL. 
Viral suppression is generally regarded as a proxy for individual adherence to 
treatment in the absence of accurate adherence measures. Where adherence is 
reported, it is based on pill counts, pharmacy records and/or patient recall. 
In those patients retained and alive with viral loads, virologic outcomes were 
excellent up to seven years on ART. This could be interpreted as a reflection of good 
adherence to ART among patients retained in a program. However this finding 
should be tempered by a) the proportion of missing viral load measures, and b) the 
possibility that patients who had viral loads measured may be different from 
patients who did not.  
 
2.4.4.1  Estimates of adherence and viral suppression 
In a context of high-level concern about whether Africans could successfully take 
ART(101), two studies from pilot sites addressed the issue of adherence at an early 
stage. Gugulethu reported 94% median adherence among some of the earliest 
patients on ART(102). Adherence was better among patients who spoke the same 
language as site staff, and with simplified dosing. In Khayelitsha, 70% of patients 
achieved  undetectable viral loads after 24 months on ART(103).  
 
With duration on ART, good virologic outcomes were sustained in a range of 
settings. For example, 80-90% of patients were virologically suppressed up to seven 
years in large cohorts in Themba Lethu, Khayelitsha and Gugulethu(35,54,55).  A 
large private sector program also provided evidence of good virologic suppression, 
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with 80% suppressed over five years of ART(56) while 84% of rural patients with 
more than three months follow-up were virologically suppressed after two to four 
years on ART(58).  
 
Any interruption in care resulted in poorer outcomes. The SACBC network of 
treatment clinics reported a 30% increase in detectable viremia among patients 
who had interrupted care compared with those retained(74), confirming that 
virologic outcomes are poorer among patients who interrupt or are lost to care(94).  
 
2.4.4.2   Conclusion 
The literature describes good virologic responses to ART among patients with viral 
load measures, sustained up to seven years of treatment.  
 
2.4.5 Immunologic responses to ART 
Immunologic responses are an important measure of the effectiveness of ART(104). 
Previous studies have established that immunologic response is strongly predicted 
by CD4+ cell count at ART initiation and that there are gender differences in 
baseline and subsequent CD4+ cell counts. In general despite low baseline CD4+ cell 
count this review found a consistent increase in immunologic response up to five 
years on ART, with women responding better to ART than men.  
 
2.4.5.1   CD4+ cell count increases from baseline 
Although reported baseline CD4+ cell counts are low, immunologic response was 
generally good among patients with available laboratory measures. In Khayelitsha, 
for example, where patients started with the lowest median CD4+ cell counts, 
median increases at 12, 24 and 36 months of ART were 192, 282 and 341 cells/µL 
respectively(55). Similar immunologic responses up to three years are reported by 
Themba Lethu(66) while in Gugulethu after 48 weeks on ART, the proportion of 
patients with a CD4+ cell count <200 cells/ µL proportion dropped to 21%-31%, 
depending on the year of enrollment(54). Even patients in a rural ART program 
responded well to ART, with a median increase of 236 cells/µL after 24 months(78). 
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These responses are better than those in a large collaborative analysis of patients in 
SSA, Latin America and Asia with a median baseline CD4+ cell count of 114 cells/µL, 
which reports median increases from baseline of 147, 189 and 258 cells/ µL in the 
same time periods(104).  
 
Several investigators found gender differences in baseline CD4+ cell count and in 
immunologic responses. In the IeDEA-SA cohort, women started ART at higher CD4+ 
cell counts (110 vs. 85 cells/µL) and had better immunologic responses than 
men(63). These findings are in line with results from four ART programs in SSA 
These gender differences may partly explain why the poorest immunologic 
responses are from a predominantly male workplace program, which reports 
median increases from baseline of 90, 113 and 164 cells/µL at 6, 12 and 24 
months(68). 
 
Two rural cohorts also reported good immunologic responses despite patients 
having started ART at low CD4+ cell counts. Patients who initiated ART in 
Mpumalanga at a median CD4+ cell count of 67 cells/µL had a median gain of 297 
cells/µL after 12 months on treatment(78). Reporting longer term outcomes in 
Ndlovu cohort, 87% of patients had good immunologic responses over two to four 
years(58). These studies provide evidence that ART is effective even when patients 
start treatment with severely compromised immune systems. 
 
2.4.5.2   Conclusion 
In general, despite poor baseline immunologic status, patients in these cohorts 
appear to have had good immunologic responses on ART, sustained over three 
years. Women had higher baseline CD4+ cell counts and slightly better immunologic 
responses.  
 
2.4.6 Mortality among patients transferred and lost from ART  
As ART programs continue to scale-up, it is essential that sites transfer patients 
efficiently to ensure uninterrupted linkage to care for optimal outcomes. Patients 
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have been transferred between ART facilities in South Africa for some years yet 
almost nothing is known about their outcomes after TFO. Indeed only one paper 
specifically explored TFO as an outcome (105) while most papers simply reported 
the proportion TFO. In Gugulethu cohort, 13% were TFO over seven years and the 
probability of TFO increased with each successive year of enrollment. The IeDEA-SA 
study reported a range in the proportions TFO and increased mortality directly after 
TFO and LTF compared with patients retained(62). Excluding this elevated mortality, 
the risk of death was similar in patients TFO and retained, but LTF patients had 
three times the mortality of those retained in care.  
 
2.4.6.1   Definition of transfer out 
Studies reported TFO as recorded by sites(63). Generally TFO was regarded as 
different from referral, which could include up-referral to a higher level of care for 
patients who require more specialized management and down-referral of patients 
who are stable on ART and whose treatment could be managed with less expertise. 
As these groups of patients are very different, outcomes of such patients could be 
expected to differ. In the IeDEA-SA cohorts patients were TFO for convenience, 
relocation to another geographic area or at the patient’s request, reason unknown. 
Patients were regarded as TFO from Hlabisa rural cohort if they had formally 
transferred care to another facility(75).  
 
2.4.6.2   Estimates of transfer out 
On average about 10% of patients had TFO over four years(70) or longer periods of 
follow-up(63,66). The lowest proportion was reported by Hlabisa rural cohort 
(6%)(75) while in Gugulethu cohort 13% had TFO over seven years(105). In addition 
the probability of being transferred by one year on ART increased substantially from 
1% to 9% among patients enrolled in 2002-2004 compared with 2009, with an 




2.4.6.3   Analytic approach to transfer out 
Most studies censor patients’ observation time at the date of TFO(55,63,66) or at 
the date of last clinic visit(75). This analytic approach assumes implicitly that 
mortality after TFO is similar to mortality among patients who are retained in care. 
If this is not the case, differential outcomes after TFO may bias mortality estimates 
on ART(62). The IeDEA-SA study was undertaken in response to the lack of literature 
on TFO and outcomes thereafter(62). In this study, the mortality hazard was three 
times higher among TFOs than among patients retained (aHR 3.11, 95% CI 2.42-
3.99). Excluding deaths within three months after TFO, the mortality hazard was 
comparable in TFOs and patients retained (aHR 0.75, 95% CI 0.54-1.03). In these 
cohorts, the low incidence of TFO and subsequent death meant that censoring TFOs 
did not bias mortality estimates. However in cohorts which TFO a large proportion 




This literature review has identified one of the major gaps in our understanding of 
ART services. With poor monitoring systems, little is known about mortality after 
TFO compared with patients retained at the site of ART initiation. Future cohort 
analyses should explicitly consider the proportions TFO and mortality event rates 
when exploring whether their estimates are biased.  
 
2.4.7  Age in ART programs  
This review found that although most studies report age as a baseline covariate, 
little is known about its specific effect in ART programs in South Africa. Both HIV 
and ART impact on the body’s aging process, appearing to mimic the effects of 
natural aging(106-110), possibly through acceleration (hastening premature aging) 
or accentuation (increasing the incidence of morbid co-infections)(106). This 
accelerated or accentuated aging is compounded by long-term toxicity of ART and 
interactions with co-medications for other age-related conditions. In recent years it 
has been suggested that aging may occur faster with AIDS in Africa(111) and that 
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ART may change the age composition of the HIV epidemic in sub-Saharan 
Africa(112). Despite the importance of age in ART programs, this review identified 
only two papers explicitly assessing its effect(113,114).  Further research is needed 
to understand and plan for the impact of age on ART outcomes. 
 
2.4.7.1    Definition of age 
A striking feature of the literature reviewed on age and ART is that most 
epidemiologic measures related to ART use end at 49 years of age. Surprisingly, 
there is also no universal definition of ‘old’, ‘older’ or ‘elderly’. The United Nations 
defines older as being older than 60 years, based on retirement ages in most 
developed countries. However, as most old persons in sub-Saharan Africa live in 
rural areas and do not work in formal sector employment, the World Health 
Organization (WHO) has accepted ≥50 years as a working definition for the 
Minimum Data Set Project on Ageing(115). 
 
2.4.7.2    HIV prevalence and ART initiation among older individuals 
HIV prevalence in older ages is generally underestimated. HIV prevalence estimates 
are derived from antenatal clinic surveillance (limited to women of child-bearing 
age), nationally representative household surveys limited to individuals <50 years 
with a few unrepresentative samples of men up to 60 years and targeted surveys 
within specific groups. In the absence of data on older individuals, Negin et al 
reported the most conservative estimates of approximately 7% in patients aged 55-
59 years and 3% in those aged 60-64 years(116). The 2012 South African Household 
Survey reported higher levels, notably 10% among females aged 55-59  years(117). 
The highest estimates were from two rural demographic surveillance sites. In 
Hlabisa, older prevalence peaked at ages 50-54 years (30% vs. 17%, men vs. 
women)(118). In the Agincourt rural site, peak prevalence occurred later and was 
higher than in Hlabisa: in patients 55-59 years, prevalence peaked at 27% for 
females and 35% for males(119). The study also documented prevalence above 10% 
through to 70 years of age and even reported prevalence among individuals over 80 
years old. These results suggest that there may be a high burden of undiagnosed 
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HIV in older individuals. Information on ART initiation among older adults is similarly 
scarce. The 2012 National HIV Survey estimated that 1.6 million adults 15-49 years 
old had ever initiated ART, but did not report any statistics for individuals ≥50 
older(120). Given the aging of the world, and in particular the aging of the HIV 
epidemic, it is essential that epidemiologic and ART data are collected on older 
individuals. 
 
2.4.7.3    Outcomes of older individuals on ART  
Prior to ART, the two major determinants of survival in Europe, North America and 
Australia were age at, and time since, seroconversion(121). In recent years 
numerous papers have focused on ART outcomes among older individuals in 
developed countries. Although this review will not cover these papers, it may be 
useful to have a sense of their scope. Broadly these articles explore the long-term 
impact of both HIV and ART on the body’s natural aging process, the additional 
burden of co-morbidities common with increasing age as well as opportunistic 
infections common with HIV, long-term toxicities of ART and potential interactions 













Figure 2.2.  Among patients who successfully suppress HIV, a range of factors may 
be causally associated with premature development of aging-related complications 
Adapted with permission from:  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity,  
Steven G Deeks & Andrew N Phillips, BMJ 2009; 338:a3172 
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whether HIV and ART accelerate or accentuate the aging process i.e. whether the 
aging process occurs faster or co-morbidities are more frequent(122). (See also 
Supplementary Figures S2.1 and S2.2, acceleration and accentuation.)  
 
Within South Africa, age is routinely reported as an explanatory variable. Two 
published studies and one in press have explored the issue in more 
depth(60,113,114). In Hlabisa rural cohort, 10% of patients on ART were older than 
50 years of age with an overall mortality rate of 9/100 pyrs compared with 6/100 
pyrs among 16-24 year old patients(114). After one year on treatment, there was no 
significant difference in mortality rates by age. Immunologic response was poorer 
among older patients. Despite higher baseline immunologic status in older patients, 
the proportion who failed to increase ≥50 cells/µL in the first six months was 
highest in those aged ≥50 years (20 vs. 11% in 16-24 year olds). Conversely virologic 
response was better in older than young patients (90 vs. 82%). Themba Lethu also 
reported poorer ART outcomes with increasing age(113). There was a dose 
response in the impact of age on mortality and after twenty four months on ART. 
Patients aged 60 years and older had nearly twice the adjusted hazard of patients 
18-29 years old (aHR 1.74, 95% CI 1.00-3.03). In contrast the risk of LTF decreased 
with age. As was reported in Hlabisa, immunologic responses were poorer and 
virologic responses better in older than younger patients.  
 
Chapter 6 is an attempt to address the current gap in the literature on age in ART 
programs in South Africa(60). In a study of over 80,000 patients, increasing 
proportions of older patients started ART and were retained in care each successive 
year of enrollment. Mortality increased with age at enrollment up to two years of 
ART, after which only patients 50 years or older at enrollment had an increased risk 
compared with patients 16-29 years. Baseline immunologic status was similar across 
all ages, and modified the effect of age on mortality. Over time, immunologic 






There is a surprising dearth of studies on the effect of age in ART programs in South 
Africa. Estimates of prevalence on older individuals are variable and epidemiologic 
measures generally stop at 50 years of age. Mortality increases with age on ART up 
to two years.  
 
2.4.8 Gender in ART programs  
Gender differences in access to and outcomes on ART appear to be context-specific. 
Studies from developed countries document poorer access and outcomes for 
women, while those from Southern Africa report the same for men. Differences in 
patterns of health may be attributed to sex or gender, i.e. biological influences or  
social factors which may be different for men and women. Given the numerous 
ways in which biologic and social factors overlap, this review uses the term gender 
to encompass both. As there are few publications on gender and ART in South 
Africa, key studies and reviews from elsewhere have been included. 
 
2.4.8.1    Gender and access to ART 
Women have had better access to ART than men in Southern Africa. In 2007, Muula 
et al reported that disproportionately more women than men were accessing ART 
in Southern Africa, even after taking into account the slightly higher prevalence in 
women(123). In this review, 60-70% of patients were female. This is in line with 
results from a meta-analysis of twenty-three African cohort studies which reported 
a pooled proportion of 35% of men receiving ART(124). It has been suggested that 
men might be the ‘losers of the antiretroviral treatment scale-up’(125) while others 
have argued that there is a blindness towards men’s health, particularly in ART 
programs(47,50,63).  
 
Three studies enrolled more male than female patients. Two studies with 
predominantly male enrollment were undertaken in workplace programs for male 
miners. The third study took place in two KwaZulu hospitals and reported almost 
equal proportions male and female on ART(67). Patients in this study were charged 
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a subsidized fee for services. As unemployment is higher among women than men 
in South Africa(126), having to pay for services may have restricted women’s access 
in this study. Notably, despite almost equal gender balance in enrollment, men 
were still less likely than women to start ART. 
 
In a range of studies from resource-constrained settings, women started ART at 
younger ages and with less advanced HIV infection than men. The IeDEA-SA 
collaboration confirmed these findings(63). Women had a median age of 33 vs. 38 
years, higher baseline CD4+ cell counts (110 vs. 85 cells/µL) and a smaller 
proportion in WHO stages III/IV (77% vs. 86%) than men.  These results conflict with 
review findings that men in the USA and Europe initiated ART at an earlier stage of 
infection than women(127), suggesting that gender differences in access to ART 
may be context-specific. 
 
2.4.8.2  Gender and mortality on ART 
In South Africa, men had higher mortality on ART than women. Two studies 
specifically explored the impact of gender on ART outcomes(63,128). In the IeDEA-
SA analysis, men were 31% more likely to die than women over 36 months on 
ART(63). Although the hazard ratios for the site of ART initiation ranged from aHR 
1.15 to 1.68, male mortality was consistently higher in all eight cohorts. After 
adjusting for men’s later initiation on ART, the observed gender difference in 
mortality persisted and appeared likely due to gender differences in mortality in the 
South African population unrelated to HIV/AIDS or ART. Even within a virally 
suppressed group of patients, men had higher mortality and poorer immune 
responses than women(128).  
 
2.4.8.3  Conclusion 
There is a dearth of studies on gender and ART in South Africa. This review found 
that disproportionately fewer men than women access ART in South Africa. Men 
start ART at older ages and with more advanced HIV disease than women and their 
immunologic responses are poorer. Gender differences at enrollment account for 
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some of the increased mortality among men. However men’s increased mortality on 
ART may also reflect men’s elevated mortality risk regardless of HIV and ART. There 
is a need for a greater focus on men’s access to, and outcomes on, ART. 
 
2.5 Discussion 
The literature reflects the evolution of our knowledge of ART cohorts and cohort 
analysis. Studies track the remarkable expansion of antiretroviral services in South 
Africa over ten years from a series of small, closely-managed pilot sites to the 
largest ART program worldwide. Early outcomes are comparable with those of 
patients initiating ART at low CD4+ cell counts in the developed world. From 2004 
onwards, there are massive increases in enrollment, with good outcomes up to 
seven years after ART initiation. High early mortality in the first few months on ART 
reflects the burden of untreated HIV in the community. After this peak, mortality 
drops steeply to approximately 10%, with corrected mortality about twice this. 
Immunologic and virologic responses are good. One of the main challenges to 
program effectiveness is LTF, which increases with each calendar year and with 
duration on ART.  In general women have better access to, and outcomes on, ART 
than men. Only one study explicitly addresses the outcomes of patients TFO and 
LTF, highlighting a clear gap in the literature. Aging and male gender are associated 
with poorer outcomes on ART and are also under-researched in South Africa.  
 
This review also highlights a number of cross-cutting themes in the literature which 
impact on enrollment and outcomes on ART. These include the variability in 
definition and measurement of outcomes, the challenge of missing data, the 
location of ART services (rural vs. urban), public compared with private ART 





2.5.1 Definition and measurement 
Variability in the definition and measurement of outcomes impacts on estimates 
and renders comparisons within and between programs difficult. For example, 
mortality was either observed (site-recorded) or corrected, which was about twice 
observed mortality. Thus a comparison between programs that estimate or report 
mortality in different ways might be meaningless. In another example, LTF was 
defined as anything from 30 to 400 days late for a visit. In the study, redefining as 
LTF those patients who had interrupted laboratory monitoring but subsequently 
returned to care would have increased the LTF proportion from 17-28%, a 
considerable difference. The lack of standardized measures hampers the evaluation 
of program effectiveness.  
 
2.5.2 Missing data 
Missing data pose a challenge in the analysis and interpretation of HIV 
observational data. Data which are not missing at random may bias estimates. In 
the light of this, it was surprising that most of the studies under review did not 
report the proportion of missing values on important covariates as well as missing 
outcomes. In particular, accurate ascertainment of deaths is a major challenge in 
the analysis of routine data, particularly in programs with high rates of LTF.  
 
2.5.3 Location of ART services 
This review found that the location of ART services impacted on patients outcomes. 
The lowest LTF and highest retention of patients on ART was reported from rural 
programs. There are several possible explanations for this finding. Both mortality 
ascertainment and retention may be better in rural areas due to the existence of 
strong community networks. If mortality ascertainment is better, there would be 
less misclassified mortality and consequently lower levels of LTF. Indeed some rural 
cohorts reported site-observed mortality on a par with corrected mortality. Finally, 
data collection may be better in rural sites, particularly the DHSS sites with annual 
community surveys. For example rural cohorts reported far higher HIV prevalence in 
older age groups than any other study and these estimates may be more accurate 
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than those from population-level surveys. Improved patient outcomes in some rural 
compared with urban areas may be due to improved community support as well as 
improved ascertainment of vital status. 
 
2.5.4 Public vs. private 
Although a large number of individuals have started ART through the private sector, 
few studies report on outcomes. The outcomes of private patients might plausibly 
be better than outcomes of patients accessing public sector ART as private patients 
access treatment with less advanced HIV disease and may receive more 




In conclusion, this review has found evidence of a successful, rapidly expanding ART 
program in South Africa with good outcomes sustained over seven years. Studies in 
the early years focused on proving feasibility and demonstrating similar outcomes 
among patients in care compared with developed countries. Later studies assessed 
short- and long-term outcomes of large numbers of patients on ART.  
 
This review identified a number of gaps in the literature including the impact of 
gender and aging on outcomes and mortality among patients TFO and LTF from 
ART. Both gender and age impact on access to treatment as well as outcomes on 
ART. The thesis attempts to address these gaps in the form of chapters focusing 
specifically on these issues. However ongoing research is needed to understand 
how gender and age impact on long-term outcomes of ART. Mortality after TFO and 







Reprinted with permission from: Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the 
United States. An Intern Med 2010, 153(7):452-460. 
 
Supplementary Figure S2.1.  Hypothetical examples of age distributions of cancers in the 
AIDS and general populations. (A) Accentuated; cancer occurs at the same ages but more 
often among HIV-infected participants than among HIV-uninfected comparators. (B) 
Accelerated and accentuated: cancer occurs younger among HIV-infected participants 
compared with HIV-uninfected comparators and there are more cancer events.
 49 
 
Reprinted with permission from: Guaraldi G et al. Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population. Clin Infect Dis. 2011;53:1120-1126 
 
Supplementary Figure S2.2.  Comparative risk of hypertension, diabetes mellitus, renal failure, cardiovascular disease, and fracture, by age, among 
patients versus controls. Solid line: HIV-positive individuals, dotted line: age-matched HIV-negative controls 
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Chapter 3: 
Monitoring the South African National 
Antiretroviral Treatment Program, 2003-2007 
 
 
Cornell M, Technau K, Fairall L, Wood R, Moultrie H, Van Cutsem G, Giddy J, Mohapi 
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To introduce the combined South African cohorts of the International 
epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) 
collaboration as reflecting the South African national antiretroviral 
treatment (ART) program; to characterize patients accessing these services; 
and to describe changes in services and patients from 2003 to 2007. 
 
Design and setting 
Multi-cohort study of eleven ART programs in Gauteng, Western Cape, Free 
State and KwaZulu-Natal.  
 
Subjects 
Adults and children (<16 years old) who initiated ART with three or more 
antiretroviral drugs before 2008. 
 
Results 
Most sites were offering free treatment to adults and children in the public 
sector, ranging from 264 to 17,835 patients per site. Among 45,383 adults 
and 6,198 children combined, median age (interquartile range) was 35 years 
and 43 months (15-83), respectively. Of adults, 68% were female. The 
median CD4+ cell count (IQR) was 102 cells/µl (44-164) and was lower 
among males than females, 86 cells/µl (34-150) vs. 110 cells/µl (50-169), 
p<0.001. Median CD4% among children was 12% (7-18). Between 2003 and 
2007, enrollment increased 11-fold in adults and 3-fold in children. Median 
CD4+ count at enrollment increased for all adults (67-111 cells/µl, p<0.001) 
and for those in WHO stage IV (39-89 cells/µl, p<0.001). Among children 




IeDEA-SA provides a unique opportunity to report on the national ART 
program. The study describes dramatically increased enrollment over time. 
Late diagnosis and ART initiation, especially of men and children, need 
attention. Investment in sentinel sites will ensure good individual-level data 





The World Health Organization (WHO) estimated that in 2007, 9.7 million people in 
low- and middle-income countries needed antiretroviral treatment (ART)(129), 9% 
of whom were living in South Africa(130). By the end of 2007, the South African 
DoH reported that 371,731 people had initiated highly active antiretroviral therapy 
(HAART)(130), making it the largest ART program in the world(129). As the public 
health system has only provided ART since 2004, this has involved a massive scale-
up of services within a comparatively short space of time.  
 
In the context of such an ambitious undertaking, trends in enrollment and key 
outcomes must be understood in order to plan for the changing needs of health 
services and patients.  Monitoring is a major challenge to effective delivery of ART 
at a national level(130), and it becomes increasingly important as the continued 
scale-up of ART creates a tension between service provision and collecting good 
data.  
 
The International epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa 
collaboration (IeDEA-SA) has assembled a collaborative individualized dataset of 
children and adults starting ART at sites in South Africa. Numerically the 
collaboration represents 20% of all children and 10% of all adults entering the public 
sector roll-out program. This provides a unique opportunity to report in detail, 
based on individual patient data, on a subset of the national ART program. 
 
This paper aims to introduce the South African cohorts participating in IeDEA as a 
collaboration that reflects the South African national ART program, to characterize 
the children and adults accessing these services, and to describe changes in services 
and patients over the past five years.  
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3.2  Background and setting 
3.2.1 The IeDEA collaboration 
IeDEA is an international collaboration of seven regional data centers funded by the 
National Institutes of Health (NIH). It was established to pool data across numerous 
cohorts of patients on ART, creating large datasets to address research questions 
that cannot be answered within single cohorts. 
 
3.2.2 IeDEA Southern Africa  
IeDEA-SA is the regional cohort collaboration of southern Africa. Since its 
establishment in 2006, 22 sites have joined the collaboration. The current database 
includes cohorts from South Africa, Zimbabwe, Mozambique, Zambia, Malawi and 
Botswana. Some countries have more than one cohort participating, providing an 
opportunity to describe characteristics and outcomes at a national level, in the 
absence of good routine national monitoring systems. In South Africa, eleven large 
sites from four provinces have joined the collaboration. 
 
3.2.3 The South African ART program 
Since the start of the national ART roll-out program in 2004, the South African 
guidelines for initiation of ART(31) have recommended treatment for adults with 
CD4+ cell counts <200 cells/µl or WHO stage IV illness except for extrapulmonary 
tuberculosis, who are assessed to be willing and ready to take and adhere to ART. 
Before this, most sites offering ART followed similar criteria, based on the 2002 
WHO guidelines(10). First-line therapy in ART-naïve adults, unless contraindicated, 
is stavudine (d4T), lamivudine (3TC) and efavirenz (EFV) or nevirapine (NVP). 
Women of child-bearing age who are unable to guarantee reliable contraception 
should receive NVP instead of EFV. Patients receive monthly medication and are 
seen by a doctor at four, eight and twelve weeks and three-monthly thereafter if 
well. CD4+ count and viral load are measured six-monthly. Patients with a 
detectable viral load (>400 copies/µl) receive a stepped-up adherence package. If 
their viral load persistently exceeds 5,000 copies/µl despite adherence support, 
they may be switched to second-line therapy. Second-line therapy comprises 
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zidovudine (AZT), didanosine (ddI) and lopinavir/ritonavir (LPV/r). Drug 
substitutions are also made if patients experience toxicity on first-line therapy. 
 
The 2004 South African pediatric guidelines(31) recommend ART initiation based on 
a confirmed HIV diagnosis (HIV DNA polymerase chain reaction (PCR) testing if the 
child is <18 months of age) and one of the following criteria: (i) recurrent 
hospitalizations (more than two admissions/year) or prolonged hospitalization 
(exceeding four weeks) for HIV-related illness; (ii) WHO stage III/IV disease; or (iii) 
CD4 <20% if under 18 months or <15% for older children. Based on the new WHO 
staging(131), most pediatric sites changed from the three- to the four-stage system 
towards the end of 2004, which may have impacted to some extent on the pediatric 
staging data in this dataset. Pediatric first-line ART for children from six months to 
three years is d4T, 3TC and LPV/r. For children older than three years who weigh 
above 10 kg, EFV replaces LPV/r. 
 
3.3  Methods  
3.3.1 Study population 
Most participating ‘sites’ comprise single clinics in urban or peri-urban areas. The 
definition of site is broad: one site encompasses three clinics, and another includes 
all the facilities within an entire province, from primary to tertiary level. The study 
included data on all adults and children (<16 years old) with documented age, 
gender and ART start date who initiated ART with at least three antiretrovirals 
before 2008. 
 
3.3.2 Data collection and management 
The study utilized data that are routinely collected by sites. All sites have current 
ethics committee approval for contribution of their data to IeDEA analyses. The 
data were all anonymized before transfer to the data center. Sites submitted data 
during the course of 2007 and early 2008. Data on program-level characteristics 
were collected through site assessment questionnaires.  
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3.3.3  Data analysis 
Cleaning, coding and analysis of data were done in Intercooled STATA 10.0 for 
Windows (STATA Corporation, College Station, TX). Continuous variables were 
described by medians and interquartile ranges and categorical variables as 
proportions. Temporal trends were tested using the Kruskal-Wallis test (continuous 
variables) and the chi-square test (categorical variables). 
 
3.4 Results 
3.4.1 Program-level characteristics 
Seven of the sites offer services to children and adults, either in separate or 
combined clinics (Table 3.1); one site treats children and pregnant women and the 
other sites treat children or adults exclusively. Nine sites are public programs 
funded largely by the DoH with strong research partnerships. One site is funded 
entirely by donor funding and another is a not-for-profit hospital that receives a 
DoH subsidy and external funding for research projects. The study utilized data on 
adult patients from eight sites, contributing between 642 and 17,835 patients. 
Seven sites contributed data on pediatric patients, contributing between 264 and 
2,226 patients.  
 
Treatment was free to all patients except those attending the state-subsidized 
hospital, who were charged a small inclusive monthly co-payment. Although most 
sites reported active follow-up of patients, follow-up of defaulting patients was 
generally limited owing to resource constraints. Patients were referred for 
treatment primarily from clinics, hospital wards and other medical facilities. 
Treatment readiness and patient preparation was fairly consistent across sites, 
involving a baseline psychosocial assessment and three individual or group 
education sessions over three consecutive weeks. This process could be fast-tracked 
if the patient was pregnant or required immediate treatment for medical reasons. 
Patients were encouraged to disclose their HIV status and to have ‘treatment 
buddies’, and were referred to support groups where available.  
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All levels 1,088 
children 
Public & research Children & 
pregnant women 
2002 Free No Hospital wards 
         Free State provincial 
roll-out program 
All levels  17,835 adults Public  Adults & children, 
mostly combined  




Clinics, TB, antenatal 
         Gugulethu,  
Cape Town 
Primary 2,924 adults 
264 children 
Public & research  Adults & children, 
separate clinics 
2002 Free Active tracing  Other facilities; clinics: 
PMTCT, TB  
         Harriet Shezi clinic, 
Johannesburg 
All levels 2,226 
children 
Public & research Children only 2002 Free Active tracing  Hospital wards 
         Khayelitsha, Cape 
Town 
Primary 8,119 adults 
662 children 
Public & research  Adults & children, 
combined clinic 
2001 Free Phone call 
only 
Clinics: PMTCT, TB; other 
facilities 
         Masiphumelele,  
Cape Town 
Primary  642 adults 
 
Public & research  Adults & children 2003 Free Active tracing Clinics: PMTCT, STIs, TB; 
other facilities 
         McCord Hospital, 
Durban 
 





Adults & children, 
combined clinic 
1999 (drug trial); 2000  




Active tracing  Clinics: PMTCT, TB; other 
medical facilities 




Tertiary 948 adults Research Adults & children, 
combined clinics 
2004 with some trials <2004 Free Active tracing  Wellness program for 
people with HIV  
         Red Cross Children’s 
Hospital, Cape Town 
Tertiary 859 children Public & research Children only 2001 Free Active tracing  Hospital wards  
         Themba Lethu, 
Johannesburg 
Tertiary 9,250 adults Public & research  Adults  2004 Free Active tracing  Other medical facilities 
         Tygerberg Hospital, 
Cape Town 
Tertiary 1,504 adults 
684 children 
Public & research  Adults & children, 
separate clinics 
2004, with some trials 
<2004 
Free Active tracing  Other medical facilities; 
clinics: PMTCT, TB 
* Active tracing implies dedicated resources to undertake one or more of the following: telephone call, home follow-up, physician’s report and/or data linkage. 
 LTF = lost to follow-up;  PMTCT = prevention of mother-to-child-transmission program;  TB = tuberculosis; STIs: sexually transmitted infections.
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3.4.2 Characteristics of patients 
The analysis included 45,383 adults and 6,198 children. The median age among 
adults was 35 years (interquartile range (IQR) 30-41) and among children 43 months 
(IQR 15-83) (Table 3.2). Of children, 21% (N=1,315) were younger than one year old 
and 39% (N=2,411) were aged five years and older. Adult patients were 
predominantly female (68%, N=30,684). In contrast, the gender balance of children 
was even. 
 
Among adults, the median CD4+ cell count was 102 cells/µl (IQR 44-164). The 
median CD4+ cell count was lower among adult males than females (86 vs. 110 
cells/µl, p<0.001). Among patients with baseline CD4+ cell counts, the majority 
(89%, N=30,105) commenced therapy with CD4+ cell counts below 200/µl. A total of 
9,363 adult patients (28%) initiated ART with CD4+ cell counts <50 cells/µl.  
 
Among children, the median CD4% was 12% (IQR 7-18), and 65% of pediatric 
patients (N=3,004) initiated therapy with CD4% <15%. In cohorts reporting WHO 
staging (28% of adults, N=12,763 and 67% of children, N=4,120) most patients had 
advanced HIV disease (WHO stage III or IV).  
 
In line with the national protocol, the majority of adult patients (88%, N=31,852) 
started on a regimen containing d4T and 3TC as the two nucleoside reverse 
transcriptase inhibitors (NRTIs); 68% (N=24,734) of adults and 53% (N=2,846) of 
children started on a regimen containing EFV. Data on previous ART and prevention 
of mother-to-child (PMTCT) exposure were limited. Where previous ART exposure 
was recorded, most adults (93%, N=22,062) and children (96%, N=4,100) were 
reportedly ART-naïve. In cohorts that reported PMTCT exposure, 13% (N=696) of 
women and 25% of children (N=617) were known to have been exposed. Reliable 
data on tuberculosis (TB) at ART initiation were available from two adult and two 
pediatric cohorts. Among these adult patients, 3,722 (21%) had TB, while the 
proportion among children was slightly higher (32%, N=1,052). Of the three adult 
cohorts that provided pregnancy data (N=8,828 female patients), 7% of female 
patients (N=633) were pregnant at ART initiation. In these cohorts, median CD4+  
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Table 3.2.  Patient characteristics at ART initiation: 45,383 adults and 6,198 children 
followed up in 11 IeDEA-SA sites in South Africa, 2003-2007. 
Characteristic 





      Adults (years), median (IQR) 
      Children (months), median (IQR) 
Age categories, N (%) 
      <12 months 
      12-23 months 
      24-59 months 











2,411 (39)  
Gender 





Absolute CD4+ cell count (cells/μl) 
    All adults, median (IQR) 
    Men 
    Women 
CD4+ cell count categories, N (%) 
      <50                  
      50 - 199               
      ≥200 






















      Median (IQR)   
CD4% categories, N(%)  
      <15% 
      15 - 19% 









WHO stage, N (%) 
      I  
      II 
      III  

















HIV RNA level (log10 copies/ml)  







1st-line ART regimen used, N (%) 
      d4T+3TC+EFV 
      d4T+3TC+NVP 
      AZT+3TC+NVP  
      AZT+3TC+EFV  
      d4T+3TC+KLT
††
 
      d4T+3TC+RTV 



















Previous ART exposure, N (%) 





N=4,262 (69)  
162 (4) 
PMTCT exposure, N (%)  









TB at ART initiation, N (%)  







Pregnant at ART initiation, N (%) 








*   Data from all cohorts; CD4+ cell counts not always provided. 
†   Data from six pediatric cohorts. 
‡    Includes data from four cohorts.  
§    Data from all cohorts; WHO stage not always provided in 
dataset. 
¶    Stages III & IV combined for children. 
ǁ    Data from all cohorts; viral load not always provided in dataset. 
**   Only listed those regimens prescribed to >4% of adult patients. 
††   Includes 209 children on ritonavir and Kaletra. 
‡‡    Data from three cohorts. 
§§    Data from two cohorts. 
¶¶   Data from four cohorts. 
ǁǁ    Data from two cohorts. 
***   Data on female patients from three               
cohorts. 
†††   Data not provided in pediatric datasets. 
 
IQR = interquartile range; TB = tuberculosis. 
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cell count was higher among pregnant women than those who were not pregnant 
(150 vs. 104, p<0.001) and higher among non-pregnant women than men (104 vs. 
80, p<0.001).  
 
3.4.3 Temporal trends 
Table 3.3 shows temporal trends in enrollment, absolute CD4+ cell counts and CD4 
percentages and WHO stage. Over five years, patient numbers increased nearly 11-
fold among adults (from 1,462 to 15,628), and three-fold among children (from 376 
to 1,139). The majority of adults in this analysis (63%, N=28,643) started treatment 
in 2006-2007. Although pediatric enrollment appeared to drop substantially in 
2007, this is probably because data from one of the largest pediatric cohorts were 
not available for the second half of 2007.  
 
There was an increase in overall adult baseline CD4+ cell count, from a median of 67 
cells/µl (IQR 23-134) in 2003 to 111 cells/µl (IQR 49-171; p<0.001) in 2007, although 
the rate of increase declined over the years. Of all the pediatric patients, 3,787 
(61%) were under five years of age. Among these patients, baseline CD4% was 
available for 76% (N=2,884) and median CD4% increased from 12% (IQR 7-18) in 
2004 to 16% (11-23; p<0.001) in 2007. In cohorts that provided data on staging, the 
proportion of adult patients in stage IV at enrollment fell from 50% (N=494) in 2003 
to 27% (N=800) in 2007 (p<0.001). This was mirrored by an increase in median CD4+ 
cell count in this group from 39 cells/µl (IQR 13-93) in 2003 to 89 cells/µl (IQR 40-
162; p<0.001) in 2007. Over time, the availability of baseline CD4+ cell counts 
decreased from 72% to 65%.  
 
3.4.4 Variation between sites  
Tables 3.4 and 3.5 demonstrate some degree of heterogeneity in patient 
characteristics between sites. Median adult age at enrollment ranged from 32 to 36 
years. Baseline median CD4+ cell count ranged from 85 to 121 cells/µl. Within the 
pediatric sites, patients at two exclusively tertiary pediatric hospitals were younger, 
with a greater proportion under one year of age, than those from other sites.  
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   Table 3.3.  Temporal changes in enrollment, baseline immunologic status and availability of baseline laboratory tests. 




Patients enrolled, N (%)                
     Adults   1,462 (3) 5,340 (12) 9,938 (22) 13,015 (29) 15,628 (34)  45,383 (100) 
     Children    376 (6) 1,094 (18) 1,849 (30) 1,740 (28) 1,139 (18)  6,198 (100) 
Baseline CD4+ (cells/µl)         
     All adults N  1,055 4,597 8,476 9,417 10,127  33,672  
  Med. (IQR) 67 (23-134) 86 (38-147) 101 (43-159) 105 (45-168) 111 (49-171) <0.001 102 (44-164) 
         
     Men N  341 1,433 2,726 3,177 3,397  11,074 
  Med. (IQR) 54 (18-123) 74 (33-138) 87 (33-149) 88 (34-154) 93 (36-154) <0.001 86 (34-150) 
         
     Women N 714 3,164 5,750 6,240 6,730  22,598  
  Med. (IQR) 74 (26-138) 91 (41-150) 107 (48-164) 115 (52-174) 120 (56-179) <0.001 110 (50-169) 
         
Children <5 years N   638
*
 1,160 1,091 684  3,787 
    CD4% Med. (IQR)   12 (7-18) 12 (8-18) 14 (9-20) 16 (11-23) <0.001 13 (9-19) 
         
Adults in stage IV N (%) 494 (50) 708 (39) 998 (31) 999 (27) 800 (27)  3,999 (33) 
  Med. CD4+ count,   
cells/µl (IQR) 
39 (13-93) 54 (20-115) 68 (24-138) 74 (29-147) 89 (40-162) <0.001  66 (25-236) 
         
Availability of 
laboratory tests at 
baseline, % 
CD4+ cell count 
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    *In this table, all children younger than five years old before 2004 were combined owing to low numbers and erratic enrollment in different sites. 
    Med. = median; IQR = interquartile range.
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McCord PHRU Themba Lethu Tygerberg 
Adults enrolled, N (%) 17,835 (39) 2,924 (6) 8,119 (18) 642 (1) 3,575 (8) 948 (2) 9,836 (22) 1,504 (3) 
         
Age (years), med. (IQR) 36 (31-43) 33 (29-39) 33 (28-39) 32 (27-37) 35 (30-41) 34 (30-40) 35 (30-41) 34 (29-41) 
         
CD4+ cell count 
 (cells/µl), med. (IQR) 
114 (55-167) 101 (48-158) 101 (45-165) 121 (46-193) 85 (31-152) 108 (43-171) 88 (32-158) 116 (52-174) 
         
Patients with CD4+ cell count 
<50 cells/µl, N (%) 
2,175 (22) 631 (25) 1,932 (27) 152 (26) 1,025 (35) 197 (26) 2,966 (34) 284 (24) 




Table 3.5.  Pediatric patient characteristics by cohort. 
Cohort Empilweni Gugulethu Harriet Shezi Khayelitsha McCord Red Cross Tygerberg 
Children enrolled, N (%) 1,088 (18) 264 (4) 2,226 (36) 662 (11) 415 (7) 859 (14) 684 (11) 
        
Age (months), med. (IQR) 44 (16-85) 47 (19-82) 56 (22-90) 42 (20-74) 72 (33-109) 16 (6-50) 22 (9-57) 
        
Children <1 year, N (%) 216 (20) 42 (16) 331 (15) 97 (15) 31 (7) 361 (42) 237 (35) 
        
Children <5 years, CD4%, med. (IQR) 14 (9-19) - 12 (7-17) 14 (10-20) 13 (9-17) 14 (9-21) 16 (11-23) 
        
Children <5 years with CD4 <15%, N (%) 243 (54) - 707 (66) 145 (52) 30 (58) 367 (56) 168 (44) 
med. = median; IQR = interquartile range. 
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3.5 Discussion 
3.5.1 IeDEA-SA: the South African collaborative cohort 
This paper introduces the South African sites of IeDEA-SA, a dynamic collaboration 
that offers an excellent opportunity to provide information on the South African 
ART program. It describes the baseline characteristics and temporal trends of the 
largest national cohort yet assembled of adults and children starting ART. The 
collaborative cohort is representative of patients accessing ART through the 
national program in large urban centers, which constitute the largest part of this 
program. It is constrained by the absence of cohorts from some provinces and by 
limited participation from rural sites. Many of the sites linked to research programs 
may also have more capacity for monitoring than other sites in the national 
program. The cohorts included in this collaboration have dramatically increased 
enrollment in line with the national roll-out of treatment, and demonstrate the 
same uniformity of clinical practice and patient preparation recommended in 
national guidelines.  
 
3.5.2 Evidence of national scale-up 
The massive increase in enrollment over time, especially over the last two years, 
provides strong evidence of the successful scale-up of ART in South Africa. Patients 
are enrolling with less advanced disease in urban sites: among patients with a 
baseline measure, there has been a trend towards higher CD4+ cell counts at 
initiation, and the proportion of patients in WHO stage IV has decreased.  
 
3.5.3 Late diagnosis and initiation of treatment 
Patients in this combined cohort were still being diagnosed later than 
recommended in national and international guidelines, increasing their risk of early 
mortality on treatment(132). In our collaborative cohort, more than 25% of patients 
started with a CD4+ cell count <50 cells/µl, and similarly with stage IV disease. 
Earlier diagnosis and initiation of ART would reduce the risk of morbidity and 
mortality among these patients, especially for men, who present with more 
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The pediatric component of this collaboration is to our knowledge the largest 
national cohort of children on ART in the world. While the successful enrollment of 
so many children on ART is encouraging, limited success in preventing vertical 
transmission of HIV remains a major concern.  
 
In addition, children also started ART later than is now internationally 
recommended(129). South African data have demonstrated the high risk of disease 
progression and mortality in the first year of life(93,133). The low proportion 
enrolled in the first year of life in this cohort, and high numbers of children with 
advanced disease, suggest massive under-diagnosis and missed treatment 
opportunities, and an enormous hidden burden of morbidity and mortality among 
children.  
 
3.5.5 First-line regimen 
Unlike many countries in southern Africa, in which the first-line regimen is a fixed-
dose combination of d4T, 3TC and NVP, EFV use predominates in adults on 
treatment in South Africa in spite of the higher cost of EFV-based regimens. 
Analyses in South Africa have, however, reported inferior virological outcomes in 
patients on NVP-containing compared with EFV-containing regimens(134,135). For 
many adults starting ART, concomitant TB at the time of starting ART precludes the 
use of NVP. In addition, the greater toxicity profile of NVP compared with EFV has 
discouraged many clinicians from using it as first-line treatment. The use of 
protease inhibitors (PIs) versus non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) in children in this analysis is in line with the proportions of children 
starting ART above and below three years of age.  
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3.5.6 Data challenges and the need for sentinel surveillance 
Although South Africa has implemented the largest number of individuals on 
treatment in the world, the ability to monitor the program closely has not kept pace 
with this expansion(130). The lack of complete data on baseline characteristics in 
these cohorts - among the best-monitored ART programs nationally - provides 
insight into the pressures facing the public health system.  
 
Numerous challenges face cohort analysis of ART programs in developing countries, 
chiefly the need to balance service provision and the collection of good-quality data 
in the face of rapidly increasing patient numbers. An 11-fold increase in patients 
over five years is bound to result in a corresponding decrease in data quality unless 
substantial resources are provided to support monitoring systems. For health care 
workers, providing access to clinical care is - and should be - the priority. It is 
therefore essential to find ways to avoid overwhelming health care providers and 
prioritizing monitoring over service provision(136). Establishing selected, 
representative sentinel surveillance sites may facilitate the collection of good-
quality individual data on a subset of patients in the national program, thus freeing 
most government sites to continue with simplified aggregate reporting(134).  
 
3.6. Conclusion 
The South African cohorts participating in IeDEA-SA provide a unique opportunity to 
undertake analyses of the national ART program based on individual patient data, 
to complement routine monitoring. This analysis demonstrates the massive scale-up 
in recent years and the improvement in the level of disease severity at ART 
initiation. Earlier diagnosis and enrollment of patients, particularly children and 
men, need to be prioritized. A solid investment in representative sentinel 
surveillance could support a context-appropriate national ART monitoring system. 
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Temporal changes in program outcomes among 
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Little is known about the temporal impact of the rapid scale-up of large ART 
services on program outcomes. We describe patient outcomes (mortality, 
loss to follow-up [LTF] and retention) over time in a network of South 
African ART cohorts.  
 
Design 
Cohort analysis utilizing routinely collected patient data. 
 
Methods 
Analysis included adults initiating ART in eight public sector programs across 
South Africa, 2002-2007. Follow-up was censored at the end of 2008. 
Kaplan-Meier methods were used to estimate time to outcomes, and 




Enrollment (n=44,177, mean age 35 years; 68% female) increased 12-fold 
over five years, with 63% of patients enrolled in the last two years. 12-
month mortality decreased from 9-6% over five years. 12-month LTF 
increased annually from 1% (2002/03) to 13% (2006). Cumulative LTF 
increased with follow-up from 14% at 12 months to 29% at 36 months. With 
each additional year on ART, failure to retain participants was increasingly 
attributable to LTF compared to recorded mortality. At 12 and 36 months 
respectively, 80% and 64% of patients were retained. 
 
Conclusion  
Numbers on ART have increased rapidly in South Africa, but the program has 
experienced deteriorating patient retention over time, particularly due to 
apparent LTF. This may represent true loss to care, but may also reflect 
administrative error and lack of capacity to monitor movements in and out 
of care. New strategies are needed for South Africa and other low- and 
middle-income countries to improve monitoring of outcomes and maximize 




South Africa has the largest antiretroviral therapy (ART) program in the world(129).  
Between 2004 (the start of the national ART program) and 2007, an estimated 
370,000 people initiated treatment in the public sector(137).  But despite the scope 
and rapid growth of this program there are no data on outcomes at a national level. 
The International epidemiologic Databases to Evaluate AIDS collaboration of 
Southern Africa (IeDEA-SA) has assembled a series of HIV treatment cohorts from 
across the country that includes approximately 10% of all adults who initiated public 
sector ART in South Africa by the end of 2007. The aim of this paper is to describe 
trends in mortality, loss to follow-up (LTF) and program retention of these adult 
patients over the first five years of the country’s national ART program.   
 
4.2 Methods 
4.2.1 Study design, population & eligibility criteria 
The South African cohorts of IeDEA-SA have been described in detail elsewhere(64). 
Briefly, the collaboration includes eight adult cohorts providing ambulatory ART 
services located in the four largest provinces in the country (Western Cape, Free 
State, Gauteng and KwaZulu-Natal). This analysis included all HIV-positive adults 
(≥16 years) who initiated ART in these cohorts between 2002 and 2007. 
 
4.2.2 Variables and definitions  
Baseline characteristics included demographics (age, sex), available measures of 
disease severity (CD4+ cell count, WHO stage and viral load) and calendar year of 
ART initiation. Outcome measures were mortality, LTF and program retention. 
Deaths and transfers were defined by active or passive follow-up at site level. 
Patients were defined as LTF if their last patient contact was more than six months 
before the date of closure of the cohort database and were censored at their last 
contact date. Patients who were transferred out were censored at the transfer 
date. For patients who started ART but had no further contact with the clinic, one 
day of follow-up was added to allow their inclusion in survival analyses. Program 
 68 
retention was defined as those who were enrolled and alive (including transfers 
out) at analysis closure. Person-time in the database included patients commencing 
ART from January 2002 until December 2007. Database closure was on or before 31 
December 2008 (with minor variation across cohorts).  
 
4.2.3 Analysis 
Baseline characteristics were described with summary statistics (medians, 
interquartile ranges and proportions). Due to variability in the completeness of 
baseline data, patient numbers are reported for each analysis. Mean age, median 
CD4+ cell count and proportion in WHO Stage IV were calculated by year of 
enrollment. Temporal trends were tested with the nonparametric test for trend 
across continuous variables (age and CD4+ cell count). Differences between 
proportions were tested with the chi-square test. Time to death, LTF and overall 
program retention were analyzed using Kaplan-Meier methods and presented by 
year of enrollment with use of the log rank test for trend of the survivor function.  
 
Separate proportional hazards regression models, stratified by cohort, were used to 
assess crude and adjusted associations between patient characteristics and 
different outcomes. We modeled the proportional hazards of death separately for 
different time periods as the risk factors for death vary, particularly during the first 
year on ART(132,138). The proportional hazards assumption was confirmed using 
Schoenfeld and scaled Schoenfeld residuals. Models were built by adding relevant 
variables with progressively less complete data, to preserve as many observations 
as possible. Data on WHO staging, an important predictive variable, were missing 
for 74% of patients. Consequently, we present two final models (including and 
excluding WHO stage) for each time period. We report findings from the models 
excluding WHO stage, and where WHO staging impacted appreciably on results, we 
report this.  
 
Although the national ART roll-out program started on 1 April 2004, we included a 
small proportion of adults who had received ART through donor-funded programs 
 69 
prior to this date. There were no differences in baseline characteristics between 
patients started in 2002/2003 and those started in 2004, and in a sensitivity analysis 
(not shown) no aspect of the study findings was substantively different when 
patients starting ART in 2002/2003 were excluded. Data were analyzed using STATA 
11.0 (STATA Corporation, College Station, Texas, USA). Two-sided statistical tests 
were used at alpha=0.05.   
 
4.3 Results 
4.3.1  Patient characteristics  
This analysis included 44,177 adults who started ART between 2002 and 2007 
(median age 35 years; 68% female, Table 4.1), contributing a total of 66,434 person-
years of follow-up (median 1.3 years, interquartile range (IQR) 0.6-2.2). Among 
those with CD4+ cell counts at baseline (83%, n=36,549), median CD4+ cell count 
was 103 cells/µL (IQR 45-164), and 27% had a measure <50 cells/µL. The median 
baseline log viral load measure (available on 18,684 participants, 42%), was 4.9 
copies/ml (IQR 4.4-5.4). A total of 11,393 (26%) patients had baseline staging, and 
80% of these (n=9,079) were classified WHO stage III/IV.  
 
4.3.2  Temporal changes in patient characteristics and outcomes 
Enrollment increased each calendar year, from 1,173 in 2002/03 to 14,728 in 2007 
(Table 4.2). The majority of patients were enrolled in the last two years of the 
period under analysis (63%, n=27,833). With each successive year of the program, 
patients were enrolled at older ages and with less advanced HIV disease. Mean age 
increased from 34 years in 2002/03 to 37 years in 2007 (p<0.001). Median CD4+ cell 
count increased from 68 cells/µL in 2002/03 to 113 in 2007 (p<0.001). Over the 
same period, among patients with baseline WHO staging, the proportion of patients 
with Stage IV disease decreased from 50% to 28% (p<0.001).  Between 2002/3 and 
2006, 12-month reported mortality declined from 9% to 6% (p<0.001) (Table 4.2). 
Meanwhile 12-month LTF increased with each calendar year of enrollment, from 1% 
in 2002/03 to 13% in 2006 (p<0.001), and 12-month program retention declined 
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from 90% to 82% over the same period (p<0.001).  The crude effect of calendar year 
persisted over five years of follow-up (Figures 4.1a-c).  
 
 
Table 4.1.  Patient characteristics at ART initiation. 
Characteristic Adults (≥16 years) n=44,177 
Gender, n(%) 44,177 (100) 
      Female 29,904 (68) 
Age, n(%) 44,177 (100) 
      Adults (years), median (IQR) 35 (30-42) 
Age categories, n(%)  
      16-24 2,306 (5) 
      25-34 17,654 (40) 
      35-44 16,177 (37) 
      45+ 8,040 (18) 
Year of initiation, n(%) 44,177 (100) 
      2002 & 2003 1,173 (3) 
      2004 5,262 (12) 
      2005 9,909 (22) 
      2006 13,105 (30) 
      2007 14,728 (33) 
Absolute CD4+ cell count (cell/μL),  n(%) 36,549 (83) 
      All adults, median (IQR) 103 (45-164) 
CD4+ cell count, categorical,  n(%)  
      <50 9,947 (27) 
      50-199 22,703 (62) 
      >=200 3,899 (11) 
HIV RNA level, log10 copies/ml, n(%) 18,684  (42) 
      Median (IQR) 4.9 (4.4-5.4) 
RNA level, categorical, n(%)  
      <=5 Log 10,405 (56) 
      >5  Log 8,279 (44) 
WHO stage, n(%) 11,393 (26) 
      I 979 (9) 
      II 1,335 (12) 
      III 5,463 (48) 
      IV 3,616 (32) 
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Table 4.2.  Baseline characteristics and 12-month outcomes by calendar year of ART 
initiation.  
 YEAR OF ART INITIATION 
 2002/03 2004 2005 2006 2007 
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LTF increased with duration on treatment (Table 4.3, Figure 4.1b) and made an 
increasing contribution to overall patient attrition. At six months on ART, one-third 
of the losses to program were due to mortality: 5% of patients had died while 9% 
were LTF. By 36 months, mortality accounted for one-quarter of patient losses: 10% 
were dead and 30% were LTF. Overall program retention dropped from 86% at six 
months to 71% at 24 months and 64% at 36 months. 
 
4.3.3 Associations with baseline characteristics 
In all time periods, there was a slight increase in the crude and adjusted risk of 
death for older patients (adjusted hazard ratio (aHR) 1.03, 95% CI, 1.02-1.04, Table 
4.4, 12-36 months). There was a strong association between year of enrollment and 
the risk of death on ART. With each successive year of enrollment the risk of 
mortality decreased. The risk of death in the first four months on ART among those 
enrolled in 2007 was 31% lower than in those enrolled in 2002/2003 (aHR 0.69, 95% 




























































Figure 4.1.  Kaplan-Meier plots showing by year of ART initiation, 60-month:  
(a) mortality, (b) loss to follow-up, (c) retention. 
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Table 4.3.  Kaplan-Meier estimates of mortality, loss to follow-up and retention by 




Mortality Loss-to-follow-up Retention 
% (95% CI) % (95% CI) % (95% CI) 
6 months 35,627 (81) 5 (5-5) 9 (9-10) 86 (86-87) 
12 months 26,315 (60) 7 (6-7) 14 (14-15) 80 (80-80) 
18 months 18,788 (43) 8 (7-8) 19 (18-19) 75 (75-75) 
24 months 13,115 (30) 9 (8-9) 22 (22-23) 71 (71-72) 
36 months 5,486 (12) 10 (9-10) 29 (28-29) 64 (64-65) 
48 months 803 (2) 11 (10-11) 33 (32-34) 60 (59-61) 
60 months 185 (0) 13 (11-15) 36 (34-37) 56 (54-58) 
 
 
CD4+ cell count was strongly associated with early mortality on ART in both crude 
and adjusted analyses: in the first four months on ART, patients with CD4+ cell 
counts <50 cells/µL had a six-fold higher risk of mortality than those with ≥200 
cells/µL (aHR 5.85, 95% CI 4.47-7.65, Table 4.4). With longer duration on ART, 
patients with baseline CD4+ cell count <50 cells/µL continued to be at an elevated 
risk of death compared with those above 200 cells/µL: the risk was nearly three-fold 
higher for patients 4-12 months on treatment (aHR 2.83, 95% CI 2.08-3.85) and two-
fold higher for patients 12-36 months on ART (aHR 1.84, 95% CI 1.24-2.71). The 
addition of WHO staging attenuated the association between CD4+ cell count and 
death over all durations on ART, particularly in the group of patients with CD4+ cell 
counts 50-199 cells/µL at baseline.  
 
In crude and multivariable analysis, younger patients were more likely to be LTF 
than older (aHR, 0.99, 95% CI 0.98-0.99, Table 4.5). Year of enrollment strongly 
predicted the risk of LTF in the early and later time periods on ART: the risk of LTF 
increased substantially with each successive year of enrollment and the strength of 
the association persisted after controlling for baseline age and CD4+ cell count. 
After adjustment for these factors, patients enrolled on ART in 2007 had a 12-fold 
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Table 4.4.  Cox’s proportional hazards models of 0-4, 4-12 and 12-36 month mortality by baseline characteristics and year of ART initiation*.  
 0-4 months 4-12 months 12-36 months 
 Univariate Multivariable models Univariate Multivariable models Univariate Multivariable models 














Variables HR (95% CI) aHR (95% CI) aHR (95% CI) HR (95% CI) aHR (95% CI) aHR (95% CI) HR (95% CI) aHR (95% CI) aHR (95% CI) 
Age (years)  1.01 (1.00 -1.02) 1.01 (1.00-1.01) 1.01 (1.00-1.02) 1.02 (1.01-1.02) 1.02 (1.01-1.03) 1.03 (1.01-1.04) 1.03 (1.02-1.04) 1.03 (1.02-1.04) 1.05 (1.03-1.07) 
Year of 
enrollment   
         
       2002/2003 1 1 1 1 1 1 1 1 1 
2004 0.65 (0.50-0.86) 0.62 (0.46-0.82) 0.82 (0.60-1.13) 1.03 (0.70-1.53) 0.89 (0.59-1.35) 0.98 (0.61-1.57) 1.13 (0.78-1.65) 1.03 (0.68-1.57) 1.01 (0.67-1.59) 
2005 0.71 (0.55-0.91) 0.73 (0.56-0.96) 0.70 (0.620-0.96) 0.95 (0.65-1.39) 0.87 (0.58-1.30) 0.85 (0.54-1.33) 0.86 (0.60-1.27) 0.82 (0.54-1.25) 0.73 (0.45-1.20) 
2006 0.56 (0.43-0.72) 0.62 (0.47-0.81) 0.62 (0.45-0.85) 0.83 (0.57-1.22) 0.73 (0.49-1.10) 0.64 (0.40-1.02) 0.69 (0.45-1.05) 0.66 (0.42-1.06) 0.84 (0.23-1.22) 
2007 0.63 (0.49-0.82) 0.69 (0.52-0.91) 0.56 (0.37-0.86) 0.49 (0.32-0.73) 0.47 (0.30-0.72) 1.10 (0.37-3.22) 0.24 (0.11-0.51) 0.25 (0.11-0.57) - 
CD4+ cell count 
(cells/µL)  
         
     ≥200 1 1 1 1 1 1 1 1 1 
     50-199 1.67 (1.27-2.19) 1.64 (1.25-2.16) 0.93 (0.60-1.44) 1.50 (1.11-2.03) 1.41 (1.04-1.91) 0.78 (0.46-1.32) 1.24 (0.85-1.81) 1.16 (0.79-1.69) 1.07 (0.51-2.22) 
     <50 5.95 (4.55-7.78) 5.85 (4.47-7.65) 2.80 (1.83-4.28) 3.00 (2.21-4.07) 2.83 (2.08-3.85) 1.53 (0.90-2.59) 1.94 (1.31-2.87) 1.84 (1.24-2.71) 1.39 (0.66-2.95) 
WHO Stage           
     I & II 1 - 1 1 - 1 1 - 1 
     III 3.27 (2.03-5.28) - 2.35 (1.41-3.91) 2.01 (1.21-3.34) - 1.49 (0.87-2.53) 1.48 (0.83-2.66) - 1.32 (0.72-2.54) 
     IV 10.21 (6.41-16.26) - 5.82 (3.51-9.62) 4.12 (2.50-6.79) - 2.78 (1.62-4.74) 2.54 (1.43-4.52) - 1.98 (1.04-3.75) 
HIV RNA level,  
log10 copies/ml   
         
     <=5 Log 1 - - 1 - - 1 - - 
     >5  Log  1.90 (1.63-2.22) - - 1.32 (1.09-1.59) - - 1.42 (1.12-1.82) - - 
*Also adjusted for cohort. **Model 1 excludes WHO staging.  ***Model 2 includes WHO staging. 
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Table 4.5.  Cox’s proportional hazards models of loss to follow-up at 0-12 and 12-36 months by baseline characteristics and year of ART initiation*.  
 0-12 months 12-36 months 











Variables HR (95% CI) aHR (95% CI) aHR(95% CI) HR (95% CI) aHR (95% CI) aHR (95% CI) 
Age (years) 0.99 (0.99-0.99) 0.99 (0.99-0.99) 0.98 (0.97-0.99) 0.99 (0.98-0.99) 0.99 (0.98-0.99) 0.97 (0.96-0.99) 
Year of enrollment       
2002 & 2003 1 1 1 1 1 1 
2004 6.69 (3.77-11.89) 5.74 (3.06-10.79) 2.63 (1.29-5.39) 2.76 (1.96-3.89) 3.37 (2.20-5.15) 3.54 (2.17-5.77) 
2005 7.68 (4.34-13.59) 6.29 (3.36-11.76) 4.99 (2.54-9.80) 4.13 (2.92-5.84) 4.98 (3.25-7.65) 3.57 (3.94-10.93) 
2006 9.40 (5.32-16.61) 7.67 (4.10-14.34) 9.27 (4.76-18.05) 7.27 (5.11-10.35) 8.01 (5.17-12.40) 10.62 (5.73-19.68) 
2007 15.34 (8.68-27.13) 11.89 (6.36-22.25) 10.89 (5.47-22.10) 12.77 (8.78-18.59) 12.58 (7.91-20.00) - 
CD4+ cell count (cells/µL)       
      ≥200 1 1 1 1 1 1 
      50-199 0.77 (0.71-0.85) 0.83 (0.76-0.91) 1.03 (0.77-1.38) 0.92 (0.80-1.07) 0.98 (0.85-1.14) 0.55 (0.39-0.78) 
      <50 0.97 (0.88-1.07) 1.05 (0.95-1.15) 1.30 (0.95-1.79) 0.85 (0.72-1.00) 0.91 (0.77-1.08) 0.56 (0.38-0.83) 
WHO stage       
      I & II 1 - 1 1 - 1 
      III 0.98 (0.79-1.21) - 1.16 (0.92-1.46) 0.86 (0.65-1.13) - 1.07 (0.78-1.45) 
      IV 1.12 (0.90-1.39) - 1.35 (1.04-1.74) 0.67 (0.49-0.91) - 0.95 (0.68-1.35) 
HIV RNA level (log10 copies/ml )       
      <=5 Log 1 - - 1 - - 
       >5  Log 0.98 (0.89-1.08) - - 0.92 (0.81-1.03) - - 







increase in the risk of being LTF during the first year on ART compared with those 
starting treatment in 2002/03 (aHR 11.89, 95% CI 6.36-22.25). Those with a baseline 
CD4+ cell count 50-199 cells/µL were less likely to be LTF in the first year on 
treatment than those with a CD4+ cell count ≥200 (aHR 0.83, 95% CI 0.76-0.91). This 
association did not persist when WHO staging was added to the model (aHR 1.03, 
95% CI 0.77-1.38).  
 
4.4 Discussion 
This analysis demonstrates the increasing role played by LTF over time in the 
program outcomes of the South African national ART program. The rapid pace of 
ART scale-up in South Africa is evident from the 12-fold increase in this analysis in 
the number of patients starting ART since 2002, with 63% of all patients initiating 
ART during 2006 and 2007 alone. While recorded mortality has declined during this 
period, observed LTF has increased substantially and presents a major threat to 
evaluating the effectiveness of the national program.  
 
Patient retention is a vital measure of the effectiveness of ART services(139,140). 
Retention in long-term care is complex, especially in low- and middle-income 
countries(141-143), but not a new issue: primary health care services have long 
faced the problem of patient attrition in providing care for chronic 
diseases(139,144). A systematic review of ART programs in Sub-Saharan Africa 
found large variation in patient retention across programs, ranging from 46-85% 
after two years on ART(100). At the start of the South African national program, 
based on experience with other chronic diseases, it was suggested that the ART 
service may retain 60-80% of patients annually(144). Retention in the earlier years 
of the program exceeded this expectation: at two years, 71% of all patients were 
still known to be in care, but the steady increase in attrition during the first 12 
months on ART in successive years of enrollment is cause for concern. 







months was 6.6%, which is comparable with results from other developing 
countries(127). With successive years of enrollment, 12-month mortality decreased. 
This may be a true decline due to improved coverage of services and patients 
enrolling with less advanced HIV disease(21). It is also plausible that as a program 
expands, its ability to accurately ascertain patient deaths deteriorates, and high 
observed LTF may be associated with poor mortality ascertainment(145). It is likely 
that our study, based on routine surveillance, underestimates true mortality in 
these cohorts. Recent corrected mortality estimates for single South African ART 
cohorts (based on linkage to the national death register) found that at three years 
on ART, corrected cumulative mortality was 12-15%(55,90) compared with our 
uncorrected estimate of 10%. There is an urgent need to improve ascertainment of 
deaths in low- and middle-income countries(146-148). 
 
Yet even with such underestimation, mortality is not the major reason for patient 
attrition in large ART programs in developing countries. The greater threat to the 
success of the South African ART program may be the observation of high levels of 
LTF, insofar as this outcome reflects patients who have truly left care. The size and 
pace of ART scale-up may have contributed to observed LTF. The program has 
grown in size dramatically, with our combined cohort increasing enrollment 12-fold 
over five years. Such rapid increases have placed considerable strain on health 
services that were already overburdened(12,55,141) and may have undermined the 
program’s ability to monitor and retain patients in care. During 2007 alone, 33% of 
patients in this study were enrolled onto ART: compared with the 2002/2003 cohort 
of patients, they had a 12-fold higher risk of appearing LTF. In addition, with longer 
duration on ART, observed LTF accounted for an increasing proportion of overall 
program attrition: from 9% at six months to 29% at 36 months on ART.  
 
If the rapid expansion of ART services does increase observed LTF, the situation may 







WHO treatment guidelines, adult ART coverage in South Africa was an estimated 
40% in 2008(149). In addition, the South African government recently revised its 
treatment guidelines to include all infected infants below one year of age, pregnant 
women with CD4+ cell counts ≤350 cells/µL, patients co-infected with TB(150). 
South Africa and many other countries in sub-Saharan Africa will need to continue 
to expand services while retaining large numbers of patients in care. This will 
require strengthening systems for chronic disease care in these countries(139), 
where most health programs are oriented towards episodic illnesses and acute 
care. 
 
Successfully re-orienting health systems towards long-term chronic care will require 
a better understanding of the phenomenon of LTF. Often viewed as a single 
construct, observed LTF in an ART cohort more likely represents a range of patient 
outcomes including patients truly LTF (i.e. lost to care) as well as those classified LTF 
through administrative error or inadequate patient monitoring systems(145,151). In 
a situation of rapid scale-up of ART in resource-limited health systems, the ability to 
capture and report patient data may become increasingly inadequate(151). Indeed, 
our results suggest that larger cohorts may have become more subject to these 
challenges in recent years. For example, the apparently sharp increase in observed 
LTF among patients enrolled in 2007 is likely to reflect the cumulative burden of 
increasing patient numbers on both ART services and health informatics systems. 
This phenomenon may be particularly acute at larger and rapidly expanding ART 
sites, some of which enrolled up to 50% of their cumulative number of patients in 
2007 alone.  
 
Despite the scope of the problem of observed LTF in ART services in southern Africa, 
relatively little is known about this phenomenon. These cohorts, which are largely 
funded by the national Department of Health, report active tracing (i.e. dedicated 







up, physician’s report and/or data linkage(64). However, largely due to resource 
constraints, funding for patient follow-up, particularly at this scale, is limited. There 
is a small literature on factors associated with patient retention highlighting the 
possible role of patient preparation(103), treatment supporters(152), patient costs 
(143,153), improved databases(151), community support(154) and simplified 
services(139). However, research is needed to better understand observed LTF and 
the relative contributions of true LTF (patients dropping out of ART services) versus 
administrative LTF (patients who are retained in care but appear LTF due to 
problems with data capturing and reporting). In contrast to these individuals, 
patients who are truly LTF are likely to be non-adherent to treatment and at higher 
risk of death(55,155). In addition, they face increased risk of drug resistance to ART, 
undermining the long-term effectiveness of treatment programs(55,100).  
Additional research is needed into the program-level determinants of LTF, better 
characterization of patients classified LTF and insights into patients’ movements in 
and out of care.  
 
This is the first report on outcomes from multiple cohorts in the world’s largest 
antiretroviral therapy program, and to our knowledge, the largest analysis of 
individuals starting ART in sub-Saharan Africa. It is strengthened by up to five years 
of patient follow-up on more than 40,000 patients. The results are likely 
generalizable to the patient population accessing public sector ART in most of South 
Africa(64) where 80% of the population rely on the public sector for services(156). 
However, this analysis has several important limitations. As is the case with other 
large-scale ART programs based on routine M&E, it is constrained by issues of 
outcome ascertainment and missing data(151). Outcome ascertainment should 
improve as more cohorts in South Africa link to the death register, presumably 
increasing observed mortality and decreasing observed LTF. Data completeness may 
continue to present a challenge, particularly as programs continue to expand. WHO 







multivariable analysis impacted on the association between baseline CD4+ cell 
count and outcomes, highlighting the importance of complete baseline data. Finally, 
this paper reports on averages across cohorts which may differ in data quality, 
completeness and outcome ascertainment. Despite these constraints, this analysis 
utilizes routinely collected data to provide valuable insight into the effectiveness of 
a huge national program, and has important implications for South Africa and for 
other programs in similar contexts. 
 
In summary, this analysis demonstrates that the South African national ART 
program has undergone rapid scale-up over the past five years. While recorded 
mortality has decreased, program retention has deteriorated, as decreasing patient 
mortality has been greatly offset by high and increasing levels of LTF. This increased 
LTF may represent true loss to care, but also may be due to increasing difficulty in 
monitoring patients enrolling into care as well as patient movements in and out of 
care. These possibilities require further investigation. Innovative, effective 
strategies are needed to follow and retain patients in large HIV treatment programs 
while rapidly expanding access to ART services.  
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Background & objectives 
Little is known about outcomes after transfer out (TFO) and loss to follow-up 
(LTF) and how differential outcomes might bias mortality estimates, as 
analyses generally censor or exclude TFOs/LTF.  Using data linked to the 
National Population Register (NPR), we explored mortality among patients 
TFO and LTF compared with patients retained and investigated how linkage 
impacted on mortality estimates. 
 
Methods 
A cohort analysis of routine data on adults with civil-identification numbers 
starting ART 2004-2009 in four large South African ART cohorts. The number, 
proportion, timing and mortality of TFOs and LTF were reported. Mortality 
was compared using Kaplan-Meier curves, Cox’s proportional hazards and 
competing risks regression.  
 
Results 
Before linkage, 1,207 patients (6%) had died, 2,624 (13%) were LTF, 1,067 
(5%) were TFO and 14,583 (75%) were retained. Compared with retained, 
mortality risk was three times higher among TFOs (aHR 3.11, 95% CI 2.42-
3.99) and 20 times higher among LTF patients (aHR 22.03, 95% CI 20.05-
24.21). Excluding early deaths after TFO or LTF, the risk was comparable 
among TFOs and retained (aHR 0.75, 95% CI 0.54-1.03) and higher among 
LTF (aHR 2.85, 95% CI 2.43-3.33). After linkage, corrected mortality was 
higher than site-reported mortality. Censoring did not however lead to 
substantial underestimation of mortality among TFOs.  
 
Conclusions 
While TFO and LTF predicted mortality, the lower incidence of TFO and 
subsequent death compared with LTF meant that censoring TFOs did not 
bias mortality estimates. Future cohort analyses should explicitly consider 







5.1 Introduction  
Over the past ten years, antiretroviral therapy (ART) programs have undergone 
rapid expansion. There are now numerous large ART programs in developing 
countries. As patient numbers increase, particularly in countries like South Africa 
with highly mobile populations, health systems will need to transfer patients 
efficiently to ensure uninterrupted linkage to care for optimal outcomes.  
 
Although many programs report the proportion of patients who are transferred out 
(TFO) to other services, little is known about how patients transition between 
services and their outcomes after TFO. Sites have limited capacity to keep track of 
large numbers of patients enrolled for on-going care, while also continuing to 
increase enrollment onto ART(64), and accurate estimation of mortality within and 
outside ART programs presents major challenges(63).  
 
In recent years there has been a major focus on improving outcome ascertainment 
for patients who are lost to follow-up (LTF). Studies have documented increased 
mortality in LTF patients, especially within three months of being lost(91,155,157). 
There have been attempts to standardize a definition of LTF in order to improve 
comparability across sites(158), and studies have used different methods in order to 
correct for unascertained deaths among patients LTF(88,91,92,159). In contrast 
with the growing body of literature on patients who are LTF, the group of patients 
who are TFO to another facility has received less attention. This is a significant 
group: in South Africa about 10% of patients who started ART over five years were 
TFO(61). In addition, the probability of being TFO increased with each successive 
year of ART initiation(75,105). Despite the scale of these losses, there is a dearth of 
information regarding patient outcomes after TFO and the extent to which 
differential outcomes after TFO may bias mortality estimates on ART. Most analyses 
censor TFO patients’ observations at the date of TFO(160-163), implicitly assuming 







exclude them from analysis(100).   
 
Large and rapidly expanding ART programs are unable to follow patients and 
confirm their vital status(164), and tracing studies are expensive and time-
consuming. The International epidemiologic Databases to Evaluate AIDS Southern 
African (IeDEA-SA) collaboration is uniquely placed to assess mortality after 
TFO/LTF. South Africa’s vital registration system was estimated to capture 94% of 
deaths in the period 2007-2011. Many IeDEA-SA cohorts collect civil identification 
(ID) numbers, and using linkage to the National Population Register (NPR), we can 
ascertain the vital status of patients with ID numbers after TFO/LTF. 
 
In this study, we used data linked to the NPR to explore mortality among patients 
TFO and LTF compared with patients who were retained at the site of ART initiation. 
In addition, we investigated the extent to which the inclusion of deaths ascertained 
through linkage to the NPR for TFO and LTF patients impacted on mortality 
estimates compared to censoring at the time of TFO or LTF. 
 
5.2 Methods  
This was a cohort analysis of routine data from four large South African adult IeDEA-
SA sites which collect ID numbers:  Hlabisa, a large rural program encompassing 
seventeen primary health care clinics; Khayelitsha, a primary care public sector 
clinic; McCord, a private/public urban hospital; and Themba Lethu, an urban public 
hospital. Treatment was free except in the McCord cohort, where patients paid a 
small co-payment. All ART-naïve HIV-positive adults (≥16 and ≤80 years) with ID 
numbers who started ART 2004-2009 were eligible for inclusion. The analysis was 
restricted to patients with ID numbers (65% overall) in order to ensure near-
complete mortality ascertainment. Patients with and without ID numbers were 







Mortality was reported uncorrected (as recorded at site) and corrected (after 
linkage to the National Population Register). Once the data had been linked we 
checked whether patients had a date of death recorded. Patients whose date of 
death from the NPR preceded the date recorded for their outcome were recoded as 
dead, with the date from the NPR. TFO was defined by sites and was considered 
different from up-referral for treatment or down-referral for programmatic reasons. 
Generally patients were TFO at their own request for reasons of relocation, 
convenience or cost. A transfer letter and clinical summary were given to the 
patient along with sufficient ART to last until re-engaging in care. Patients were 
recorded as TFO and their status was updated in the database. There was no further 
follow-up. In Hlabisa, patients transferring between clinics within the sub-district 
were not regarded as TFOs. LTF was defined as no contact with the health facility 
for six months prior to analysis closure(63,91) and not documented to be dead or 
TFO. Analysis was closed six months prior to database closure to allow time for this 
definition to be met for all individuals. The last contact date was taken as the date 
of LTF for those who met this definition.  
 
Summary baseline characteristics (median, interquartile range (IQR) and 
proportions) were described by status (TFO, LTF and retained) for each cohort and 
overall.  Differences between groups were tested with the chi-squared test 
(categorical variables) and the Wilcoxon rank-sum test (continuous). A sensitivity 
analysis was undertaken to compare baseline characteristics of patients with and 
without IDs. The number, proportion, timing and mortality of patients TFO and LTF 
up to analysis closure were reported.  
 
TFO and LTF were treated as time-varying covariates to avoid potential survivor bias 
in that these patients could not have died before TFO/LTF. All patients started in the 
retained group, with the date of ART initiation as the origin. Patients who were 







they were transferred or lost, after which they contributed time to the relevant 
exposure category. Mortality was compared using Kaplan-Meier curves and Cox’s 
proportional hazards regression. As there was high mortality directly after TFO/LTF, 
we undertook sensitivity analyses limited to, and then excluding, the first three 
months after TFO/LTF to ascertain whether there was a persistent difference in the 
risk of death. Three crude and multivariable models of associations between 
baseline characteristics, status (retained/lost to follow-up/transferred) and 
mortality are presented: Model 1 - overall period; Model 2 restricted to three 
months following the date of TFO/LTF; and Model 3 restricted to deaths beyond this 
period. Kaplan-Meier methods were used to estimate  i) cumulative loss to 
program; ii) mortality after TFO and LTF compared to retained patients, and iii) 
mortality after ART initiation in which patients previously classified as TFO or LTF 
were reclassified as having survived to analysis closure or having died based on NPR 
linkage. In addition, competing risks regression was used to estimate the cumulative 
incidence functions of death, LTF and TFO at 12 and 24 months after ART initiation. 
We assessed whether the effect of TFO on mortality risk was modified by the site of 
ART initiation (“cohort”) by including interaction terms in the models and testing 
with the F-test.  
 
5.3 Results 
Overall 19,507 eligible ART-naïve adults with ID numbers started ART during the 
study period (Figure 5.1). Of these, 26 (0.1%) were excluded due to: invalid dates 
(n=25) or unknown sex (n=1). The analysis included 19,481 patients followed for 
350,463 person-months. The median duration of follow-up on ART was 16 person-
months (IQR 6-28). At analysis closure, 1,067 (5%) patients had been transferred 
out, 1,207 (6%) had died, 2,624 (13%) were LTF and 14,583 (75%) were retained. 
Patients who were retained were more likely to be female than those LTF (68 vs. 
61%, p<0.001, Table 5.1). Compared with those retained, the median CD4+ cell 








Figure 5.1.  Flowchart of 19,507 ART-naïve adults with civil identification numbers  
initiating ART 2004-2009 
 
p<0.001), both overall (Table 5.1) and within each cohort (Table S5.1). At two years 
after ART initiation, the unadjusted cumulative incidence proportions were: 7% 
death, 15% LTF and 6% TFO (Figure 5.2). Overall 82 (8%) patients died after transfer 
date (Table 5.2). McCord transferred a far higher proportion of patients than the 
other sites (21% vs. <6%) and had a higher proportion of deaths among TFOs (9% vs. 
6-8%).  The majority of deaths after transfer took place during later ART (>3 months 
on ART), ranging from 77% in Khayelitsha to 100% in Themba Lethu. Among TFOs 
who died, the median time from ART to TFO was 4 months (IQR 1-11 months), and 
was shorter in Khayelitsha and McCord hospital (<3 months) than in the other 
cohorts (7-8 months). The median baseline CD4+ cell count in patients who died 
was nearly half the median count in patients who survived (53 vs. 94 cells/µL, 




















TFO vs. retained 
p-value 
LTF vs. retained 
Gender, female, n(%) 744 (70) 1,613 (61) 9,939 (68) 12,992 (67) 0.286 <0.001 
Age, years, median (IQR) 34 (29-41) 34 (29-41) 34 (29-41) 35 (30-42) <0.001 <0.001 
CD4+ cell count,  cells/μL       
      Median (IQR) 90 (39-152) 85 (35-155) 109 (51-168) 103 (44-164) <0.001 <0.001 
      0-24   n(%) 160 (15) 453 (17) 1,791 (12) 2,718 (14)   
      25-49 127 (12) 316 (12) 1,433 (10) 2,071 (11)   
      50-99 223 (21) 511 (19) 2,803 (19) 3,771 (19)   
      100-199 362 (34) 818 (31) 5,782 (40) 7,236 (37)   
      >=200 67 (6) 223 (9) 1,378 (9) 1,743 (9)   
      missing, n(%) 128 (12) 303 (12) 1,396 (10) 1,948 (10)   
Hemoglobin, g/dL 
      Median (IQR) 11 (9.6-12.1) 11 (9.2-12.1) 11.1 (10-12.6) 11 (9.8-12.4) <0.001 <0.001 
Weight, kg 
      Median (IQR) 58 (51-66) 58 (50-66) 60 (53-68) 59 (52-68) <0.001 <0.001 
Calendar year ART initiation, n(%) 
      2004 205 (19) 342 (13) 1,303 (9) 1,990 (10) <0.001 <0.001 
      2005 312 (29) 639 (24) 2,381 (16) 3,613 (19)   
      2006 261 (25) 607 (23) 3,283 (23) 4,447 (23)   
      2007 145 (14) 489 (19) 3,199 (22) 4,128 (21)   
      2008 120 (11) 389 (15) 2,804 (19) 3,461 (18)   
      2009 24 (2) 158 (6) 1,613 (11) 1,848 (9)   








































19,481 11,404(3,300) 6,115(995)Death, LTF & TFO   
19,481 11,404(2,688) 6,115(719)Death & LTF   













Table 5.2.  Number (%), timing and mortality of patients transferred and lost to follow-up. 
 Total Hlabisa Khayelitsha McCord Themba Lethu p-value* 
 n=19,481 n=8,208 n=3,397 n=1,641 n=6,235  
Patients transferred out (TFO), n(%) 1,067 (5) 287 (3) 161 (5) 349 (21) 270 (4) <0.001 
   Deaths after transfer date, n(%) 82 (8) 21 (7) 13 (8) 31 (9) 17 (6) <0.001 
      Deaths during early ART (0-3 months) 7 (9) 2 (10) 3 (23) 2 (6) 0 (0) 0.026 
      Deaths during later ART (> 3 months) 75 (91) 19 (90) 10 (77) 29 (94) 17 (100) 0.721 
      Among deaths during later ART, deaths <3 months after TFO 27 (36) 8 (42) 6 (60) 5 (17) 8 (47) 0.151 
   Median months from ART start to transfer 9 (4-19) 9 (4-19) 8 (3-16) 9 (4-19) 11 (4-20)  
      Median months from ART start to TFO in patients who died  4 (1-11) 7 (3-12) 2 (0-6) 3 (2-7) 8 (3-15)  
   Median months from TFO to death 4 (1-12) 3 (1-7) 1 (1-3) 8 (3-15) 5 (1-18)  
   Median months from ART to death 12 (5-20) 13 (6-17) 5 (4-10) 13 (9-21) 20 (7-25)  
   Median baseline CD4+ cell count in patients who died, cells/µL (IQR) 53 (14-121) 90 (11-162) 40 (17-99) 41 (12-90) 77 (14-121) 0.005** 
   Median baseline CD4+ cell count in patients who survived, cells/µL (IQR) 94 (41-153) 116 (53-167) 88 (38-134) 92 (42-158) 79 (30-137)  
Patients lost to follow-up (LTF), n(%) 2,624 (13) 921 (11) 281 (8) 265 (16) 1,157 (19) <0.001 
   Deaths after LTF, n(%) 972 (37) 380 (41) 94 (33) 114 (43) 384 (33) <0.001 
      Deaths during early ART (0-3 months) 379 (39) 170 (45) 46 (49) 52 (46) 111 (29) <0.001 
      Deaths during later ART (> 3 months) 593 (61) 210 (55) 48 (51) 62 (54) 273 (71) 0.105 
      Among deaths during later ART, deaths <3 months after LTF 379 (64) 147 (70) 38 (79) 37 (60) 157 (58) <0.001 
   Median months from ART start to LTF 7 (1-17) 6 (1-16) 8 (2-17) 5 (1-12) 7 (1-18)  
      Median months from ART to LTF in patients who died  2 (0-8) 2 (0-9) 2 (1-6) 2 (1-7) 3 (1-9)  
   Median months from LTF to death 1 (0-2) 1 (0-2) 0 (0-1) 1 (0.-2) 1 (1-4)  
   Median months from ART to death  5 (2-13) 4 (1-12) 3 (1-10) 3 (1-11) 7 (3-16)  
   Median baseline CD4+ cell count in LTF who died, cells/µL (IQR) 59 (19-121) 69 (24-136) 65 (34-122) 40 (11-88) 52 (15-110) <0.001** 
   Median baseline CD4+ cell count in LTF who survived, cells/µL (IQR) 104 (48-168) 117 (60-177) 113 (57-169) 79 (36-114) 98 (42-163)  
* proportions across cohorts       







The proportions LTF varied by site from 8% in Khayelitsha to 19% in Themba Lethu 
(Table 5.2). Mortality among LTF patients was 37% (n=972) (Table 5.2), ranging from 
33-43% (Khayelitsha and McCord respectively). Mortality was high during later ART, 
ranging from 51-71% across cohorts. Among those who died during later ART, the 
majority of deaths occurred within three months of the LTF date, ranging from 58% 
in Themba Lethu to 79% in Khayelitsha, p<0.001. The median time from ART 
enrollment to LTF in patients who died was two months. The median baseline CD4+ 
cell count in LTF patients who died was about half that of patients who survived (59 
vs. 104 cells/µL), p<0.001. 
 
Transfer was predicted by CD4+ cell count and site of ART initiation (Table S5.2). In 
multivariable analysis, patients with a CD4+ cell count ≥200 cells/µL were less likely 
to be TFO than patients with a baseline count <25 cells/µL (aHR 0.74, 95% CI 0.60-
0.91). McCord was five times as likely as Khayelitsha to transfer patients (aHR 5.24, 
95% CI 4.27-6.42) and Hlabisa and Themba Lethu less likely (respectively aHR 0.74, 
95% CI 0.60-0.91 and aHR 0.70, 95% CI 0.57-0.87) (Table S5.2). The effect of 
baseline CD4+ cell count on the likelihood of transfer was different in McCord from 
the other cohorts (p=0.04). Patients with higher baseline CD4 counts were less likely 
to be transferred except at McCord where CD4 count was not associated with risk 
of transfer. TFOs increased cumulative program loss by 24 months from 22% to 28% 
compared to accounting only for mortality and LTF (Figure 5.2).  
 
Figure 5.3 shows mortality with LTF and TFO treated as time-varying to remove 
potential survivor bias (presented separately by cohort in Figure S5.1). Patients TFO 
had higher mortality than patients retained. At 24 months on ART, 21% of the TFO 
patients compared with 8% of those retained had died. Patients who were LTF had 
extremely high early mortality. Twenty four months after starting ART, cumulatively 








Figure 5.3.  Mortality among patients transferred and lost to follow-up compared with 
patients retained. LTF and TFO are included as time-varying and not baseline covariates. 
 
In crude analysis, mortality was associated with male gender, age, baseline CD4+ 
cell count, cohort and having been TFO or LTF (Table 5.3, Model 1). Men were more 
likely than women to die (HR 1.65, 95% CI 1.52-1.79). The risk of death increased 
with age and adults aged 45+ years compared with those 16-24 years had the 
highest mortality risk (HR 1.58, 95% CI 1.30-1.93). Mortality was inversely 
associated with baseline CD4+ cell count (HR 0.32, 95% CI 0.26-0.39, CD4+ cell count 
≥200 vs. 0-24 cells/µL). Compared with Khayelitsha, patients in McCord and Hlabisa 
had higher crude mortality risk (HR 2.26 and HR 1.48 respectively) and Themba 
Lethu patients had comparable risk (HR 1.06, 95% CI 0.94-1.22). In comparison with 
patients retained, the risk of death was higher for LTF patients (HR 20.2, 05% CI 
18.5-22.05) and those TFO (HR 3.71, 95% CI 2.96-4.65).  
 
In multivariable analysis of the total time period, adjustment for baseline 
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between mortality and male gender (aHR 1.19, 95% CI 1.09-1.31) and strengthened 
the association with age (Table 3, Model 1). The impact of ART initiation site on 
mortality varied: the effect at Hlabisa and McCord was attenuated after controlling 
for the effect of LTF on mortality (Table 5.3, model 2), with little additional impact 
of controlling for the effect of TFO on mortality (Table 5.3, model 3). In Themba 
Lethu, adjustment for baseline characteristics reduced mortality estimates relative 
to other cohorts (aHR 0.59, 95% CI 0.51-0.69), with or without the inclusion of 
deaths amongst patients TFO or LTF. In sensitivity analyses, mortality was extremely 
high in the three-month period directly following LTF/TFO: aHR 32.21 (95% CI 29.18-
35.56) and aHR 3.54 (95% CI 2.52-4.98) for LTF and TFO respectively compared with 
retained (Table 5.3 Model 2). Excluding deaths in the three months after TFO and 
LTF substantially changed mortality estimates for the effect of ART initiation site 
and TFO/LTF status (Table 5.3, Model 3). Compared with Khayelitsha, the effect of 
Hlabisa and McCord were strengthened and the effect of Themba Lethu was 
attenuated. Compared with patients retained, the risk among LTF was reduced from 
aHR 22.03 to aHR 2.85 (95% CI 2.43-3.33) and patients who were TFO had 
comparable mortality risk (aHR 0.75, 95% CI 0.54-1.03). In testing for interaction, 
Khayelitsha had higher mortality after TFO than the other cohorts, consistent with 
Supplementary Figure S5.1. However, the impact of these additional deaths on 







Table 5.3.  Associations with mortality, with time-varying status (retained/lost to follow-up/transferred). 
Variable Model 1* Model 2** Model 3*** 
 Total time period 3 months after TFO/LTF Excluding 3 months after TFO/LTF 
 Crude HR aHR Crude HR aHR Crude HR aHR 
Male gender 1.65 (1.52-1.79) 1.19 (1.09-1.31) 1.67 (1.53-1.83) 1.21 (1.10-1.33) 1.56 (1.41-1.73) 1.27 (1.14-1.42) 
Age (years)       
   16-24 (reference) 1 1 1 1 1 1 
   25-34 1.13 (0.94-1.36) 1.29 (1.05-1.57) 1.11 (0.92-1.35) 1.23 (0.99-1.52) 1.11 (0.88-1.39) 1.14 (0.89-1.46) 
   35-44 1.28 (1.06-1.54) 1.48 (1.20-1.82) 1.24 (1.02-1.52) 1.35 (1.09-1.68) 1.22 (0.97-1.54) 1.22 (0.95-1.57) 
   45+ 1.58 (1.30-1.93) 1.99 (1.61-2.47) 1.60 (1.30-1.96) 1.85 (1.48-2.32) 1.52 (1.19-1.93) 1.58 (1.22-2.05) 
CD4+ cell count  (cells/µl)       
   0-24 (reference) 1 1 1 1 1 1 
   25-49 0.77 (0.68-0.88) 0.72 (0.63-0.82) 0.76 (0.66-0.87) 0.70 (0.61-0.81) 0.82 (0.69-0.96) 0.78 (0.66-0.92) 
   50-99 0.52 (0.46-0.58) 0.50 (0.44-0.57) 0.50 (0.44-0.57) 0.48 (0.42-0.55) 0.53 (0.46-0.62) 0.51 (0.44-0.60) 
   100-199 0.32 (0.29-0.36) 0.33 (0.29-0.37) 0.30 (0.27-0.34) 0.32 (0.28-0.36) 0.33 (0.29-0.38) 0.31 (0.27-0.36) 
   >=200 0.32 (0.26-0.39) 0.29 (0.24-0.36) 0.30 (0.25-0.38) 0.29 (0.24-0.36) 0.36 (0.29-0.46) 0.33 (0.26-0.42) 
Cohort       
   Khayelitsha (reference) 1 1 1 1 1 1 
   Hlabisa 1.48 (1.30-1.69) 1.27 (1.10-1.46) 1.46 (1.28-1.68) 1.27 (1.09-1.47) 1.54 (1.31-1.80) 1.48 (1.25-1.75) 
   McCord 2.26 (1.92-2.66) 1.21 (1.01-1.46) 2.13 (1.79-2.53) 1.25 (1.03-1.51) 2.8 (2.20-3.27) 1.92 (1.54-2.39) 
   Themba Lethu 1.06 (0.94-1.22) 0.59 (0.51-0.69) 0.96 (0.83-1.11) 0.61 (0.52-0.71) 0.96 (0.81-1.15) 0.74 (0.61-0.89) 
Status (time-varying)       
   Retained (reference) 1 1 1 1 1 1 
   Lost to follow-up 20.20 (18.50-22.05) 22.03 (20.05-24.21) 31.59 (28.83-34.63) 32.21 (29.18-35.56) 2.38 (2.06-2.76) 2.85 (2.43-3.33) 
   Transferred  3.71 (2.96-4.65) 3.11 (2.42-3.99) 3.54 (2.52-4.98) 3.03 (2.09-4.40) 0.93 (0.69-1.24) 0.75 (0.54-1.03) 








Figure 5.4 shows the impact of correcting mortality estimates via NPR linkage. In all 
cohorts, crude (site-reported) mortality substantially underestimated mortality. 
Correction for deaths among patients LTF substantially increased mortality 
estimates, while additionally accounting for unascertained deaths in the smaller 




In this analysis of 19,481 ART-naïve adults with civil identification numbers starting 
ART between 2004 and 2009, patients who were transferred had higher mortality 
than patients retained at the ART initiation site. Mortality among TFOs was low, 
with one third occurring in the three-month period directly after TFO. Mortality 
after LTF was far higher, particularly during early ART and in the period directly after 













Figure 5.4.  The impact on mortality estimates of correction via the  





















19,481 11,527(1,716) 6,169(370)With TFO  
19,481 11,504(1,675) 6,157(344)With LTF   












patients TFO and retained was similar, but patients LTF had three times the 
mortality risk of those retained. After linkage to the NPR, correction for deaths 
among patients TFO had limited impact on mortality but correction for LTF 
substantially increased mortality estimates. The inclusion of deaths after LTF, but 
not those after TFO, changed the association between treatment cohort and 
mortality. 
 
The South African ART program has undergone rapid expansion since its inception 
in 2004. In 2009/10, a total of 550 accredited facilities were established to offer 
ART(165). By 2012, 3,686 facilities (80% of the total) offered ART(166). This 
expansion in facilities offering ART has provided more opportunity for TFOs within 
the health system. Indeed the probability of TFO at one year increased from 1% in 
patients enrolled 2002-2004 to 9% in patients enrolled in 2009(105). Lowering the 
threshold of ART eligibility is likely to increase patient numbers further(75) and may 
mean that more mobile individuals are enrolled on ART. In addition, evidence 
suggests that even in low-income countries, patients actively seek better quality 
health care despite higher costs if they believe that this may improve their 
outcomes(167). There is thus a need for a robust system in order to ensure that 
patients who are TFO successfully re-engage in care in another facility without 
increased risk of mortality. Our study highlighted a number of issues related to 
patient transfers which have programmatic implications. 
 
Firstly, over a third of deaths in those TFO during later ART occurred in the three 
month period directly after TFO.  It is plausible that patients may have been 
requesting transfer at a time of severe illness in order to be cared for at home or in 
the expectation of death(168), or may have been actively transferred to better 
equipped services due to illness. South Africa has a long history of circular labor 
migration. Individuals leave home to find work in urban areas and return home to 







suggest the need for close monitoring after TFO to ensure that TFO patients have 
successfully linked to care, and for the rapid recall of lost patients. 
 
Second, patients who were transferred had comparable or lower mortality than 
those retained beyond the three months following transfer (aHR 0.75, 95% CI 0.54-
1.03, Table 5.3, Model 2). This is important new information on a group of patients 
whose outcomes have been largely unknown. Our finding differs from a Malawi 
study which reported improved survival among TFOs compared with patients 
retained over 24 months (5% vs. 12%)(170). Our results suggest that once patients 
have stabilized on treatment, TFO may not impact on mortality, or that beyond the 
early months on ART stable patients are more likely than others to be transferred. 
Indeed, in Malawi, patients who were transferred had less advanced clinical stage 
of disease and better survival than those retained. 
 
Third, some transfers may have been due to resource constraints among patients 
battling to access health care. For example, McCord Hospital transferred a far larger 
proportion of patients, and experienced far higher mortality after TFO. In this 
cohort, patients were required to make a small co-payment towards their 
treatment. The co-payment covered all HIV-related out-patient care for the month, 
with no additional costs for any investigation or treatment, but did not cover in-
patient admission care. Previous research has found free provision of ART 
associated with lower mortality in low-income countries(127). It is plausible that 
patients requesting transfer in this cohort were unable to afford even the small co-
payment, which increased from R120 per consultation in 2005 to R140 in 2008.  
 
Fourth, our study confirms the major threat that LTF poses to program 
effectiveness(61,91,99,171-173). Almost half of the LTF patients had died, mostly 
within three months of being LTF. The timing of deaths was similar to deaths after 







after LTF, LTF patients still had nearly three times the risk of death compared with 
retained patients (AHR 2.85, 95% CI 2.43-3.33). Retention in chronic HIV care has 
long been recognized as a major challenge(61,70,145,160,172), with LTF increasing 
by calendar year as ART programs scale-up enrollment(61,145,166). Numerous 
strategies have been proposed to retain patients in care including decentralizing 
ART provision and task shifting(174), reducing clinic caseloads(175) and managing 
ART at community(176) and home-level(177). Urgent attention is needed to prevent 
LTF particularly in the first few months on ART. 
 
Finally, although in all cohorts the median CD4+ cell count at ART initiation was 
lower among TFOs and LTF than those retained, there was substantial 
heterogeneity across sites including in the proportions TFO/LTF, the incidence of 
mortality, the median time from ART initiation to TFO/LTF in patients who died, and 
the median baseline CD4+ cell count in patients who died compared with those who 
survived.  Such variability suggests that although TFO is reported as a single 
outcome, it may have different meanings in different sites which may impact on 
mortality. Sites need to understand what TFO means in their own context. 
 
In addition to the implications for patient care, our analysis has implications in 
terms of program evaluation. Accurate ascertainment of mortality poses major 
challenges, particularly in large programs in developing countries with limited 
capacity to actively follow patients. In the absence of additional outcome 
ascertainment, many studies censor the follow-up time of patients who are TFO, 
assuming that mortality is the same as among patients retained. Using linkage, our 
study provides evidence that in a context of low TFO rates and mortality rates after 
TFO, censoring follow-up time at TFO date did not lead to a substantial 
underestimation of mortality. In contrast, including deaths among LTF compared 
with censoring at the time of LTF impacted on mortality estimates and the effect of 







transferred and the event rates were higher, it might be necessary analytically to 
treat TFO in a similar way to LTF. In situations where additional outcome 
information is available from, for example, tracing studies or linkage to a population 
register, statistical methods such as inverse probability weighting and/or multiple 
imputation (MI) can be used(96). In the absence of such information, options 
include the use of a nomogram to correct mortality estimates(92) and use of 
selection and pattern-mixture models(178).  
 
So what are the implications of our findings, particularly in the context of policy 
initiatives to test and treat all people with HIV? The study highlights the need for 
improved follow-up especially in the months after TFO and LTF. South Africa has a 
number of factors which should support good patient follow-up. ART is widely 
available; by 2013, approximately 80% of all primary health care facilities were 
offering ART services and this number appears set to increase(150).  In addition, 
there are standardized ART guidelines which are widely disseminated, ensuring a 
fairly unified approach to treatment across facilities and providers. These guidelines 
could be substantially strengthened by a standardized approach to transferring and 
following patients, with a particular focus on the timing of patients transferred. We 
recommend: 1) extreme caution in transferring patients until they are clinically 
stable on ART;  2) prompt and comprehensive reassessment at the receiving facility 
to ensure continuity of care, not only in terms of ART but also for co-morbid 
conditions, particularly in the three-month period directly after TFO/LTF; 3) prompt 
follow-up of patients who are LTF; and 4) a single patient identifier for all health 
facilities and much improved national health information systems to support 
monitoring and evaluation. 
 
To our knowledge, this is the first study to report mortality among patients TFO, 
using data from linkage to the NPR. Most analyses from large ART programs 







strengthened by our ability to explore the vital status of patients after leaving a 
program, which would generally only be possible by undertaking expensive tracing 
studies with limited success. The analysis only included patients with ID numbers, 
ensuring good mortality ascertainment. A limitation is that patients with ID 
numbers may have been different from those without ID numbers which may have 
led to some underestimation of the true mortality after TFO. However, in sensitivity 
analysis there was no evidence of any substantial differences between those with 
and those without IDs. A further limitation is the possible misclassification of 
outcomes. Patients classified as LTF may be silent TFOs, while some patients LTF 
may be incorrectly classified as TFO.  In addition, different reasons for patient 
transfer may independently impact on mortality risk but cohorts did not capture 
patients’ reasons for TFO. Finally, due to the observational nature of the study, we 
were unable to determine whether the increased risk of mortality in those 
transferred was causally related to the transfer itself or was related to unmeasured 
characteristics of the individuals transferred, or information bias due to 
misclassification. 
 
In summary, improved administrative and clinical procedures to ensure continuity 
and quality of care for patients TFO and LTF are needed. As the proportion of 
patients TFO grows, it will become increasingly important in cohort analyses to 



































Females, n(%) 744 (70) 1613 (61) 9939 (68) 117 (73) 183 (65) 1948 (70) 241 (69) 157 (59) 549 (63) 198 (73) 745 (64) 3056 (67)
Age, years, median (IQR) 34 (29-41) 34 (29-41) 35 (30-42) 34 (30-40) 32 (28-37) 33 (29-39) 34 (30-41) 34 (29-40) 35 (30-40) 36 (30-43) 35 (30-41) 35 (31-41)
CD4+ cell count,  cells/μL
Median (IQR) 90 (39-152) 85 (35-155) 109 (51-168) 84 (34-136) 96 (46-159) 112 (55-168) 85 (41-157) 66 (17-132) 92 (32-151) 79 (30-
135)
81 (32-149) 91 (36-156)
Haemoglobin, g/dL
Median (IQR) 11 (9.6-12.1) 11 (9.2-12.1) 11.1 (10-12.6) 10.4 (9.5-11.5) 10.6 (9.1-11.8) 11.1 (9.7-12.2) 10.8 (9.4-12.1) 10.7 (9.3-12) 11 (9.7-12.4) 11 (10-13) 11 (10-13) 12 (10-13)
Weight, kg
Median (IQR) 58 (51-66) 58 (50-66) 60 (53-68) 56 (50-65) 57 (50-65) 60 (53-69) 61 (51-70) 56 (49-68) 61 (54-68) 59 (50-66) 58 (50-66) 60 (52-68)




Table S5.2. Associations between baseline characteristics, cohort and the probability of being 
transferred out 
Variable Crude AHR
Male gender 0.96 (0.84-1.09) 0.89 (0.77-1.03)
Age
16-24 1 1
25-34 0.95 (0.75-1.20) 0.91 (0.71-1.16)
35-44 0.81 (0.63-1.03) 0.81 (0.63-1.05)
45+ 0.73 (0.56-0.96) 0.83 (0.62-1.10)
CD4+ cell count, cells/µL
<25 1 1.00
25-49 1.02 (0.81-1.29) 1.07 (0.85-1.35)
50-99 0.95 (0.77-1.16) 1.06 (0.86-1.30)
100-199 0.81 (0.67-0.97) 0.90 (0.74-1.08)
>=200 0.63 (0.47-0.83) 0.73 (0.55-0.97)
Cohort
Khayelitsha (ref) 1 1
Hlabisa 0.67 (0.55-0.82) 0.74 (0.60-0.91)
McCord 5.09 (4.22-6.13) 5.24 (4.27-6.42)

















Figure S5.1. Mortality among patients transferred and lost to follow-up compared with 















Figure S5.2: The impact of correcting mortality via linkage to the  
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Age is routinely reported in epidemiologic studies but little is known about its 
specific effect in South African ART programs. We explored the effect of age on 




A cohort analysis of routine data on adults with civil-identification numbers 
starting ART 2004-2013 in six large South African public sector ART cohorts. 
Mortality was estimated using Cox’s proportional hazards and competing risks 
regression.  HIV-positive and non-HIV mortality were compared. Interaction 
between baseline CD4+ cell count and age was tested. Immunologic responses 
were graphed by age and duration on ART. 
  
Results 
83,756 patients were followed for 214,400 patient-years. The median age was 
35 (IQR 29-42) years and 10% were classified as older (≥50 years). Patients <35 
years were predominantly female, notably 81% of the youngest age group. The 
proportion of older patients enrolling increased with calendar year from 6 to 
10% while the number retained in care increased from 2% to 20%. The hazard 
of mortality increased with age in a dose response. Patients with HIV had an 
11% higher five-year cumulative mortality hazard than HIV-negative individuals 
and this was consistent across all ages. Despite similar baseline CD4+ cell counts 
across age groups, immunologic response deteriorated with increasing age. The 
effect of age on mortality was mediated by baseline immunologic status and 
was most pronounced in patients enrolling with CD4+ cell counts <50 cells/µL. 
 
Conclusions 
There is a need to test and treat young men. Health services need re-orientation 
towards diagnosing and starting ART in older individuals. Policies are needed for 






The world’s population is aging rapidly. By 2025, it is estimated that there will be two 
billion elderly people worldwide, 80% in developing countries(109). South Africa has 
the largest population of people above 50 years in SSA(179) and one of the highest 
population prevalences of HIV in the world. These numbers are expected to increase 
and by 2025, nearly 5.23 million people will be above 60 years(180). In addition to this 
rapid aging in the general population, the HIV epidemic in sub-Saharan Africa (SSA) is 
aging. Recent estimates suggest that the total number of HIV-positive individuals older 
than 50 years in SSA may triple from one in seven in 2011 to more than one in four in 
2040(112). South Africa also has the largest ART program worldwide, having enrolled 
an estimated 2 million individuals on treatment. The country is now facing the 
challenges of a successful ART program in the middle of a major demographic 
transition(181). As access to treatment expands, we are likely to see increasing 
numbers of older patients starting ART and remaining in care for longer periods. 
 
Initiating and retaining older individuals on ART has major implications for the South 
African public health system. Health care workers are less likely to ask older patients 
about sexual practices and to consider HIV as a possibility when older individuals 
present for care. There are no campaigns that target older people for HIV prevention 
and testing(130). As a result older people may be diagnosed and enter ART services 
with more advanced HIV disease than younger people. In addition, older people are 
more likely to have co-morbidities and will require more specialized care than younger 
patients(109,182,183). Poorer outcomes on ART have been reported in older than 
younger adults(107,184). In South Africa, for example, mortality rates appear higher 
among older than younger adults in cohorts from both rural and urban settings 
(113,114,185).  
 
While HIV increases the risk of mortality as people age, there is debate about the 




combination of HIV and/or ART use accelerate biological aging through the same 
pathways as the natural aging processes; alternately HIV and/or ART may  accentuate 
aging by acting as additional risk factors for specific chronic disease processes 
(186,187). In many ways, HIV appears to mimic the effects of aging in the immune 
system, compounded by long-term ART toxicity and interactions with co-medications 
for other age-related conditions(106-110). Whether HIV accelerates or accentuates 
aging may be specific to the co-morbidity and/or affected organ(186).  
 
To date there has been limited research on aging and ART programs in resource-
constrained settings. The International epidemiologic Databases to Evaluate AIDS-
Southern Africa (IeDEA-SA) collaboration provides a unique opportunity to explore the 
long-term outcomes of a large number of older individuals starting ART in since 2002. 
We investigated the association between age and mortality risk and whether this effect 
was modified by pre-ART immunologic status. 
 
6.2 Methods 
The study was a cohort analysis of routine data from six large South African cohorts of 
IeDEA-SA. Four of these cohorts have been described previously(64): Gugulethu and 
Khayelitsha, two primary care public sector clinics, McCord, a public/private urban 
hospital, and Tygerberg, a tertiary level public sector hospital. Two additional cohorts 
are Hlabisa, a large rural cohort in KwaZulu Natal, and Themba Lethu, a large urban 
cohort based in Gauteng. All ART-naïve HIV-positive adults (≥16 and ≤80 years) who 
started ART 2004-2013 were eligible for inclusion.  
 
Patients were followed from the time of ART initiation to one of the following: death, 
loss to follow-up (LTF), transferred out (TFO) or alive at analysis closure. The primary 
outcome was death and LTF was the secondary outcome. TFOs were censored at the 
date of TFO. Mortality was reported by sites and estimates were corrected for patients 




we used inverse probability weighting to correct mortality and LTF for deaths 
misclassified as LTF(96). LTF patients with ID numbers were linked to the National 
Population Register to confirm their vital status (and date of death if deceased) and 
weighted to represent all LTF patients. TFO was defined by sites and was considered 
different from up-referral for treatment or down-referral for programmatic reasons. 
LTF was defined as no contact with the health facility for six months and not 
documented to be dead or TFO.  The analysis excluded patients enrolled up to six 
months prior to database closure to allow time for the LTF definition to be met for all 
individuals, and with the last contact providing the LTF date.  
 
Patients were analyzed by age group (16-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 
60-65, 65+). Summary baseline characteristics (median, interquartile range (IQR) and 
proportions) were described by age group and overall.  The number and proportion of 
patients dead, the median follow-up times to death and the incidence of mortality 
were reported by age. The proportions of patients ≥50 years old at baseline and by 
calendar year of enrollment were reported. 
 
Cox’s proportional hazards models were used to assess crude and adjusted associations 
between patient characteristics and outcomes. Mortality was estimated using Kaplan-
Meier and competing risks methods. Models were adjusted for baseline patient 
characteristics (gender, CD4+ cell count, WHO stage, hemoglobin, TB, weight and site 
of ART initiation), by duration on ART. As hemoglobin levels vary by gender, the 
variable anemia was generated from the hemoglobin value (measured in g/dl), which 
was defined as: none: females >11.9, males >13.1; mild: females 10-11.9, males 11-
13.1; moderate: females 8.1 to <10, males 8.1 to <11; severe: <8.1(188). Assuming that 
data were likely missing at random, we used MI(189) by chained equation 
methods(190) to impute missing baseline covariates. We multiply imputed ten times 
CD4+ cell count (baseline, 12-month and 24-month), baseline WHO stage, weight, 




mortality risk was modified by baseline CD4+ cell count by including interaction terms 
in the models and testing with the F-test. We also recategorized age (16-39, 40-49 and 
≥50 years) and baseline CD4+ cell count (<50, 50-199, ≥200 cells/µL) and generated a 
combined variable with age 16-39 and CD4+ cell count <50 as the reference category. 
We plotted the effect of this variable. The five-year cumulative hazards of HIV and non-
HIV mortality were graphed by age group. To compare age-related differences in 
mortality in our cohorts with expected age-related differences in the HIV-negative 
population, we calculated HIV-negative mortality in the South African population age-
standardized to our patients. Age-specific HIV-negative mortality rates in males and 
females were obtained from the Actuarial Society of Society Africa (ASSA) estimates of 
non-HIV mortality in the year 2005, which are derived from vital registration statistics 
as well as census and survey data(31). The five-year cumulative hazard of HIV and non-
HIV mortality was graphed by age. The median CD4+ cell count responses were 
graphed by age group and duration on ART.  
 
6.3 Results 
Overall 84,078 eligible ART-naïve adults started ART in these cohorts from 2004-2013. 
Of these, 502 were excluded due to: missing/invalid dates (n=494) and unknown sex 
(n=8). The analysis included 83,576 patients followed for 214,400 person-years (pyrs).  
 
Patient characteristics and outcomes by age 
Patients were predominantly young, with a median age of 35 (IQR 29-42) years. The 
proportion of patients enrolled in each age group decreased from 28% (16-29 year 
olds) to 1% (≥65 years) (Table 6.1). Patients in the younger age groups were 
predominantly female, comprising 80% of patients aged 16-29 and 66% of those aged 
30-34. Above 40 years of age, the gender proportions were nearly equal. There was no 
difference in median CD4+ cell count between the youngest and the oldest patients 
(137 vs. 135 cells/µL, p=0.129). From 40 to 60 years of age, the proportions enrolled 




Table 6.1.  Baseline characteristics, mortality estimates and patient outcomes by age at enrollment. 
16-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+ Overall
Patients enrolled, n (%) 23,261 (28) 19,372 (23) 16,233 (19) 10,619 (13) 6,795 (8) 4,007 (5) 1,991 (2) 806 (1) 492 (1) 83,576 (100)
Females, n(%) 81 66 58 56 56 54 52 50 50 65
CD4+ cell count, 
      median cells/µL (IQR)
137 (62-210) 120 (152-188) 117 (51-186) 120 (53-186) 124 (59-190) 128 (64-195) 125 (60-190) 130 (66-195) 135 (75-208) 125 (56-192)
CD4+ cell count, categorical
0-49 3,693 (16) 3,696 (19) 3,184 (20) 2,002 (19) 1,189 (17) 615 (15) 326 (16) 111 (14) 51 (10) 14,865 (18)
50-99 3,003 (13) 2,863 (15) 2,514 (15) 1,635 (15) 1,003 (15) 653 (16) 300 (15) 117 (14) 91 (19) 12,179 (15)
100-199 6,678 (29) 5,613 (29) 4,646 (29) 3,178 (30) 2,114 (31) 1,210 (30) 637 (32) 269 (33) 143 (29) 24,467 (29)
200-349 4,030 (17) 2,826 (15) 2,267 (14) 1,471 (14) 979 (14) 649 (16) 278 (14) 136 (17) 83 (17) 12,719 (15)
350-499 377 (2) 246 (1) 232 (1) 156 (1) 118 (2) 66 (2) 32 (2) 11 (1) 10 (2) 1,248 (2)
≥500 196 (1) 120 (1) 118 (1) 78 (1) 62 (1) 40 (1) 28 (1) 4 (1) 9 (2) 655 (1)
Missing 5,305 (23) 4,008 (21) 3,272 (20) 2,099 (20) 1,330 (20) 774 (19) 390 (20) 158 (20) 105 (21) 17,441 (21)
TB at ART start 1,726 (17) 1,730 (20) 1,467 (19) 982 (18) 633 (17) 321 (15) 155 (13) 64 (14) 35 (12) 7,112 (18)
Missing 55% 54% 51% 49% 46% 45% 42% 42% 24% 52%
Year of ART initiation
2004 1,419 (28) 1,335 (27) 1,030 (21) 583 (12) 342 (7) 178 (4) 69 (1) 27 (1) 16 (0) 4,999 (100)
2005 1,976 (29) 1,745 (26) 1,340 (20) 799 (12) 527 (8) 242 (4) 108 (1) 39 (1) 18 (0) 6,794 (100)
2006 2,292 (26) 2,181 (26) 1,629 (19) 1,162 (14) 623 (7) 375 (4) 167 (2) 59 (1) 34 (0) 8,522 (100)
2007 2,265 (26) 2,129 (25) 1,737 (20) 1,166 (13) 714 (8) 379 (4) 202 (2) 67 (1) 38 (0) 8,697 (100)
2008 2,751 (27) 2,347 (23) 1,990 (20) 1,294 (13) 841 (8) 506 (5) 244 (2) 94 (1) 63 (1) 10,130 (100)
2009 2,893 (26) 2,615 (23) 2,169 (19) 1,475 (13) 997 (9) 588 (5) 289 (3) 121 (1) 57 (1) 11,204 (100)
2010 3,606 (30) 2,664 (22) 2,322 (19) 1,440 (12) 938 (8) 589 (5) 319 (3) 127 (1) 84 (1) 12,088 (100)
2011 3,304 (29) 2,346 (20) 2,149 (19) 1,492 (13) 956 (8) 639 (6) 347 (3) 150 (1) 100 (1) 11,483 (100)
2012 & 2013 2,756 (29) 2,010 (21) 1,867 (19) 1,208 (13) 857 (9) 511 (5) 246 (3) 122 (1) 82 (1) 9,659 (100)
Outcome at analysis closure, n(%)
Deaths 1,820 (8) 1,746 (9) 1,558 (10) 1,127 (11) 768 (11) 516 (13) 275 (14) 136 (17) 93 (19) 8,039 (10)
Lost to follow-up 6,828 (29) 5,229 (27) 4,068 (25) 2,536 (24) 1,500 (22) 815 (20) 417 (21) 186 (23) 88 (18) 21,667 (26)
Transferred out 2,749 (12) 2,128 (11) 1,672 (10) 1,060 (10) 667 (10) 385 (10) 187 (9) 73 (9) 40 (8) 8,961 (11)
Alive 11,864 (51) 10,269 (53) 8,935 (55) 5,896 (56) 3,860 (57) 2,291 (57) 1,112 (56) 411 (51) 271 (55) 44,909 (54)
Mortality rate per 100 pyrs 2.1 2.2 2.4 2.6 3.1 3.6 3.9 6.0 7.7 2.4





had TFO, 21,667 (26%) were LTF and 44,909 (54%) were alive. The median duration of 
follow-up to death was 811 person-days (IQR 311-1539) and decreased with age. The 
proportion of patients ≥50 years old alive and in care increased from 2% in 2004 to 20% 
in 2012/2013 (Supplementary Table S6.1).   
 
6.3.1 The effect of age on mortality  
The cumulative incidence of death, having not experienced the competing risks of LTF 
or TFO, at 12 and 36 months was 4% and 6% respectively (Supplementary Table S6.2). 
Mortality increased with age from 2 to 8/100 pyrs in the youngest and oldest groups 
(Table 6.1). In keeping with this the median time to death halved between individuals 
aged 40-44 and 65+ years (841 vs. 438 days). In univariate analysis, there was a dose 
response in the effect of age on the hazard of mortality (Table 6.2). Compared with 
patients 16-29 years, the crude hazard was slightly higher in those 30-34 (HR 1.08, 95% 
CI 1.01-1.15) and three-fold higher in patients aged ≥65 years old (HR 2.94, 95% CI 
2.35-4.67). These associations were attenuated but persisted in multivariable analysis 
adjusted for baseline characteristics (aHR 2.14, 95% CI 1.63-2.79, 65+ vs. 16-29 years 
old). Other baseline characteristics which increased the risk of mortality were male 
gender, decreasing CD4+ cell count and WHO stages III/IV vs. I & II.  
 
HIV increased mortality risk across all ages. On average, the five-year cumulative 
hazard of death was consistently approximately 10% higher among patients with HIV 
than in the HIV-negative population with the same age profile (Figure 6.1). For example 
an HIV-positive patient aged 16-29 starting ART had a similar five-year cumulative 
hazard of mortality compared to an HIV-negative 60 year old patient. At older ages HIV 
mortality increased compared with non-HIV mortality and the difference was greatest 






Table 6.2.  Crude and adjusted mortality after multiple imputation, overall and by duration on ART. 
 Overall 0-12 months 12-24 months 24-36 months 
 HR aHR aHR aHR aHR 
Age (years)      
16-29 1 1 1 1 1 
30-34 1.08 (0.99-1.17) 1.05 (0.97-1.15) 1.05 (0.90-1.22) 0.99 (0.73-1.35) 0.83 (0.56-1.23) 
35-39 1.17 (1.07-1.27) 1.12 (1.03-1.23) 1.14 (0.99-1.32) 1.11 (0.82-1.50) 0.83 (0.57-1.22) 
40-44 1.25 (1.14-1.38) 1.21 (2.20-1.34) 1.26 (1.09-1.46) 1.14 (0.84-1.55) 0.78 (0.53-1.17) 
45-49 1.48 (1.33-1.64) 1.41 (1.26-1.58) 1.37 (1.17-1.60) 1.39 (1.01-1.91) 0.87 (0.57-1.32) 
50-54 1.71 (1.51-1.94) 1.62 (1.42-1.85) 1.52 (1.28-1.80) 1.63 (1.16-2.27) 1.26 (0.82-1.93) 
55-59 1.77 (1.50-2.09) 1.65 (1.38-1.97) 1.89 (1.57-2.27) 1.85 (1.30-2.66) 1.87 (1.20-2.92) 
60-64 2.57 (2.04-3.24) 2.28 (1.78-2.93) 2.04 (1.63-2.54) 1.77 (1.11-2.82) 2.44 (1.45-4.10) 
65+ 3.11 (2.39-4.05) 2.53 (1.90-3.38) 2.79 (2.21-3.53) 3.21 (2.04-5.06) 2.06 (1.07-3.98) 
Male gender 1.63 (1.54-1.73) 1.43 (1.35-1.53) 1.28 (1.19-1.37) 1.38 (1.20-1.59) 1.74 (1.45-2.10) 
CD4+ cell count (cells/µL)      
<50 1 1 1 1 1 
50-99 0.64 (0.60-0.71) 0.71 (0.65-0.78) 0.60 (0.55-0.65) 0.82 (0.69-0.97) 0.91 (0.72-1.17) 
100-199 0.41 (0.38-0.44) 0.54 (0.80-0.59) 0.40 (0.37-0.44) 0.61 (0.52-0.72) 0.85 (0.68-1.06) 
200-349 0.24 (0.21-0.27) 0.38 (0.33-0.43) 0.30 (0.26-0.35) 0.53 (0.41-0.68) 0.60 (0.42-0.86) 
350-499 0.33 (0.25-0.44) 0.47 (0.35-0.63) 0.43 (0.31-0.59) 0.64 (0.34-1.22) 1.25 (0.58-2.70) 
≥500 0.22 (0.13-0.36) 0.33 (0.20-0.56) 0.39 (0.25-0.62) 0.40 (0.13-1.26) 1.60 (0.59-4.31) 
WHO stage      
I & II 1 1 1 1 1 
III 2.28 (2.04-2.54) 1.62 (1.44-1.82) 1.61 (1.34-1.93) 1.70 (1.34-2.16) 1.53 (1.12-2.08) 
IV 3.39 (3.00-3.83) 2.26 (1.94-2.62) 2.42 (1.98-2.97) 2.15 (1.69-2.75) 2.14 (1.52-3.02) 
Anemia      
none 1 1 1 1 1 
mild 1.76 (1.64-1.89) 1.37 (1.23-1.53) 1.51 (1.31-1.75) 1.37 (1.10-1.71) 1.33 (1.00-1.76) 
moderate 3.10 (2.87-3.35) 1.99 (1.80-2.20) 2.40 (2.05-2.81) 1.77 (1.41-2.22) 1.57 (1.14-2.15) 
severe 4.72 (4.00-5.56) 2.89 (2.49-3.35) 3.89 (3.35-4.52) 2.03 (1.46-2.84) 1.66 (1.04-2.64) 
TB at enrollment 1.53 (1.40-1.65) 0.82 (0.75-0.90) 0.81 (0.73-0.91) 0.83 (0.66-1.04) 0.92 (0.72-1.18) 




The effect of age on mortality modified by duration on ART 
The effect of age on mortality changed with duration on ART (Table 6.2). In the first 
year on ART, there was an increase in the risk of mortality at all ages ≥40 years 
compared with the youngest age group. With longer duration on ART, the age 
threshold for elevated mortality increased: in the second year on treatment, mortality 
was higher among patients ≥45 years at baseline. In the third year on ART, only 
patients who had started ART ≥55 years of age had a higher risk of death than those 16-
29 years. The effects of other baseline characteristics were attenuated but persisted 
over time on ART. 
 
6.3.3 Age, immunologic status and mortality 
Although there was no age difference in the baseline median CD4+ cell count between 
the youngest and oldest groups, immunologic responses on ART were clearly age-
related, with smaller gains in CD4+ cell counts on ART with increasing age (Table 6.3, 
Figure 6.2). The pattern of response by age was sustained over three years. After 36 
months on ART, the median CD4+ cell count increase from baseline was 290 cells/µL, 
ranging from 310 cells/µL in the youngest to 193 cells/µL in the oldest group. The 
differences observed over time appeared to be driven by changes in the first year on 
treatment (Figure 6.2). In subsequent years, immunologic response followed the same 
age pattern as in the first year. The effect of age on mortality was modified by baseline 
immunologic status and was more pronounced at lower baseline CD4+ cell counts 
(Figure 6.3). Comparing patients 50+ years old with those 16-39, there was a 1.5-fold 
higher hazard of death if they started ART at  ≥200 cells/µL and a 2.5-fold higher hazard 
if they started at <50 cells/µL (aHR 1.54, 95% CI 1.33-1.78 vs. aHR 2.52, 95% CI 2.04-




























































Figure 6.1.  Five-year cumulative hazard of HIV* and non-HIV** mortality by age. 
              *   HIV mortality was corrected via linkage to the National Population Register. 
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Table 6.3.  Immunologic responses by age and duration on ART. 
 Age categories (years) 
CD4+ cell count (cells/µL) 16-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+ TOTAL 
Baseline           
Median 137 120 117 120 124 128 125 130 135 125 
12 months on ART           
Median 324 294 274 273 273 261 263 266 234 291 
Median increase from baseline 194 173 156 155 147 138 127 120 102 167 
24 months on ART           
Median 403 376 350 349 343 330 323 322 298 367 
Median increase from 12 months 79 82 76 76 70 69 60 56 64 76 
Median increase from baseline 266 256 233 229 219 202 198 192 163 242 
36 months on ART           
Median 447 426 402 397 397 379 354 333 328 415 
Median increase from 24 months 44 50 52 48 54 49 31 11 30 48 

































Figure 6.3.  Hazard ratios of the interaction between the effects of  




6.3.4 The effect of age on LTF 
The cumulative incidence of LTF, having not experienced the competing risks of TFO or 
death, at 12 and 36 months was 12% and 23% respectively (Supplementary Table S6.2). 
In contrast to mortality, the proportion of patients LTF decreased with increasing age 
(Table 6.1). In crude and multivariable analysis after correction via the NPR, patients 
aged 16-29 had the highest hazard of LTF (Supplementary Table S6.3). All patients >50 
years had a 20-30% lower hazard of being LTF than those aged 16-29 years (aHR 0.69, 





6.4 Discussion  
In this study of 83,576 ART-naive individuals starting treatment from 2002-2013, we 
observed increasing proportions of older patients initiating ART and remaining in care 
in successive calendar years. The majority of patients were aged <35 years and 9% 
were ≥50 years old. Eighty percent of the youngest age group were female. Mortality 
increased with baseline age up to two years on ART but by the third year, only patients 
who started treatment at ≥50 years had a higher risk than those 16-29 years. Baseline 
CD4+ cell counts were similar across all age groups. The effect of age on mortality was 
modified by baseline immunologic status and was more pronounced at lower CD4+ cell 
counts. Immunologic responses were diminished over time in older patients. 
 
In recent years there has been growing concern about the lack of data on HIV and ART 
in older adults in Africa(106-108,116,182,183,191). Our study provides important new 
evidence that a substantial proportion of older individuals are initiating ART across 
South Africa, and that this proportion has increased each successive year. We found 
that despite the absence of a program targeting older individuals for HIV testing and 
treatment, nearly ten percent of all new patients were ≥50 years, paralleling recent 
findings from Malawi(192), Uganda(184) and nine countries in sub-Saharan Africa(193).  
 
Baseline immunologic status modified the effect of age on mortality. The effect of age 
was stronger at lower baseline CD4+ cell counts. This new finding has important clinical 
implications, suggesting that both age and baseline CD4+ cell count need to be 
considered when enrolling patients on ART. The development of a mortality risk index 
for Africa such as the Veterans Aging Cohort Study (VACS) Index has previously been 
mooted(107) and a prognostic model for patients starting ART in SSA has been 
reported (188). Both approaches include age and CD4+ cell count, and would be 





The effect of age on mortality was also modified by duration of ART use. During the 
first year on ART there was an apparent increase in mortality risk for every additional 
five years of age at enrollment. However with increasing duration of therapy, the 
association between age and mortality diminished in the younger age groups: by the 
second year on ART, risk was elevated in patients aged ≥45 years and by the third year, 
only among adults ≥55 years compared with 16-29 years. In sensitivity analysis with age 
as a binary (<50 vs. ≥50 years), individuals 50 years and older had nearly twice the 
hazard of death compared with individuals younger than 50 years (aHR 1.72, 95% CI 
1.59-1.85). These data have programmatic implications, suggesting that individuals >50 
years starting ART should be considered a high risk category with specific clinical and 
policy considerations up to three years on ART.  
 
While we have found evidence that HIV and/or ART increase mortality as patients age, 
it remains unclear whether this is due to acceleration or accentuation of the natural 
aging processes. However our results suggest that mortality may be higher among 
older people because of acceleration. We observed a higher five-year cumulative 
hazard of death in all age groups of HIV-infected adults compared with an HIV-negative 
population with the same age-profile. In an African context, accelerated aging has 
major social and financial implications. Older people, particularly older women, are 
often the primary caregivers(194). In 90% of the poorest households in South Africa, 
old age pensions are the only form of income. Benefits extend to the broader 
household and include improved child health status, especially for girls living with 
grandmothers who receive pensions. Given their social roles, the removal of older 
adults will have broad impact. 
 
If HIV accentuated the natural aging process, we would expect HIV to increase 
mortality disproportionately with increasing age. Instead we found a fairly constant 
difference in the mortality hazard across all HIV-positive age groups. This is in keeping 




Study of Global Aging and Adult Health (SAGE) which found no association with HIV 
despite a higher incidence of chronic conditions among South African adults ≥50 years 
compared with those 18-49 years(191). In contrast, the Dutch AGEhIV Cohort Study 
reported more co-morbidity among HIV-positive individuals than controls (195). The 
establishment of a prospective cohort study of older individuals starting ART could 
provide important evidence on whether HIV accentuates aging in a South African 
context.  
 
Several commentators have noted that older individuals have been neglected in 
understandings of the HIV epidemic, particularly in SSA. This analysis makes a novel 
contribution to understanding one aspect of the HIV epidemic in older adults. However 
there remains an urgent need for more epidemiologic data on HIV in older African 
adults. For example, HIV prevalence is not generally measured in older individuals. 
Prevalence estimates are largely based on data from antenatal surveys limited to 
women of reproductive age and Demographic & Health Surveys (DHS) restricted to 
adults ≤50 years. Estimates of prevalence among older adults in South Africa are highly 
variable and are twice as high in two rural health and socio-demographic surveillance 
system (DHSS) sites as in other ART roll-out sites (114,119,196). There is an urgent need 
to extend epidemiologic measures beyond 50 years of age and to include older 
individuals in studies to ensure their successful engagement in ART services.  
 
Finally, it is well established that women in Africa have better access to ART than 
men(63,123,197). However we found that the gender difference in enrollment is 
largely concentrated in the ages 16-34. One interpretation of this novel finding is that 
there may be undiagnosed HIV in younger men. In 2012 HIV prevalence in South Africa 
was reportedly highest in 30-34 year old women and 35-39 year old men (36% vs 29%), 
suggesting that men are infected at older ages than women(2). While this may be true, 
our results suggest that prevalence in young males may be underestimated given the 




men for HIV prevention, testing and linkage to HIV care. In addition, analyses should 
disaggregate data by gender and age in order to identify and address pronounced 
differences that may be masked by overall estimates.  
 
To our knowledge this is the first study to report that baseline immunologic status 
modifies the effect of age on mortality in ART programs. The study is strengthened by 
large patient numbers including a substantial number of patients ≥50 years and lengthy 
patient follow-up time. A further strength is consistency of findings across cohorts, 
increasing confidence in the overall estimates (Supplementary Table S6.4). However, 
interpretation of these results is subject to several limitations. These data come from 
numerous ART programs and there is a substantial amount of missing data. For 
example, national identity (IDs) numbers were only available on 50% of patients and it 
is possible that there are systematic differences between patients with and without IDs 
which has not been accounted for. Data were missing for baseline CD4+ cell count, 
which we addressed by using MI and sensitivity analyses to confirm our main findings. 
Data on time since infection could have informed interpretation of the findings, but 
these were not available. Lastly, we have not observed mortality in HIV-negative 
populations where our study populations are located, but used a national-level 
actuarial model to estimate HIV-negative mortality. We were also unable to 
differentiate between mortality from HIV and from other causes as these data are not 
routinely available. All-cause mortality is differentially higher in older persons than in 
younger individuals, which might explain some of the age differential in mortality. It is 
likely that our findings are generalizable to the national ART program and to other 
settings in SSA, but further research is needed in different contexts. 
 
Age is routinely reported as a demographic variable but its specific effect on HIV-
related mortality has received surprisingly little attention in African ART programs. 
With increasing numbers of older individuals on ART, the emphasis in developed 




in care and managing premature complications associated with age(106). Ten years 
into the national ART program, a similar shift is required in South Africa. Prevention 
and testing campaigns need to target older adults. Health care workers need training in 
initiating and managing older individuals on ART, to ensure good outcomes on 
treatment. The risk of co-morbidities and polypharmacy in older patients needs to be 
quantified, whether through longitudinal studies or the linkage of data platforms. 




Supplementary Table S6.1.  Patient enrollment, median age, proportions of patients ≥50 years enrolled and in care, by calendar year of 
enrollment. 
2004 2005 2006 2007 2008 2009 2010 2011 2012 /13 OVERALL
Patients enrolled (n) 4,999 6,794 8,522 8,697 10,130 11,204 12,088 11,483 9,659 83,592
Median age (years) 34 34 35 35 35 35 35 35 35 35
Percentage enrolled ≥50 years old 6 6 8 8 9 9 9 11 10 9








Failure function (%) Cumulative 
Incidence Function
Failure function (%)
12 months 4.1 (4.0-4.2) 4.4 12.0 (11.8-12.2) 9.6
24 months 5.4 (5.2-5.6) 6 17.6 (17.4-17.9) 16.2




Supplementary Table S6.3.  Crude and adjusted estimates of the hazard of loss to follow-up. 
 Crude HR Adjusted HR 
Age groups (years)   
16-29 1 1 
30-34 0.87 (0.84-0.90) 0.81 (0.78-0.84) 
35-39 0.87 (0.84-0.90) 0.76 (0.73-0.79) 
40-44 0.84 (0.80-0.87) 0.73 (0.70-0.77) 
45-49 0.81 (0.76-0.85) 0.69 (0.66-0.74) 
50-54 0.80 (0.74-0.85) 0.66 (0.62-0.72) 
55-59 0.93 (0.85-1.01) 0.74 (0.67-0.82) 
60-64 1.17 (1.02-1.33) 0.90 (0.78-1.04) 
65+ 0.93 (0.76-1.13) 0.82 (0.67-1.02) 
Male gender 1.25 (1.21-1.28) 1.26 (1.22-1.29) 
CD4+ cell count, median 
(cells/µL) 
  
<50 1 1 
50-99 0.94 (0.90-0.98) 1.01 (0.96-1.05) 
100-199 0.93 (0.89-0.96) 1.02 (0.98-1.06) 
200-349 0.98 (0.94-1.03) 1.01 (0.95-1.06) 
350-499 1.01 (0.90-1.14) 1.15 (1.00-1.31) 
≥500 1.03 (0.88-1.20) 1.23 (1.04-1.45) 
WHO stage   
I & II 1 1 
III 0.97 (0.94-1.00) 1.00 (0.96-1.04) 
IV 0.95 (0.91-1.00) 0.96 (0.90-1.01) 
Anemia   
none 1 1 
mild 1.08 (1.04-1.12) 1.09 (1.05-1.14) 
moderate 1.20 (1.15-1.26) 1.20 (1.15-1.27) 
severe 1.27 (1.19-1.35) 1.34 (1.26-1.43) 
TB at ART start 1.06 (1.01-1.11) 1.10 (1.04-1.16) 
Cohort   
Gugulethu 1 1 
Hlabisa 0.26 (0.24-0.27) 0.14 (0.14-0.15) 
Khayelitsha 0.33 (0.32-0.35) 0.19 (0.19-0.20) 
McCord 1.45 (1.39-1.51) 0.71 (0.67-0.75) 
Themba Lethu 0.50 (0.48-0.52) 0.37 (0.35-0.39) 
Tygerberg 0.25 (0.23-0.27) 0.17 (0.16-0.19) 
Year   
2004 1 1 
2005 1.38 (1.30-1.47) 1.61 (1.50-1.72) 
2006 1.80 (1.69-1.91) 2.45 (2.29-2.62) 
2007 2.27 (2.13-2.42) 3.23 (3.01-3.47) 
2008 2.58 (2.41-2.75) 4.06 (3.78-4.37) 
2009 3.68 (3.45-3.93) 5.76 (5.34-6.20) 
2010 4.43 (4.15-4.73) 8.29 (7.68-8.95) 
2011 4.57 (4.26-4.91) 11.76 (10.84-12.77) 




Supplementary Table S6.4. Hazard ratios of the interaction between the effects of 
baseline CD4+ cell count and age on mortality. 
 
Age (years) <50 50-199 ≥200
16-39 1 1 1
40-49 1.49 (1.24-1.80) 1.25 (1.15-1.36) 1.14 (1.03-1.27)
≥50 2.52 (2.04-3.11) 1.79 (1.62-1.98) 1.54 (1.33-1.78)





Supplementary Table S6.5.  Exploring heterogeneity between cohorts:  median age and proportion of patients ≥50 years old and estimates of the effect 
of age on mortality adjusted for baseline characteristics, by cohort. 
 Cohort 
 Gugulethu Hlabisa Khayelitsha McCord Themba Lethu Tygerberg 
Age, median (years) 34 (29-40) 35 (29-42) 34 (29-40) 35 (30-42) 36 (31-43) 34 (29-41) 
Proportion of patients ≥50 years old 407 (7) 2,167 (11) 1,473 (6) 612 (9) 2,294 (10) 346 (8) 
       
Age categories (years) Adjusted Hazard Ratios (aHR), effect of age on mortality adjusted for baseline characteristics, by cohort 
16-29 1 1 1 1 1 1 
30-34 0.92(0.69-1.23) 1.07 (0.94-1.22) 1.06 (0.93-1.21) 1.02 (0.71-1.47) 1.03 (0.90-1.19) 1.01 (0.73-1.41) 
35-39 1.18 (0.87-1.61) 1.11 (0.97-1.27) 1.07 (0.93-1.24) 1.28 (0.91-1.80) 1.21 (1.04-1.40) 1.17 (0.84-1.63) 
40-44 1.41 (1.03-1.94) 1.11 (0.96-1.30) 1.26 (1.07-1.49) 1.68 (1.16-2.45) 1.38 (1.18-1.61)( 1.34 (0.95-1.88) 
45-49 1.42 (0.99-2.03) 1.40 (1.19-1.65) 1.37 (1.09-1.73) 1.89 (1.20-2.97) 1.44 (1.20-1.73) 1.00 (0.66-1.51) 
50-54 1.40 (0.89-2.18) 1.53 (1.24-1.91) 1.58 (1.23-2.03) 3.57 (2.21-5.76) 1.77 (1.44-2.17) 1.97 (1.26-3.06) 
55-59 2.41 (1.30-4.48) 1.35 (1.04-1.74) 2.42 (1.82-3.23) 2.13 (0.97-4.69) 2.42 (1.90-3.08) 1.42 (0.69-2.92) 
60-64 3.50 (1.88-6.51) 2.35 (1.73-3.20) 3.29 (2.02-5.36) 2.35 (1.02-5.36) 2.55 (1.76-3.70) 2.71 (1.31-5.59) 
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Abstract    
 
Introduction 
Increased mortality among men on antiretroviral therapy (ART) has been 
documented but remains poorly understood. We examined the magnitude 
of, and risk factors for, gender differences in mortality on ART. 
 
Methods and findings 
Analyses included 46,201 ART-naïve adults starting ART between January 
2002 and December 2009 in eight ART programs across South Africa (SA). 
Patients were followed from initiation of ART to outcome or analysis closure. 
The primary outcome was mortality; secondary outcomes were loss to 
follow-up (LTF), virologic suppression and CD4+ cell count responses. 
Survival analyses were used to examine the hazard of death on ART by 
gender. Sensitivity analyses were limited to patients who were virologically 
suppressed and patients whose CD4+ cell count reached >200 cells/µL. We 
compared gender differences in mortality among HIV+ patients on ART with 
mortality in an age-standardized HIV-negative population. 
 
Among 46,201 adults (65% female, median age 35 years), during 77,578 
person-years of follow-up, men had lower median CD4+ cell counts (85 vs. 
110 cells/µL, p<0.001), were more likely to be classified WHO stage III/IV (86 
vs. 77%, p<0.001), and had higher mortality in crude (9 vs. 6 deaths/100 
person-years, p<0.001) and adjusted analyses (aHR 1.31, 95% CI 1.22-1.41). 
After 36 months on ART, men were more likely than women to be truly LTF 
(aHR 1.20, 95% CI 1.12-1.28) but not to die after LTF (aHR 1.04, 95% CI 0.86-
1.25). Findings were consistent across all eight programs. Virologic 
suppression was similar by gender; women had slightly better immunologic 
responses than men. Notably, the observed gender differences in mortality 
on ART were smaller than gender differences in age-standardized death 
rates in the HIV-negative South African population. Over time, non-HIV 
mortality appeared to account for an increasing proportion of observed 
mortality. The analysis was limited by missing data on baseline HIV disease 
characteristics, and we did not observe directly mortality in HIV-negative 
populations where the participating cohorts were located. 
 
Conclusion 
HIV-infected men have higher mortality on ART than women in SA programs, 
but these differences are only partly explained by more advanced HIV 
disease at the time of ART initiation, differential LTF and subsequent 
mortality, and differences in responses to treatment. The observed 
differences in mortality on ART may be best explained by background 
differences in mortality between men and women in the South African 







South Africa has the largest antiretroviral therapy (ART) program worldwide. The 
program has undergone rapid expansion with nearly 1.8 million individuals initiating 
ART since 2004(198). Given the unprecedented scale of this initiative there is an 
urgent need to evaluate the outcomes of the program in order to improve delivery 
of services. There is particular interest in gender differences in ART program access 
and survival. Disproportionately more women than men have accessed 
antiretroviral therapy (ART) in sub-Saharan Africa(123,197). Studies from Europe 
and North America suggest a higher risk of death on ART for women than men(199); 
in contrast, across sub-Saharan Africa men appear to experience greater mortality 
than women on treatment(71,200-202).  
 
A range of possible explanations for gender differentials in mortality on ART have 
been suggested but there has been no comprehensive evaluation of the putative 
mechanisms. Baseline characteristics strongly predict mortality on ART(5,132,171) 
and men initiating ART in many African programs have more advanced HIV disease 
than women(61,197,201). In addition, loss to follow-up (LTF) is associated with 
mortality(145) and men are more likely to become LTF than women in many 
settings(54,203). Evidence regarding gender differences in immunologic and 
virologic responses is mixed(199). It is vital to understand such differentials in order 
to improve health outcomes in this large and rapidly expanding health service.  
 
We examined the magnitude of, and risk factors for, gender differences in 
mortality. We included data from eligible adults starting ART in the South African 
sites of the International Epidemiologic Databases to Evaluate AIDS Southern Africa 
(IeDEA-SA) collaboration between 2002 and 2009, representing about 10% of all 
patients enrolled nationally during this period(198). We hypothesized that 
increased mortality in men on ART, if present, would be explained by differences in:  
1) baseline characteristics; 2) differential risk of LTF and subsequent mortality; 






7.2.1 Study design, population & eligibility criteria 
The South African cohorts of IeDEA-SA have been described in detail 
elsewhere(39,64). Briefly, the collaboration includes eight adult cohorts providing 
ART services in 3 of the most populous provinces (Gauteng, KwaZulu-Natal and 
Western Cape). Cohorts range in size and are predominantly government-funded 
and follow national HIV treatment guidelines. The multicenter cohort is broadly 
representative of patients accessing public sector ART in rural and urban centers. 
This retrospective cohort analysis included all ART-naïve HIV-positive adults (≥16 
and <=80 years) who initiated ART between 2002 and 2009. 
 
7.2.2 Variables and definitions   
Baseline characteristics measured immediately before ART initiation included 
demographics (age, gender), available measures of HIV disease severity (CD4+ cell 
count, WHO stage, HIV viral load), clinical and laboratory characteristics 
(hemoglobin, weight) and calendar year of ART initiation. CD4+ cell count and viral 
load measures were taken after 12, 24 and 36 months on ART. When 
measurements were not available at these time points, we included the closest 
laboratory measurement within a three-month period on either side of the date as 
available. All laboratory tests were performed by the South African National Health 
Laboratory Services. 
 
We treated the following variables as categorical: age (16-24, 25-34, 35-44, 45+ 
years), CD4+ cell count (0-24, 25-49, 50-99, 100-199, 200+ cells/µL), WHO stage (I & 
II, III, IV) and hemoglobin; we treated weight and log viral load as continuous 
variables. Due to gender variability in hemoglobin levels, we generated a categorical 
variable (anemia) from the hemoglobin level (measured in g/dL), which was defined 
as: none: females >11.9, males >13.1; mild: females 10-11.9, males 11-13.1; 
moderate: females 8.1-<10, males 8.1-<11; severe: <8.1(188). We defined virologic 





The primary outcome was mortality. Secondary outcomes were LTF, virologic 
suppression and CD4+ cell count responses. Deaths were identified by the sites or 
by linkage to the National Population Register (NPR) of the Department of Home 
Affairs.  Transfers were recorded by programs and observation time was right-
censored at the date of transfer. Patients were defined as LTF if there was no 
patient contact between analysis closure and database closure. Analysis closure 
preceded database closure by six months to allow patients to meet the LTF 
definition. LTF date was defined as the last patient contact date. In order to 
differentiate between patients who were truly LTF and patients who had died 
within three months of being LTF (misclassified deaths), we used linkage 
information to trace patients LTF with South African civil identification (ID) numbers 
(Supplementary Figure S7.1).  Patients who had a date of death within three months 
after LTF were defined as misclassified deaths. Those with ID numbers who were 
not found in the population register in this period were defined ‘true LTF’(91) For 
patients who started ART but had no further contact, we added one day of follow-
up to allow their inclusion in survival analyses.  
 
7.2.3 Missing data 
Based on the assumption that data were likely missing at random, we used MI(189) 
by chained equation methods(190) to impute missing baseline data. We multiply 
imputed (20 times) baseline CD4+ cell count, WHO stage, viral load, weight and 
hemoglobin. The MI models included all measured variables.  
 
Given that a high proportion of patients LTF are likely to have died(145), we used 
inverse probability weighting(55) to correct mortality and LTF for missing deaths 
among those defined as LTF. Briefly, LTF patients with ID numbers (approximately 
50%) were linked to the South African National Population Register registry to 
determine their true vital status (and date of death if deceased) and weighted to 







Data were analyzed using STATA 11.0 (STATA Corporation, College Station, Texas, 
USA). Baseline characteristics were described with summary statistics (median, 
interquartile range (IQR) and proportions) by gender. Differences between 
proportions and medians were tested with Pearson’s chi-squared test for 
proportions or the two-sample Wilcoxon rank-sum test. Two-sided statistical tests 
were used at alpha=0.05. Time to death and time to ‘true’ LTF were analyzed from 
date of ART initiation using Kaplan-Meier curves.   
 
Cox’s proportional hazards regression models were used to assess crude and 
adjusted associations between patient characteristics and outcomes. All available 
plausible demographic and clinical variables were considered potential confounders 
and were included in multivariable models if they altered the association between 
gender and mortality or were significantly associated with the outcome under 
study. Results are presented as hazard ratios (HRs) with a 95% confidence interval 
(CI) by duration on ART. The proportional hazards assumption was confirmed by 
testing gender/time and gender/log time interaction terms. We undertook 
sensitivity analyses limited to patients who were virologically suppressed and 
patients whose CD4+ cell count reached >200 cells/µL. We explored heterogeneity 
in analyses stratified by cohort. The gender mortality ratio was defined as the male 
divided by the female mortality rate. 
 
To compare gender differences in our cohort with expected gender differences in 
the HIV-negative population, we calculated HIV-negative mortality in the South 
African male population and female population, age-standardized to our patients. 
Age-specific HIV-negative mortality rates in males and females were obtained from 
the Actuarial Society of South Africa (ASSA) estimates of non-HIV mortality in the 
year 2005(204) which are derived from vital registration statistics as well as census 
and survey data (further explanation of the derivation of these rates is provided in 






Among 58,124 patients assessed for eligibility, 11,923 were ineligible for the 
following reasons: age <16 or >80 years (n=4,344), missing or invalid dates (birth, 
ART initiation, last visit, outcomes) (n=4,770), non-naïve (n=2,806), unknown sex 
(n=3) (Figure 7.1). This analysis included 46,201 adults who started ART between 1 
January 2002 and 31 December 2009 (median age 35 years; 65% female, Table 7.1), 
contributing a total of 77,578 person-years of follow-up. Men had a shorter median 
time to death (483 vs. 532 person-days) and ‘true’ LTF (434 vs. 495 person-days) 
than women. By the end of the study period, 29,901 patients were still on ART, 67% 
(n=20,151) of these female. 
 
At initiation of ART, men were older than women (38 vs. 33 years) and had lower 
median CD4+ cell counts (85 vs. 110 cells/µL) (Table 7.1). Men were more likely 
than women to have a CD4+ cell count <50 cells/µL (34 vs. 26%) and to be classified 
WHO stage III/IV (86 vs. 77%). The median hemoglobin level was similar for men 
and women (12 vs. 11 g/dL). Among females initiating ART, 7% were pregnant. 
Gender differences in baseline characteristics were consistent across all the eight 
cohorts (Figure 7.2).  
 
7.3.1 Gender and mortality 
In total, after correction via linkage to the National Population Register, there were 
3,946 deaths, 57% among women. Men had a higher risk of mortality (Figure 7.3). 
The crude mortality on ART was higher for men than women: 8.5 vs. 5.7/100 
person-years, unadjusted hazard ratio 1.46 (1.37-1.56), p<0.001. In multivariable 
analysis, after adjusting for baseline age, cohort, CD4+ cell count, WHO stage, log 
viral load, anemia and weight, men had a 31% higher risk of death than women 
(aHR 1.31, 95% CI 1.22-1.41) (Table 7.2). Other baseline factors associated with 
mortality were age >35 years, CD4+ cell count, WHO stage, anemia, weight and viral 
load  (Supplementary Table S7.1). The association between gender and death 
persisted with increasing duration on ART. In a stratified analysis, the elevated risk 




Excluding WHO stage from the adjusted model did not change our main finding 






Figure 7.1: Patient flowchart of a combined cohort of adult patients initiating public 




Table 7.1.  Patient characteristics among 46,201 adults initiating public-sector ART in 
South Africa, 2002-2009. 
Baseline characteristic* 
Males Females Total 
(n=16,108, 35%) (n=30,093, 65%) (n=46,201) 
Age, median (IQR), years 38 (33-44) 33 (29-40) 35 (30-42) 
16-24   n(%)** 442 (3) 3,124 (11) 3,566 (8) 
25-34 5,639 (35) 14,214 (47) 19,853 (43) 
35-44 6,486 (40) 8,810 (29) 15,296 (33) 
>=45 3,541 (22) 3945 (13) 7,486 (16) 
CD4+ cell count, median (IQR), cells/μL 85 (33-153) 110 (48-171) 101 (42-166) 
0-24  n(%) 2,785 (20) 3,770 (15) 6,555 (16) 
25-49 1,965 (14) 2,832 (11) 4,797 (12) 
50-99 3,002 (22) 5,267 (20) 8,269 (21) 
100-199 4,798 (35) 10,772 (41) 15,570 (39) 
>=200 1,321 (10) 3,353 (13) 4,674 (12) 
Missing data 14% 14% 14% 
WHO stage, n(%) 5,538  (34) 11,290 (38) 16,828 (36) 
I & II 790 (14) 2,704 (24) 3,494 (21) 
III  3,221 (58) 5,933 (53) 9,154 (54) 
IV 1,527 (28) 2,653 (24) 4,180 (25) 
Missing data 66% 62% 64% 
Viral load, n(%) 8,092 (50) 14,876 (49) 22,968 (50) 
Log10 copies/ml, median (IQR) 4.9 (4.4-5.3) 4.8 (4.2-5.3) 4.8 (4.3-5.3) 
Missing data 50% 51% 50% 
Hemoglobin, n(%) 11,714 (73) 20,237 (67) 33,239 (72) 
Median (IQR), g/dL 12 (10-14) 11 (10-12) 11 (10-13) 
Missing data 27% 33% 28% 
Anemia, n(%) 11,714 (73) 20,237 (67) 33,239 (72) 
None 3,813 (33) 4,968 (23) 8,781 (26) 
Mild 5,638 (48) 12,997 (60) 18,635 (56) 
Moderate/severe 2,263 (19) 3,560 (17) 15,823 (18) 
Weight, n(%) 12,740 (79) 23,788 (79) 36,528 (79) 
Median (IQR), kg 60 (53-67) 59 (51-68) 59 (52-68) 
Pregnant, n(%)***  1,494 (7%)  
Calendar year of ART initiation    
2002 & 2003 439 (3) 856 (3) 1,310 (3) 
2004 1,338 (8) 2,847 (9) 4,271 (9) 
2005 2,743 (17) 5,568 (19) 8,640 (18) 
2006 4,345 (27) 7,851 (26) 12,992 (26) 
2007 3,629 (23) 6,506 (22) 10,944 (22) 
2008 2,323 (14) 4,398 (15) 7,479 (15) 
2009 1,291 (8) 2,067 (7) 3,836 (8) 
Follow-up, median (IQR), person-days    
time to death 483 (172-877) 532 (216-918) 515 (200-905) 
time to 'true' LTF 434 (142-827) 495 (185-879) 476 (170-864) 
*       All differences between men and women were statistically significant (p<0.001)  
**     n(%) reflects the number (proportion) of patients with values for this variable 





Figure 7.2.  Baseline characteristics and hazard ratios for male vs. female (M:F)  































Table 7.2.  Crude and adjusted associations between male gender and mortality by 
duration on ART. 
Duration HR aHR 
0–12 months  1.28 (1.09–1.51)  1.10 (0.93–1.31) 
12–24 months 1.63 (1.37–1.94)  1.36 (1.05–1.78) 
24–36 months  1.62 (1.22–2.14)  1.39 (0.94–2.06) 
>36 months  1.71 (1.08–2.70)  1.35 (0.76–2.38) 
Total time  1.46 (1.37–1.56)  1.31 (1.22–1.41) 
Multivariable models adjusted for cohort, age, CD4+ cell count, WHO stage, anemia, weight, and log viral load at ART 




































7.3.2 Gender and loss to follow-up  
Using our initial definition, 8,303 adults were suspected LTF, 61% female 
(Supplementary Figure S7.1). We were able to ascertain the vital status of 4,389 
patients who had ID numbers (61% female). Among those patients who were LTF 
without ID numbers and whose outcomes could not be ascertained (n=3,914), 62% 
were female. After linkage to the NPR, we identified 746 patients who had died 
within three months of being suspected LTF. We regarded these as misclassified 
deaths (57% female). After correction for these deaths, a total of 3,643 patients 
were defined as ‘true’ LTF, 61% female.  
 
Men were more likely than women to experience ‘true’ LTF (Figure 7.4). The crude 
‘true’ LTF rate was 10/100 person-years, lower among women than men (9 vs. 
12/100 person-years respectively). In multivariable analysis, after adjusting for 
baseline age, cohort, CD4+ cell count, WHO stage, anemia, weight, viral load and 
calendar year of initiation, men were more likely to be ‘truly’ LTF than women 
(aHR1.20, 95% CI 1.12-1.28). Within each cohort, the trend towards increased risk 
of ‘true’ LTF was consistent but estimates were less precise. Using linkage to the 
NPR, we then explored mortality among those who were truly LTF with ID numbers 
(i.e. still alive three months after being suspected LTF). We found no gender 
difference in the hazard of death among those patients who were ‘truly’ LTF (aHR 
1.04, 95% CI 0.86-1.25). 
 
7.3.3 Gender and virologic and immunologic responses to ART 
There was a high proportion of virologically suppressed patients at 12, 24 and 36 
months on ART, with no evident gender difference in proportions (Table 7.3). When 
analysis of mortality was restricted to individuals who were virologically suppressed 
at 12 months, men still had a higher risk of death than women (aHR 1.38, 95% CI 
1.07-1.79). Women initiating ART had a higher baseline CD4+ cell count and better 
CD4+ cell count responses to men over 36 months (Supplementary Figure S7.2). The 
median incremental CD4+ cell gains for women and men at 12, 24 and 36 months 




for all comparisons). In a sensitivity analysis limited to patients who had reached a 
CD4+ cell count >=200 after a year on ART, the gender difference in mortality 
persisted (aHR 1.37, 95% CI 1.03-1.83) (analysis not shown). 
 
7.3.4   Gender and non-HIV mortality 
Given the persistence of the gender differential in mortality among patients on ART, 
we compared this to the background gender differential in mortality in the South 
African population. Figure 7.5 shows that the gender mortality ratio among patients 
on ART appears to be smaller than the age-standardized HIV-negative mortality 
ratio for men versus women in South Africa. HIV-negative men with the same age 
distribution as that in the ART cohort would be expected to die at twice the rate in 
HIV-negative women of the same age, compared with our adjusted hazard ratio of 
1.31 on ART.  
 
With increasing duration of ART, the contribution of expected non-HIV mortality to 
observed mortality increased from an estimated 5% in the first six months to 36% 
after 36 months among men, and from 3-25% among women during the same 
period (Table 7.3). In further analysis stratified by age (16-34 and 35+ years), 
expected non-HIV mortality accounted for a larger proportion of deaths in the older 
men than in the younger men (Supplementary Table S7.2). One exception was the 
proportion of observed male mortality attributable to non-HIV mortality at >36 
months, likely to be random error due to the small number of deaths at the longest 
duration. In both age groups, non-HIV mortality contributed more substantially to 
male mortality than to female mortality. In addition, over all periods on ART, 
although the expected ratio of male to female non-HIV deaths differed at younger 
and older ages, all ratios were greater than the male to female ratio of observed 





Table 7.3.  Virologic and immunologic responses by gender and duration on ART. 
Measurement 













Viral load tests       
      Total tested, n 13,529 6,600 8,280 3,798 4,225 1,958 
      Proportion suppressed
a
 0.87 0.86 0.86 0.86 0.93 0.95 
      Proportion missing data 0.36 0.38 0.37 0.44 0.43 0.50 
       
CD4+ cell counts    
      Total tested, n 15,882 7,752 9,510 4,438 4,728 2,168 
      Median, cells/µl (IQR) 294 (204-403) 239 (164-337) 381 (268-512) 315 (217-431) 437 (313-582) 359 (243-493) 
       
Median CD4+ cell count increase,
b 
(IQR) 179 (100-273) 145 (78-223) 89 (13-175) 70 (9-141) 63 (-22-147) 39 (-21-114) 
      Proportion missing data 0.24 0.28 0.28 0.35 0.36 0.45 
a   Proportion suppressed is the proportion of patients with available data who achieved a viral load ≤400 copies/ml. 
b   Median CD4+ cell count increase is the difference in CD4+ cell count at each time point between this measure and the measure taken at the previous time point; all differences between men and women were 

























Table 7.4. Observed crude mortality,* age-standardized HIV-negative mortality and 
expected non-HIV mortality as a proportion of observed mortality among men and 
women, by duration on ART. 
Gender Mortality 
Duration on ART 
0-6 mo** 6-12 mo 12-24 mo 24-36 mo >36 mo 




0.90 0.92 0.95 0.98 1.03 
 
Expected non-HIV mortality as a 
percentage of observed mortality 
5% 15% 21% 29% 36% 




0.36 0.37 0.38 0.39 0.42 
 
Expected non-HIV mortality as a 
percentage of observed mortality 
3% 8% 14% 19% 25% 





7.4 Discussion   
These analyses demonstrate that among patients initiating ART between 2002 and 
2009 at sites across South Africa, men had higher mortality than women. We 
hypothesized that gender differences in mortality would be explained by 
differences in baseline characteristics, LTF and subsequent mortality, and/or 
virologic and immunologic responses. However we found that the increased 
mortality risk among men persisted throughout each analysis, including after 
adjustment for measures of HIV disease at the time of ART initiation; in the subset 
of patients who achieved virologic suppression; and among patients with good 
immune responses to treatment.  
 
There is a large and growing body of work on gender and ART in developing 
countries, much of which documents the same association repeatedly(205): 
disproportionately fewer men than women access ART(123,125,197), and there is 
higher mortality among men than women on ART(54,64,200,202,206,207). Such 
studies typically speculate as to the possible mechanisms underlying the observed 
associations. Putative mechanisms include: poor health-seeking behaviors among 
men leading to more advanced disease at the time of ART initiation, differential  
rates of LTF leading to higher mortality, behavioral factors such as poor adherence, 
and/or biologic factors such as gender differences in immunologic responses to 
ART. However, there have been few systematic attempts to evaluate each of these 
possible mechanisms. 
 
In this study, women comprised the majority of adults starting ART across the 
country. In the early years of ART programs there were understandable concerns 
that due to gender imbalances, women may have reduced access to ART 
services(208). Contrary to this, however, there is mounting evidence that men 
appear disadvantaged in their access to ART programs. Numerous papers and a 
systematic review have suggested gender inequalities in ART access, particularly in 
Sub-Saharan Africa(123,197,202), and ART initiation in South Africa, relative to ART 





Among patients who do start ART, late presentation has been cited as one of the 
main reasons for increased male mortality in ART programs(199-202). In sub-
Saharan Africa, men appear to initiate ART at older ages and with more advanced 
HIV disease than women(64,123,197,201) and markers of advanced HIV disease at 
the time of ART initiation strongly predict early mortality on 
ART(61,69,138,171,209). However in our multivariable models we found that 
adjustment for baseline characteristics accounted for only part of the gender 
difference in mortality, and that the gender differentials in mortality continued to 
appear for several years after ART initiation. The reasons for men’s later entry into 
ART programs are poorly understood but frequently are attributed to gender 
differences in health-seeking behavior or in routes of referral(48). An alternate and 
more compelling explanation may be that while prioritizing maternal and child 
health services in many public health systems, men’s primary health care needs 
may have been neglected(48,210-212), a possibility that warrants further research 
attention. 
 
We then assessed the role of LTF in explaining mortality differentials. Increased 
mortality among patients LTF, especially within the first three months after LTF, has 
been well documented(91,155,157,173,213,214). In turn, it is plausible that if males 
are more likely to be LTF, this could explain their elevated mortality risk. Through 
linkage to the South African Population Register we were able to identify a group of 
patients who were truly LTF, and to trace their vital status after being LTF. Although 
men were more likely to be LTF compared with women, we found no gender 
difference in mortality after LTF, and deaths after LTF contributed only a small 
proportion of all deaths. Thus in these data, LTF alone did not appear to explain 
men’s increased mortality.  
 
Behavioral factors such as treatment adherence could also help to explain the 
observed increased male mortality on ART. Poor adherence to ART, measured by 




We found no apparent gender difference in virologic suppression, although 
previous studies have suggested that adherence may vary by gender(56). Of note, 
this finding was consistent across all cohorts, and in a sensitivity analysis restricted 
to patients who were virologically suppressed at twelve months, men still had a 
higher risk of subsequent death than women. As a result, gender differences in 
adherence to treatment do not appear to explain differences in mortality. 
   
Biologic differences between men and women have been suggested as shaping 
immunologic responses to ART and mortality risk. We found that women had higher 
CD4+ cell counts at ART initiation than men, and slightly better absolute CD4+ cell 
increases on treatment. This is in line with results from two collaborative studies in 
sub-Saharan Africa which documented greater immune recovery in women than in 
men, with gender-based differences increasing with time on ART(104,215). 
However even among patients with similar immunologic responses by one year on 
treatment, the gender difference in mortality persisted.  
 
In these data, the finding for persistently increased male mortality for up to three 
years on ART does not appear to be explained entirely by baseline differences in HIV 
disease status, variation in LTF, differences in virologic suppression, or sex-linked 
differences in immune responses to treatment. Having thus refuted our a priori 
hypotheses, we explored alternate explanations for the observed association. We 
examined evidence for gender differences in non-HIV adult mortality in South 
Africa, and found pronounced differences that appear independent of the HIV/AIDS 
epidemic. Specifically, evidence from actuarial modeling suggests that HIV-negative 
South African men in the same age groups as our study population have twice the 
mortality risk of women, although the male-female differences tend to be more 
pronounced in young adults than in older adults. This pattern is not unique to South 
Africa: similar trends are seen elsewhere in Africa and worldwide(216-220). This 
evidence places these data, and previous studies showing increased mortality 
among men in ART services across Africa, into perspective: among patients on ART, 




phenomenon operates in HIV-negative individuals. In fact, in South Africa the 
mortality ratio for men versus women on ART appears to be somewhat smaller than 
the age-standardized ratio for men versus women estimated for the HIV-negative 
population. Gender differentials in the mortality of HIV-negative individuals are 
well-documented in South Africa and include an increased burden of mortality 
among younger men due to traumatic causes and non-HIV TB(221). It is possible 
that through accessing ART services, men and women may access other preventive 
and curative services which reduce non-HIV mortality. While these findings are 
intriguing, it is important to recognize that our original hypotheses did not include 
gender differences in non-HIV mortality, and this phenomenon clearly requires 
further investigation.  
 
Observational studies of patients on ART face major constraints in terms of 
mortality ascertainment, LTF and missing measurements. Most cohort analyses 
from sub-Saharan Africa – and especially large collaborative analyses – have limited 
ability to ascertain true outcomes as they have little capacity to follow patients 
actively(201). In addition, few African countries have high quality vital 
statistics(219,222,223). In turn, most large ART programs have difficulty confirming 
patients’ true vital status(224) and in the absence of reliable death registration, 
researchers have undertaken targeted tracing studies(155). In South Africa, the 
National Population Register captures nearly 90% of adult deaths(89). Through our 
linkage with this register, we are able to distinguish between ‘true’ LTF and 
unrecognized mortality in many patients. Moreover, consistency of findings across 
different cohorts strengthens the generalizability of our results.  
 
Interpretation of these results is subject to several important limitations. These data 
come from multiple service delivery programs from across South Africa, and there is 
a substantial amount of missing data in this analysis. For example, SA national 
identity numbers were only available for 53% of those who were suspected to be 
LTF, and it is possible that there are systematic differences between patients with 




proportion of missing values for WHO stage and viral load; we tried to address this 
with MI and sensitivity analyses confirming our main findings. Missing data on 
specific risk factors for mortality, particularly prevalent tuberculosis at ART 
initiation(225), further limited this analysis. Finally, we did not observe mortality in 
HIV-negative populations where the participating cohorts are located, and instead 
used a national-level actuarial model to estimate mortality in men and women who 
are HIV-negative. These findings are likely to be generalizable to the South African 
national ART program, and potentially to other parts of the region, but further 
investigation in other settings is warranted. 
 
In summary, there have been concerns raised about the presence of gender 
differences in mortality on ART in South Africa and many other parts of the 
continent. In this study we systematically explored this phenomenon and found that 
none of the explanations posited for this association adequately explains the 
increased mortality observed among men on ART. Instead, the observed differences 
in mortality on ART appear may be best explained by background differences in 
death rates between men and women in the South African population, unrelated to 


































Supplementary Table S7.1: Crude and adjusted associations between male  
gender and mortality. 
  Overall Mortality 
  Crude HR Adjusted* HR 
Male gender 1.46 (1.37-1.56) 1.31 (1.22-1.41) 
Age (years)   
    16-24 ref ref 
    25-34 1.03 (0.90-1.18) 1.02 (0.89-1.17) 
    35-44 1.21 (1.06-1.39) 1.21 (1.05-1.39) 
    >=45 1.45 (1.25-1.68) 1.49 (1.28-1.73) 
WHO Stage   
    I & II ref ref 
    III 1.72 (1.36-2.16) 1.21 (0.94-1.55) 
    IV 2.80 (2.04-3.85) 1.58 (1.10-2.26) 
CD4+ cell count (cells/μl)   
    0-24 ref ref 
    25-49 0.79 (0.72-0.88) 0.81 (0.73-0.90) 
    50-99 0.52 (0.48-0.58) 0.61 (0.55-0.67) 
    100-199 0.33 (0.30-0.36) 0.46 (0.41-0.51) 
    >=200 0.31 (0.27-0.36) 0.49 (0.41-0.57) 
Weight (kg) 0.96 (0.96-0.97) 0.98 (0.97-0.98) 
Viral load (log10 copies/ml) 1.42 (1.33-1.53) 1.15 (1.06-1.26) 
Anemia   
    none ref ref 
    mild 1.64 (1.48-1.82) 1.31 (1.19-1.46) 
    moderate 2.73 (2.46-3.04) 1.85 (1.66-2.07) 
















Supplementary Table S7.2.  Mortality by duration on ART, stratified by age. 
    Duration since ART initiation 
  0-6 months 6-12 months 12-24 months 24-36 months >36 months 
Ages 16-34      
Male Observed mortality (crude) 18.3 5.9 3.2 3.6 1.5 
 HIV-negative mortality (age-standardized) 0.56 0.57 0.57 0.57 0.58 
 Expected non-HIV mortality as % of observed 3% 10% 18% 16% 38% 
 Standardized mortality rate (SMR) 32.3 10.2 5.5 6.2 2.7 
       
Female Observed mortality (crude) 12.7 4.5 2.2 2 1.5 
 HIV-negative mortality (age-standardized) 0.23 0.23 0.23 0.23 0.24 
 Expected non-HIV mortality as % of observed 2% 5% 10% 12% 16% 
 SMR 55.8 19.8 9.7 8.5 6.2 
       
Ages 35+       
Male Observed mortality (crude) 19.6 6.4 5.1 3.4 3.2 
 HIV-negative mortality (age-standardized) 1.09 1.09 1.11 1.12 1.16 
 Expected non-HIV mortality as % of observed 6% 17% 22% 33% 36% 
 SMR 18 5.8 4.6 3.0 2.8 
       
Female Observed mortality (crude) 13.8 5.2 3.3 2.2 1.8 
 HIV-negative mortality (age-standardized) 0.53 0.53 0.53 0.53 0.54 
 Expected non-HIV mortality as % of observed 4% 10% 16% 24% 30% 







Supplementary Text S7.1. Method for estimating non-HIV mortality. 
Due to the lack of vital registration systems in many developing countries(226), direct 
estimates of mortality by age and sex are often not available. To address this problem, life 
tables are often estimated for developing countries by taking ‘standard’ life tables (which 
define mortality rates by individual age and sex) and adjusting these to be consistent with 
aggregate measures of mortality (such as the under-5 mortality rate or probability of death 
between ages 15 and 60), as estimated in local surveys(227). For example, in the Brass logit 
life table system(228), the proportion of individuals who survive to age x (lx) is modelled 




































where Sxl  is the proportion of individuals who survive to age x in the standard life table. In 
this model there are only two parameters that need to be estimated in adjusting the 
standard life table to the local population: α and β (the former determines the adjustment 
to the overall level of mortality, the latter determines the adjustment to the age gradient in 
mortality rates). 
 
In South Africa and other countries facing generalized HIV/AIDS epidemics, the use of these 
simple adjustments to standard life tables has become problematic because of the dramatic 
change in the patterns of mortality (by age and sex) caused by AIDS. One possible solution 
to this problem is to split all-cause mortality into HIV mortality and non-HIV mortality, the 
former being estimated by mathematical models that are fitted to local HIV prevalence 
data, and the latter being estimated through the adjustment of standard life tables (on the 
assumption that AIDS would not substantially change the age pattern of non-HIV mortality). 
This is the process that has been followed in the estimation of mortality rates in the 
ASSA2008 AIDS and Demographic model, published by the Actuarial Society of South Africa 
(ASSA)(204). The procedure followed is to 
a) use estimates of mortality in 1985 (when HIV prevalence in the South African 
population was negligible(229,230)) as the standard in the estimation of non-HIV 
mortality; 
b) use the time-dependent Brass logit life table approach to define non-HIV mortality 
in each subsequent year; 
c) use ASSA2008 estimates of HIV-related mortality in each year (based on calibration 
to South African HIV prevalence data from antenatal clinic surveys and household 
surveys); and 
d) vary the α and β parameters and model HIV parameters until the combined model 
estimates of all-cause mortality (by age and sex) are consistent with the numbers of 
deaths in each year, as recorded in the National Population Register(89), after 
correcting for under-reporting of deaths. 
 
An obvious limitation of this method is that it involves the estimation of non-HIV mortality 
without any direct data on the cause of death. However, it is important to note that 
because of the very distinct change in the pattern of deaths by age and sex, brought about 
by AIDS, the age- and sex-specific death data over time are actually very informative 
regarding the extent of AIDS mortality, even without cause-of-death data. It is also worth 
noting that an independent assessment, based on cause-of-death data, has validated the 




Although the non-AIDS mortality estimates cannot be quantified with pinpoint accuracy, 
they are likely to be roughly of the right order of magnitude. 
 
In the present analysis, we have used the ASSA2008 lite model estimates of non-HIV 
mortality in 2005. Although other years could have been chosen, 2005 was selected 
because it was close to the median date of ART enrolment in the IeDEA-SA 
collaboration(64), and because ART coverage in South Africa in 2005 was still relatively 
low(149) (so that potential bias due to mis-specification of mortality on ART would not have 
been substantial). The ASSA2008 estimates of non-HIV mortality do not change 
substantially by year; for example, annual non-HIV mortality probabilities in 40-year old 
men drop steadily from 0.0079 in 2000 to 0.0074 in 2007, and corresponding probabilities 
in 40-year old women drop from 0.0041 in 2000 to 0.0037 in 2007. Estimates of non-HIV 








This thesis provides novel evidence of a massive, rapid scale-up of ART services in 
South Africa between 2002 and 2013, despite a delayed start due to initial political 
opposition to ART. With each successive year the number of patients enrolled has 
grown and their baseline immunologic status has improved, suggesting increased 
coverage at a population level. Among patients who are initiated and retained on 
ART, mortality after 12 months on ART decreases with each successive year of ART 
initiation and patients have good immunologic and virologic responses to ART.  
 
However ART programs in South Africa have been less successful in ensuring early 
and equitable access to ART and in retaining patients on treatment. Late diagnosis 
and initiation of treatment remain a challenge. LTF poses a threat to effectiveness 
and increases each year of enrollment and with duration on ART. The proportion of 
patients TFO between ART services is increasing, but the risk of death in these 
patients is similar to those retained in care.  
 
This thesis highlights how age and gender, both major determinants of health 
regardless of HIV status, also impact on enrollment and outcomes on ART. 
Increasing proportions of patients over 50 years of age are starting and remaining 
on treatment over time. While mortality increases with age at ART initiation, the 
effect is modified by baseline immunologic status. Men are older and have more 
advanced HIV disease than women at the start of ART. Men have higher mortality 
than women after ART initiation, but this difference is only partially explained by 
HIV disease stage at ART initiation, differential LTF and differences in responses to 




individuals than among people on ART, pointing to the need to understand context-
specific factors which may influence mortality in ART programs.  
 
In light of historical opposition to ART and the restrictive environment within which 
treatment was first rolled out in South Africa, the expansion of services to over two 
million individuals in ten years is remarkable. However, these patients constitute 
less than one-third of the six million HIV-positive individuals who will eventually 
require ART or die without treatment in the next few years(232). These challenges 
are compounded by the growing epidemic of non-communicable diseases 
particularly among older people. In turn the number of people needing care may 
continue to increase if prevention efforts are not successful. This chapter discusses 
the findings of this thesis and concludes with recommendations to increase 
enrollment on ART and to support a successful transition into chronic care for the 
millions of individuals who will require care in the near future. 
 
8.2 Discussion 
Given the results of these analyses, this discussion addresses two broad underlying 
themes which impact on the effectiveness of ART programs, namely what we 
research (and by implication what is overlooked, for instance the effects of gender 
and age on mortality) and how we research these factors and outcomes. In the first 
place, if we do not measure a construct adequately, we cannot address its potential 
impact on ART outcomes. Chapters 3-5 reported on what has been measured 
including the frequency and determinants of key measures of effectiveness such as 
patient enrollment, mortality, LTF and retention. The thesis found strong temporal 
trends in enrollment, baseline characteristics and outcomes related to scale-up, 
discussed in section 8.1.1 below. These chapters also highlighted what had not been 
studied adequately and Chapters 6 and 7 used the lenses of age and gender to 
explore patient outcomes more fully, discussed in section 8.1.2 below. 
 
Secondly, how we undertake research is equally important in interpreting our 




individual patient-level data can result in “tight confidence intervals around a 
spurious estimate”(43). Factors which could impact on the validity of inferences 
from this thesis include missing data, heterogeneity of findings, differential 
measurement and the need for simpler patient monitoring, discussed in section 8.2 
below.  
 
8.2.1    What we found in researching the ART program 
 
8.2.1.1  Temporal trends in baseline characteristics and outcomes 
Chapters 3-7 provide evidence of strong temporal trends in enrollment, baseline 
characteristics and patient outcomes in the South African cohorts of IeDEA-SA. 
Chapter 3 described patient numbers increasing with each successive year of 
enrollment, from 1,462 patients enrolled in 2002/2003 to 15,628 patients enrolled 
in 2007. These findings were extended in Chapter 6, which found that the year-on-
year increase in enrollment persisted through to 2013. Despite such rapid increases 
in enrollment the need for ART continues to grow with each new revision of the 
guidelines for ART initiation. Each lowering of the threshold for ART initiation 
increases the numbers of eligible individuals. 
 
Another temporal theme was the impact of calendar year of ART initiation on 
baseline characteristics. With each successive year of enrollment, the program 
enrolled patients with less advanced HIV disease, evident in the increasing baseline 
CD4+ cell count and decreasing proportion of patients with WHO stage IV disease. 
While the increase in baseline immunologic status suggests some improvement in 
coverage at a population level(21), patients still started ART later than was 
recommended in national guidelines, increasing their mortality risk. In Chapter 4 
nearly 30% of patients started ART with a CD4+ cell count <50 cells/µL between 
2002 and 2007. Such severely immune-compromised patients have extremely high 
early mortality(132). Earlier initiation of treatment, especially among young men, 
could prevent much early mortality and improve patient outcomes on ART. 
Integrating ART into TB as well as maternal and child health services can improve 




chronic conditions such as diabetes mellitus and hypertension can support 
retention in lifelong chronic care(172). 
 
Over five years, the availability of baseline CD4+ cell count decreased from 72% to 
65% of patients enrolling on ART(Chapter 3). In light of the rapid increases in 
enrollment, it is understandable that patients may not have all laboratory tests 
performed at baseline. Even if the tests are done, it is likely that many results are 
not recorded due to administrative overload. This thesis suggests that data 
collection should be limited to the most important variables at particular time 
points. For example, given the role of baseline CD4+ cell counts in determining the 
level of immunologic responses over three years (Chapter 6), efforts should be 
made to collect more complete baseline CD4+ cell counts. However after baseline, 
it may not be necessary to continue to monitor immunologic response. Our findings 
are in line with a recent study among 14,792 adults which found that up to ten 
years on ART, >90% of virologically suppressed patients sustained good 
immunologic responses(234). Follow-up CD4+ cell counts may be adding 
unnecessary clinical and administrative complexity and cost and consideration 
should be given to dropping these tests. 
  
The evidence for strong temporal trends in enrollment, baseline patient 
characteristics and laboratory measures informed the decision to explore whether 
similar trends existed in mortality, LTF and retention. It was encouraging to find in 
Chapter 4 that the rapid pace of scale-up does not increase mortality risk. Indeed as 
the program grows in size, mortality after 12 months on ART declines. This may 
reflect improved coverage as programs enroll patients with less advanced HIV 
disease. In contrast, increasing LTF suggests that rapid scale-up reduces the 
program’s ability to retain and trace patients, a particular concern in light of 
initiatives to offer treatment as prevention (TasP)(235). For TasP to be effective in 
improving health outcomes for people with HIV/AIDS, patients need to complete 




ART and being unable to retain them in care may result in increased resistance and 
transmission of resistant virus, reviving fears about ‘antiretroviral anarchy’(20).   
Given the need to improve retention, successfully re-orienting health systems 
towards chronic care will require a better understanding of the phenomenon of LTF. 
Often viewed as a single construct, LTF in an ART cohort more likely represents a 
range of patient outcomes including patients truly LTF (i.e. lost to care), interrupting 
care(94) and receiving care at other facilities (‘silent transfers’) as well as those 
classified LTF through administrative error or inadequate patient monitoring 
systems(151,236). For example, the apparently sharp increase in observed LTF 
among patients enrolled in more recent years is likely to reflect the cumulative 
burden of increasing patient numbers on both ART services and health informatics 
systems. In addition, risk factors for LTF may differ according to context. For 
instance, LTF may be associated with higher or lower nadir CD4+ cell 
counts(91,237). Understanding what LTF means in a specific context is the first step 
towards finding effective strategies to retain patients in care.  
 
Such strategies should include models to simplify ART delivery as LTF increases with 
patient caseload(175,237). Two recent systematic reviews used GRADE1 
methodology to assess the quality of evidence on decentralization and taskshifting. 
LTF was lower when ART was initiated and continued at the health center 
level(238), although confounding could not be excluded due to the observational 
nature of most of the studies. In terms of taskshifting, nurse-initiated care may  
decrease LTF(239). However conflicting results in the literature suggest the need for 
different models in different settings. For example, one study in South Africa found 
higher LTF in patients down-referred to nurse-managed services(240), particularly 
among males, while another reported far lower LTF among patients down-referred 
than retained at the site of treatment initiation(241). Retention in care may be 
improved by separating ART delivery for stable patients from clinical assessments. 
Other initiatives that have shown promising results include the use of mobile health 
                                                 
1 The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group was set 
up in 2000 to provide a common  approach to grading the quality of evidence and informing the strength of 




electronic technology(242,243), workplace programs to increase access and 
retention among men(244) and the use of courier services for home ART 
delivery(245). Reducing the frequency of clinical and pharmacy visits, ART 
adherence clubs, community ART distribution and patient-led community ART 
groups removed patient barriers to treatment including travel and lost income and 
reduced the burden on the health system(246). For all approaches, costs were also 
lower. Additional evidence that adherence support reduces LTF was reported in an 
ecologic study in ten SSA countries(247).  
 
Harries et al propose ten key interventions to improve retention in care in SSA(172). 
South Africa has made progress on a number of these interventions including 
improving outcome ascertainment, reducing death rates and providing fixed-dose 
combination ART. However other key interventions which could improve retention 
include a simple, standardized system for monitoring and reporting the numbers 
enrolling and key standardized outcomes, ensuring uninterrupted drug supplies (an 
ongoing challenge) as well as full decentralization and integration of ART services 
with other chronic care conditions.  
 
8.2.1.2   Impact of age and gender on ART enrollment and outcomes 
Two of the primary factors that impact on population health are age and gender, 
which strongly determine access to services and health outcomes(248). Easier to 
measure than most other determinants of health, age and gender are routinely 
reported in studies on ART outcomes but their specific impact is little understood in 
the South African setting.  
 
Despite a growing body of evidence that older people and men are disadvantaged 
in access to ART and have poorer outcomes on treatment than younger individuals 
and women, these large groups of the population remain under-researched. 
National programs and international funders continue to prioritize access for 




and planning for ART programs informed the decision to undertake the detailed 
analyses on age and gender in Chapters 6 and 7. 
 
In recent years concerns have been raised about the absence of older patients in 
HIV and ART programs in Africa(107,116,182). This thesis provided novel empirical 
evidence that increasing proportions of patients older than 50 are starting and 
being retained on ART despite the lack of HIV prevention and treatment programs 
targeting older individuals. Chapter 4 reported a 1% increase in the hazard of 
mortality for every additional year at enrollment. More detailed investigation found 
that mortality, mediated by baseline immunologic status, increases with baseline 
age up to two years on ART. Thereafter patients over 50 years old at ART initiation 
have a higher mortality risk than patients 16-29 years at baseline. Health care 
workers need training to diagnose HIV and start ART in older HIV-positive 
individuals. Nationally representative surveys need to extend data collection to 
include older individuals in order to estimate the true HIV prevalence of older 
people and address their future health needs. 
 
The health needs of men have also been neglected in the responses to the 
epidemic. Chapter 3 provided early evidence that men are disadvantaged in access 
to treatment in South Africa despite widespread concerns that the opposite would 
be true. Sixty eight percent of patients were female while HIV prevalence in 2012 
was estimated to be 60% female(196). These findings were in line with those from a 
systematic review of ART access in Southern Africa(123). Further investigation of 
the gender distribution by age in Chapter 6 uncovered a new finding, that females 
dominated enrollment only in the younger age groups. From the age of 50 onwards, 
the gender proportions were almost equal. HIV testing campaigns need to target 
boys and young men urgently. 
 
The investigation of a gender difference in mortality on ART drew attention to the 
fact that many deaths in ART programs are unrelated to HIV and ART. Concerns 




been previously reported without any attempt to acquire new knowledge(205,250). 
This phenomenon was evident in studies of gender and ART in developing 
countries, many documenting the same association repeatedly and concluding that 
men’s elevated risk of mortality is due to their poorer ‘health-seeking behavior’. 
Chapter 7 tried to avoid this circular approach by systematically assessing the 
putative mechanisms which might explain this finding. Finding a far greater gender 
difference in HIV-negative mortality than among patients on ART prompted a 
consideration of the broader context within which ART programs exist. In the 
Western Cape, for example, the leading cause of death for men in 2010 was 
interpersonal violence while HIV/AIDS was the leading cause for women(251). 
Chapter 7 also raises important questions about assumptions that are made about 
men’s health, regardless of evidence, and the need to prioritize men in prevention 
and treatment programs.  
 
Disaggregating data by age and gender provides important new insights into study 
findings. Prioritizing the earlier initiation of ART, particularly among men and older 
individuals, could impact at a population level to improve the health of people living 
with HIV. 
 
8.2.2     How we research ART programs 
Individual patient level meta-analysis has been described as the least biased way of 
addressing questions that remain unanswered by clinical trials(41). In addition it is 
argued that the findings may be more generalizable than results of trials with strict 
eligibility criteria(43). On the other hand, in the absence of randomization, 
observational studies may be more subject to bias than clinical trials. The following 
sections discuss potential sources of bias in our studies.  
 
8.2.2.1   Selection bias 
Selection bias in these ART cohort data can include biases due to ascertainment, 
attrition (LTF) and survivorship. Chapters 6 and 7 addressed possible bias due to 




NPR, see section 8.2.2 below. This thesis used a conservative, standardized 
approach to estimating LTF which increased the comparability of outcomes 
between cohorts and strengthened confidence in the finding of increased LTF with 
each successive year of enrollment. However recent research by Johnson et al(252) 
suggests that much of the apparent increase in LTF in more recent years of ART 
initiation may be due to a bias caused by brief interruptions in care which 
differentially affect patients enrolled in different time periods. Patients who enroll 
in care more recently and subsequently interrupt care have less time to re-engage 
in care than patients enrolled in earlier years, which may result in an overestimation 
of LTF. If LTF is overestimated, retention could be higher than estimates suggest.  
Finally, Chapter 5 addressed the issue of potential survivor bias in mortality after 
TFO/LTF. In this analysis, patients had to survive long enough to be TFO/LTF. This 
may lead to survivor bias in that sicker patients may have died before this point. To 
limit this bias, TFO and LTF were treated as time-varying covariates in the analysis. 
Collaborative analyses of individual-level data must attempt to address and discuss 
potential sources of bias and the implications thereof. 
 
8.2.2.2    Missing data 
One of the most common challenges facing the analysis of routine observational 
data from ART cohorts is the proportion of missing data on key variables and 
outcomes. Incomplete data on important covariates may result in biased or 
incorrect estimates of associations or failure to identify associations which 
exist(253). For instance, Chapters 4-7 highlighted the importance of baseline CD4+ 
cell count in understanding ART outcomes and in measuring improvements in ART 
coverage. In the South African context where ART eligibility depends largely on 
baseline immunologic status, most patients must have undergone testing before 
starting treatment. Despite this, a quarter of baseline CD4+ cell counts were 
missing. If patients with and without recorded baseline measures had different 
outcomes, our findings may be biased. Similarly in Chapter 4 a large proportion of 
data on WHO staging was missing yet the inclusion of staging in multivariable 




outcomes. In another example, studies reporting proportions virally suppressed 
generally restrict the denominator to patients with available viral loads at that time 
point. However patients with viral load measures may differ from patients lacking 
such measures as they have already returned to care to undergo testing(254). They 
may be more adherent than patients who do not return for testing and this may 
artificially inflate estimates of virologic suppression. In the context of a further 
three-fold increase in patient numbers, further deterioration in the collection of 
data is likely(61). With such huge patient loads, it is likely that less complete 
measures are taken at baseline and follow-up visits, and if they are taken, that they 
are recorded.  
 
Missing data on patient outcomes can bias estimates of mortality and retention. 
Mortality ascertainment is a challenge in developed as well as developing countries, 
particularly with high levels of LTF. One of the major contributions of the IeDEA-SA 
collaboration is the development of new methods for ascertaining mortality among 
those LTF. Linkage to the NPR has allowed correction of mortality for LTF. Using this 
method, we found that corrected mortality is about twice the mortality observed by 
sites and that mortality on ART declines over time. Our finding is in line with a 
recent study which found that after two years on ART, mortality in South Africa 
declines to levels below those reported from cohorts from North America, and 
approaches those reported from European cohorts(255).  
 
Surprisingly few studies report the proportion of missing data(200,206), despite its 
importance in interpreting the results of a study(256). Indeed, in Chapter 4 our first 
outcomes analysis did not explicitly report on the proportions of missing baseline 
data as the importance of this issue was not apparent at the time. Subsequent 
analyses in Chapters 6 and 7 attempted to address this concern through transparent 
reporting of missing data and the use of statistical methods such as MI and inverse 





MI is recommended over complete case analysis where data are missing for 
covariates in a regression model(253). It allows the inclusion of observations with 
missing values, increasing the power of the study, and provides more accurate 
results for associations of interest(257). However it is also more complex and time-
consuming and may not always be the appropriate analytic approach, depending on 
the outcome of interest. Decisions on using MI depend on the nature of the missing 
data. If the data are ‘missing completely at random’ (MCAR) the probability of being 
missing is independent of both observed and missing data. In this case, estimates 
from both complete cases and MI will be unbiased and there would be no benefit in 
using MI. However missing data are ‘missing at random’ (MAR) if the probability of 
being missing depends only on observed data(257). In this instance, MI produces 
unbiased results in contrast to complete cases.  The third possibility is ‘missing not 
at random’ (MNAR) where the probability of data being missing depends on the 
missing data itself.  On the assumption that our data were MAR, Chapters 6 and 7 
used MI to avoid potential bias.  
 
Further investigation found that where mortality was the outcome, the data might 
have been MCAR (Supplementary Table S8.1) as estimates were similar between 
complete cases and MI, but with tighter confidence intervals in MI. In this analysis, 
regardless of the fact that there were only 4,670 complete cases out of 83,576 
observations, using complete cases would have been simpler and quicker and 
provided similar results. In contrast, a comparison of methods with LTF as an 
outcome showed fairly large differences in associations: the adjusted effect of being 
male decreased by 50% from aHR 1.76 (95% CI 1.46-2.13) to aHR 1.26 (95% CI 1.22-
1.29), CD4+ cell count ≥500 cells/µL significantly increased the risk of LTF (aHR 1.23, 
95% CI 1.04-1.45) and the effect of calendar year of enrollment was attenuated 
particularly in the most recent years (aHR 11.76 vs. aHR 37.40 for patients enrolled 
in 2011 vs. 2004) (Supplementary Table S8.2). These findings suggest that where LTF 
is the outcome, the data might be MAR and analysis of complete cases may produce 
biased results. It is also possible that the missing data are MNAR but testing this 




different models. Depending on the nature of the analysis, MI may reduce bias and 
provide more valid estimates than complete cases. 
 
An alternative approach to missing data used to address missing outcome data for 
LTF patients is IPW, used in Chapters 6 and 7. Patients who had ID numbers and 
were LTF were linked to the NPR to confirm their vital status. Mortality was then 
corrected with these patients weighted to represent all patients LTF, improving our 
mortality estimates. This form of correction was dependent on whether the cohort 
collected ID numbers and if so, on the completeness of ID numbers. With scale-up, 
the collection of ID numbers has been less complete and the most recent analysis 
only included 50% of patients with IDs, raising questions about whether these 
patients truly represent all LTF patients. If not, these findings are once again subject 
to bias. 
 
The level of attention paid to the missingness of data in these analyses is unusual in 
HIV cohort literature. Future research should report the proportion of missing data 
to allow qualitative assessment of possible bias. In the absence of a well-maintained 
population register, researchers should use appropriate methods to correct 
mortality estimates(96). This would allow more valid comparisons of mortality 
within and between ART services and better planning for services. 
 
8.2.2.3    Heterogeneity in collaborating cohorts 
Heterogeneity between cohorts can influence the external validity of study findings 
from collaborative analyses of observational data, limiting their 
generalizability(41,258,259). A single overall estimate could conceal marked 
differences in estimates from different settings, with programmatic implications. 
For instance, among patients who died after TFO, 9% died within the first three 
months of ART but cohort-specific estimates ranged from 0 to 23%. Similarly among 
deaths in patients during later ART, 36% of patients died within three months of 
TFO, with cohort estimates ranging from 17 to 60%. These instances illustrate how 




mortality after TFO. Collaborative analyses should undertake sensitivity analyses to 
confirm that their main study findings hold across different sites as in Tables 5.2, 
S5.1, S6.5 and Figures 7.2, S5.1 and S5.2. 
 
Chapter 3 described heterogeneity in patient numbers and in characteristics at 
enrollment. The proportion of patients enrolled by cohort ranged from <2% to 39% 
cohorts. There was variability in age and in baseline immunologic status across 
cohorts. As differences in baseline age and immunologic status might explain 
differences in outcomes, later chapters also explored and reported the consistency 
of the main findings within cohorts. 
 
In these Chapters, heterogeneity in outcomes was specific to the outcome under 
analysis. When mortality was the study outcome, there was little variability 
between cohorts. This is an important finding, suggesting that mortality risk does 
not depend on site-level factors. In contrast, when TFO and LTF were the outcomes, 
there was substantial heterogeneity in the characteristics and proportions of 
patients TFO/LTF and in the incidence and timing of mortality after TFO/LTF. 
Although TFO and LTF are reported and compared as if they have a single meaning, 
such variability suggests that they may have different meanings in different 
contexts. As such differences may impact on mortality, there is a need to 
understand the specific meaning of TFO/LTF to inform the development of 
appropriate interventions and policies. 
 
8.2.2.4    Monitoring 
This thesis highlights the need for simple, effective monitoring of the South African 
ART program. At the time of writing, ten years after the program was officially 
launched in South Africa, there is still no national reporting on key program 
indicators. This gap may be partly due to the complexity of existing systems, which 
include over 40 different patient management systems with numerous non-
standard and non-networked systems in the public sector(260). Even within the 




DoH adopted a three-tier monitoring and evaluation (M&E) system for ART, a major 
step towards a more standardized system for the entire program. In place of 144 
different unstandardized indicators, six monthly data elements and 27 quarterly 
indicators are required. Despite the attempt to simplify reporting, four years later 
only the comparatively well-resourced Western Cape, which developed this system, 
has produced regular quarterly cohort reports.  
 
In 2012 the South African National AIDS Council (SANAC) produced a lengthy M&E 
framework based on findings from previous reviews(262). However the complexity 
of this framework raises concerns about perpetuating these problems. SANAC has 
produced a national core set of 34 key indicators with additional indicators to track 
‘strategic enablers’ of the NSP. Further complexity is added with the need to align 
provincial and district level indicators to national outputs and outcomes. Such 
complexity in M&E is unlikely to increase the program’s ability to enroll more 
individuals or to retain them in care. In the context of six million individuals 
requiring treatment and a health system facing multiple challenges, complex 
monitoring may result in poor data collection and meaningless results. Yet reliable 
data are required to inform planning and the provision of adequate services for 
those who need treatment(263).  
 
Notably it is essential to have accurate data on how many patients remain in care, 
in order to plan for their chronic health care services. Although mortality is an 
important metric for monitoring and evaluating program performance, this thesis 
suggests that it may not be the most useful or important measure in the long term. 
ART is effective provided patients are enrolled at an early enough stage of disease 
and are adherent to medication. Retention in care at the site of ART initiation and 
keeping patients in care as they transition between services pose greater challenges 
to sustainability. The ART program should use retention in care as a more 
meaningful and comparable measure of performance than mortality. National 
government should engage with international donors to simplify reporting systems 





In addition to a simplification of existing monitoring systems, this thesis suggests 
the need to separate detailed clinical monitoring from ART delivery services. Where 
more detailed monitoring is required, for example of older patients starting ART 
and long-term toxicity of ART as well as interaction with co-medications, this could 
be done in sentinel sites. IeDEA-SA has adopted an approach which combines the 
collection of a limited number of standardized indicators on large numbers of 
patients with smaller, more intensive studies which require additional data 
collection on specific issues.  
 
8.3 Strengths and limitations 
These analyses were strengthened by large sample sizes, the inclusion of individual 
survival times to estimate key indicators of effectiveness and the use of new 
methods to address various sources of potential bias. In addition, disaggregating 
data on the basis of gender and age provided important new insights into gaps in 
service delivery. 
 
However, the interpretation of these data is subject to a number of cross-cutting 
limitations. These studies are constrained by generalizability. IeDEA-SA does not 
claim that its cohorts are representative of the country’s national ART program and 
no formal sampling has taken place to confirm the generalizability of findings. 
Chapters 3 and 4 assumed that the inclusion of 10% of all public sector patients 
from different settings meant that the findings would be generalizable to patients 
accessing public sector ART in South Africa. However, IeDEA-SA cohorts all have 
strong academic links and it is likely that their data are better and more complete 
than data from ART roll-out sites across the country. Indeed, analyses in Chapters 5-
7 excluded data from the Free State province due to intractable data problems, yet 
this provincial cohort may more accurately represent the situation in roll-out sites 
for which we do not have data. Interpretation of these results should be tempered 
by an understanding of these differences in context. In addition, cohorts differed 




dates of patient enrollment, duration of follow-up, data quality and completeness, 
level of care, provision of services and sources of referrals. Despite these 
differences, findings that were consistent across cohorts are likely generalizable to 
the national ART program while those which were not consistent may require 
additional research within a specific context. Missing data on baseline covariates 
and outcomes was a further constraint which was partially addressed through the 
use of MI. In analyses comparing complete cases and multiply imputed data sets, 
mortality estimates were similar between complete cases and imputed data, but 
with tighter confidence intervals in the latter, while a similar comparison with LTF as 
an outcome showed fairly large differences in associations. 
 
The analyses were also constrained by our inability to distinguish between HIV- and 
non-HIV-related mortality. Including information about whether the deaths were 
HIV-related would have provided more insight into the specific effects of gender 
and age on mortality in ART programs. In addition it was only possible to correct 
mortality estimates in cohorts that collected identification numbers (IDs), and 
within these cohorts the proportion of patients with ID numbers dropped as patient 
numbers increased. However we found little evidence that patients with ID 
numbers differ from patients who lacked these. Finally, despite attempts to 
minimize confounding, residual and unmeasured confounding are ongoing 
challenges in observational studies. The aging analysis in Chapter 5, for instance, 
does not include data on co-morbidities or co-medication which may partly explain 
some of the mortality differential across ages. 
 
8.4 Future research needs 
This thesis suggests three main areas for research to strengthen and expand service 
delivery in the ART program: improving patient tracing, increasing earlier 
enrollment and improving patient retention in care. Arguably the most important 
challenge is to find an innovative, affordable and easy way of tracing patients so 
that we know who is in care and who has been lost. Possible solutions include the 




health care system at any point in the HIV treatment cascade, this information is 
recorded and the program knows the patient is still alive and accessing some form 
of care. Programs could then differentiate between patients who are in care 
elsewhere and those who are truly LTF. Reducing the proportion of patients LTF 
would facilitate active tracing to bring these patients back into care. A range of 
alternative models of care to improve enrollment and retention have been tested 
including decentralization, taskshifting, ART initiation by nurses, integration and 
adherence clubs(238,239). Future operational research should focus on ways of 
implementing and scaling up models that improve enrollment and retention(265).  
 
Other future research should include a properly sampled, representative study to 
assess the generalizability of these findings across the national ART program. Such a 
study would entail random proportional sampling of the South African cohorts in 
the IeDEA-SA database stratified on the basis of gender, age, calendar year of 
enrollment and cohort of ART initiation, factors which influence outcomes on 
ART(266). IeDEA-SA should also undertake a study to try to quantify the proportion 
of mortality on ART that is HIV-related. Such a study could benefit from the use of 
verbal autopsies, for instance, which identified HIV/AIDS-related deaths in five 
African countries with a specificity of 90% (95% CI 89-91%)(267). Further work is 
needed to understand and address the obstacles boys and men face in accessing 
ART and to increase enrollment by older individuals.  
The IeDEA-SA collaboration is well-placed to address some of these future research 
needs. The collaboration collects a limited, standardized set of indicators on a large 
number of patients starting ART nationally. In this capacity, IeDEA-SA can continue 
to provide data on key indicators to reflect the national program and to highlight 
areas which require context-specific analyses. IeDEA-SA also undertakes surveys 
and sub-studies to collect additional data for in-depth analysis. Historically such 
surveys have included, for example, the incidence and management of Kaposi’s 
sarcoma in different cohorts. Such surveys may identify questions for further 
investigation elsewhere. Separately funded sub-studies have included, for instance, 




mooted the idea of sentinel surveillance sites, an idea which was gaining currency in 
HIV cohort analysis at the time. While sentinel surveillance could provide a level of 
detail way beyond the scope of IeDEA-SA, such findings may not be generalizable to 
a routine setting.  
 
8.5 Conclusion 
This thesis suggests that the major challenges to the success of the South Africa ART 
program are not related to clinical management of patients or patient adherence to 
treatment. Instead, the major challenges relate to the health system and the way in 
which the ART program is implemented. ART services were initially provided as a 
desperate humanitarian effort which then grew with the increasing demand. At the 
same time, there was close monitoring to ensure that outcomes were comparable 
with developed countries. Although South Africa has subsequently adopted a 
public-health approach to delivering ART, it seems that we still aspire to aspects of 
the individualized approach to ART. Had the country today faced starting six million 
people in a new public health care initiative, implementation might have been very 
different. After ten years of ART, it is time to use what we know about the program 
to plan for the next period of time.  
 
In terms of what is implemented, interventions addressing the existing blindspots 
about gender and age could prevent further new infections, increase equitable 
enrollment and improve outcomes on ART. Health services require a major re-
orientation towards the health of boys and men and individuals over 50 years of 
age. Engaging with health services increases the probability of being offered HIV 
testing and treatment and may be protective against other risk factors for mortality. 
Such campaigns should link to wellness services given the dearth of primary care 
services for boys and men.  
 
Additional interventions are also required in terms of how the ART program is 
implemented and measured. A national campaign is needed to encourage earlier 




term outcomes on treatment. Integrating point-of-care CD4+ cell count testing and 
initiating ART in as many different health care facilities as possible would increase 
enrollment. A range of alternative models of care need to be tried and evaluated 
quickly and the program needs the flexibility to adopt and scale-up innovative and 
effective models for enrolling and retaining more individuals in care. 
 
Simpler, more efficient monitoring systems are needed to enable increased 
enrolment and improved retention. The program should differentiate between 
clinical monitoring, reporting to funders and monitoring to inform planning of 
services. Clinical monitoring could be made more efficient by ensuring better 
collection of baseline CD4+ cell counts and dropping follow-up measures. Program 
monitoring should be limited to four key outcomes: dead, transfers, LTF and alive, 
which should also form the basis of simpler reporting to funders. A single 
standardized measure of LTF should be used to enable comparison within and 
across programs. Finally, the program urgently needs to find a simple, inexpensive 
way of uniquely identifying patients across all health services to differentiate 
between patients who are alive and in some form of care and patients who are truly 
lost to care and require tracing. Planning for the existing program is inefficient in 
the absence of such vital information. Expanding the program three-fold may be 
catastrophic unless solutions are found.  
 
In conclusion, this thesis set out to provide a picture of ART scale-up in South Africa. 
It finds that the ART program is a remarkable example of what can be achieved with 
high levels of commitment. Over the past ten years South Africa has improved and 
extended the lives of millions of individuals who would have died without 
treatment. Addressing the gaps identified in this thesis would strengthen the 
program and help to ensure that these benefits are extended to those individuals 















16-29 1 1 1
30-34 1.11 (1.03-1.21) 1.10 (0.82-1.47) 1.08 (0.99-1.17) 1.05 (0.97-1.15)
35-39 1.21 (1.11-1.31) 1.28 (0.96-1.71) 1.17 (1.07-1.27) 1.12 (1.03-1.23)
40-44 1.29 (1.17-1.41) 1.25 (0.90-1.72) 1.25 (1.14-1.38) 1.21 (1.10-1.34)
45-49 1.47 (1.33-1.63) 1.44 (1.01-2.06) 1.48 (1.33-1.64) 1.41 (1.26-1.58)
50-54 1.68 (1.49-1.90) 1.78 (1.21-2.64) 1.71 (1.51-1.94) 1.62 (1.42-1.85)
55-59 1.76 (1.50-2.08) 1.45 (0.79-2.65) 1.77 (1.50-2.09) 1.65 (1.38-1.97)
60-64 2.52 (2.01-3.14) 2.62 (1.22-5.67) 2.57 (2.04-3.24) 2.28 (1.78-2.93)
65+ 3.03 (2.34-3.94) 2.62 (1.21-5.69) 3.11 (2.39-4.05) 2.53 (1.90-3.38)
Male gender 1.62 (1.53-1.71) 1.38 (1.13-1.68) 1.63 (1.54-1.73) 1.43 (1.35-1.53)
CD4+ cell count (cells/µL)
<50 1 1 1 1
50-99 0.61 (0.57-0.66) 0.56 (0.43-0.72) 0.64 (0.60-0.71) 0.71 (0.65-0.78)
100-199 0.39 (0.37-0.42) 0.47 (0.37-0.59) 0.41 (0.38-0.44) 0.54 (0.80-0.59)
200-349 0.23 (0.20-0.26) 0.32 (0.22-0.45) 0.24 (0.21-0.27) 0.38 (0.33-0.43)
350-499 0.36 (0.26-0.48) 0.06 (0.01-0.42) 0.33 (0.25-0.44) 0.47 (0.35-0.63)
≥500 0.24 (0.14-0.40) 0.11 (0.02-0.82) 0.22 (0.13-0.36) 0.33 (0.20-0.56)
WHO stage
I & II 1 1 1 1
III 2.62 (2.35-2.93) 1.74 (1.34-2.26) 2.28 (2.04-2.54) 1.62 (1.44-1.82)
IV 3.25 (2.87-3.67) 2.80 (1.99-3.95) 3.39 (3.00-3.83) 2.26 (1.94-2.62)
Anemia
none 1 1 1
mild 1.53 (1.38-1.71) 1.27 (0.94-1.74) 1.76 (1.64-1.89) 1.37 (1.23-1.53)
moderate 2.69 (2.42-2.99) 1.67 (1.22-2.29) 3.10 (2.87-3.35) 1.99 (1.80-2.20)
severe 4.52 (3.98-5.12) 2.81 (1.97-4.02) 4.72 (4.00-5.56) 2.89 (2.49-3.35)
TB at enrolment 1.58 (1.46-1.71) 0.82 (0.66-1.01) 1.53 (1.40-1.65) 0.82 (0.75-0.90)
Weight (kg) 0.96 (0.96-0.97) 0.98 (0.97-0.99) 0.96 (0.96-0.96) 0.98 (0.97-0.98)





Supplementary Table S8.2.  Crude and adjusted loss to follow-up in complete cases* and 
after multiple imputation.  
 
Crude HR aHR without MI
(n=4,670)
Crude HR Adjusted HR
(n=83,576)
Age groups (years)
16-29 1 1 1 1
30-34 0.85 (0.82-0.88) 0.69 (0.54-0.87) 0.87 (0.84-0.90) 0.81 (0.78-0.84)
35-39 0.82 (0.79-0.85) 0.64 (0.50-0.82) 0.87 (0.84-0.90) 0.76 (0.73-0.79)
40-44 0.80 (0.76-0.84) 0.39 (0.28-0.55) 0.84 (0.80-0.87) 0.73 (0.70-0.77)
45-49 0.76 (0.72-0.80) 0.41 (0.28-0.60) 0.81 (0.76-0.85) 0.69 (0.66-0.74)
50-54 0.75 (0.69-0.80) 0.40 (0.25-0.64) 0.80 (0.74-0.85) 0.66 (0.62-0.72)
55-59 0.86 (0.78-0.95) 0.42 (0.23-0.78) 0.93 (0.85-1.01) 0.74 (0.67-0.82)
60-64 1.06 (0.92-1.23) 0.69 (0.28-1.67) 1.17 (1.02-1.33) 0.90 (0.78-1.04)
65+ 0.90 (0.73-1.11) 0.49 (0.18-1.31) 0.93 (0.76-1.13) 0.82 (0.67-1.02)
Male gender 1.23 (1.20-1.27) 1.76 (1.46-2.13) 1.25 (1.21-1.28) 1.26 (1.22-1.29)
CD4+ cell count, median 
(cells/µL)
<50 1 1 1
50-99 0.95 (0.91-0.99) 0.66 (0.48-0.89) 0.94 (0.90-0.98) 1.01 (0.96-1.05)
100-199 0.92 (0.88-0.95) 1.01 (0.79-1.29) 0.93 (0.89-0.96) 1.02 (0.98-1.06)
200-349 1.06 (1.01-1.11) 1.04 (0.78-1.39) 0.98 (0.94-1.03) 1.01 (0.95-1.06)
350-499 1.10 (0.97-1.25) 1.01 (0.57-1.78) 1.01 (0.90-1.14) 1.15 (1.00-1.31)
≥500 1.12 (0.94-1.32) 0.93 (0.40-2.14) 1.03 (0.88-1.20) 1.23 (1.04-1.45)
WHO stage
I & II 1 1
III 0.92 (0.88-0.96) 0.93 (0.74-1.16) 0.97 (0.94-1.00) 1.00 (0.96-1.04)
IV 0.92 (0.88-0.97) 1.31 (0.92-1.87) 0.95 (0.91-1.00) 0.96 (0.90-1.01)
Anemia
none 1 1 1
mild 1.05 (1.00-1.09) 1.20 (0.94-1.52) 1.08 (1.04-1.12) 1.09 (1.05-1.14)
moderate 1.19 (1.13-1.25) 1.23 (0.95-1.59) 1.20 (1.15-1.26) 1.20 (1.15-1.27)
severe 1.36 (1.27-1.46) 1.47 (1.04-2.07) 1.27 (1.19-1.35) 1.34 (1.26-1.43)
TB at ART start 1.12 (1.07-1.18) 1.21 (0.97-1.51) 1.06 (1.01-1.11) 1.10 (1.04-1.16)
Cohort
Gugulethu 1 1 1 1
Hlabisa 0.25 (0.23-0.26) omitted 0.26 (0.24-0.27) 0.14 (0.14-0.15)
Khayelitsha 0.32 (0.31-0.34) omitted 0.33 (0.32-0.35) 0.19 (0.19-0.20)
McCord 0.60 (0.57-0.63) omitted 1.45 (1.39-1.51) 0.71 (0.67-0.75)
Themba Lethu 0.49 (0.47-0.51) omitted 0.50 (0.48-0.52) 0.37 (0.35-0.39)
Tygerberg 0.25 (0.23-0.27) omitted 0.25 (0.23-0.27) 0.17 (0.16-0.19)
Year
2004 1 1 1
2005 1.40 (1.31-1.49) 1.22 (0.15-9.89) 1.38 (1.30-1.47) 1.61 (1.50-1.72)
2006 1.84 (1.73-1.96) 3.33 (0.38-29.00) 1.80 (1.69-1.91) 2.45 (2.29-2.62)
2007 2.18 (2.04-2.33) 4.90 (0.57-42.50) 2.27 (2.13-2.42) 3.23 (3.01-3.47)
2008 2.35 (2.19-2.52) 11.58 (1.34-100.12) 2.58 (2.41-2.75) 4.06 (3.78-4.37)
2009 3.18 (2.96-3.40) 16.82 (1.94-145.70) 3.68 (3.45-3.93) 5.76 (5.34-6.20)
2010 4.02 (3.75-4.32) 24.59 (2.82-214.31) 4.43 (4.15-4.73) 8.29 (7.68-8.95)
2011 4.73 (4.39-5.09) 37.40 (4.28-326.51) 4.57 (4.26-4.91) 11.76 (10.84-12.77)
2012 & 2013 6.24 (5.75-6.78) 71.98 (8.01-647.09) 6.30 (5.81-6.92) 16.98 (15.49-18.62)
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Appendix A   
IeDEA-SA publication process 






























LA circulates final paper to WG 
 Authorship copyright forms, affiliations etc 
 LA submits to target journal 
LA revises & circulates mature draft paper to WG & SG 
 With abstract, discussion & references 
 Co-authors approve final paper, affiliations, authorship etc 
 2 weeks for comments 
 
Lead author (LA) proposes concept to Data Centres (DCs) 
 see concept sheet template 
 1 week for comments 
Project Managers (PMs) circulate concept to Steering Group (SG)  
 2 weeks for comments, decision on participation 
 
LA circulates paper outline to writing group (WG) 
 With tables, figures, main message, target journals  
 2 weeks for comments 
On acceptance: 
 PMs circulate published version to SG 
 LA checks journal submission method (NIH compliance) 
o 3 months to comply 
 LA/PM submit slide to INCC/NIH 
Journal accepts/invites revision/rejects 
 LA and WG respond to comments and resubmit OR 
 LA resubmits to alternate journal 
o PM to be updated re status & journal 
LA revise & circulates early draft paper to WG 
 With abstract, discussion & references 






A2.  Conference abstracts: 
Ideally conference abstracts will be based on concepts that have gone through the 







If the abstract is not based on an approved concept sheet, the following simpler 





















LA circulates abstract to concept writing group 
 2 days for comments 
PM circulates submitted version to participating sites & 
Project Managers 
After the conference: 
 if LA plans to develop into a paper, the full process 
outlined above must then be followed 
Project Managers circulate abstract to Steering Group 
 5 days for comments, decision on inclusion of data 
LA submits abstract  
LA circulates submitted version to participating sites & 
Project Managers 
Lead author (LA) submits abstract to Data Centres (DCs) 





A3. Fast-tracking requests: 
In the event of a request for data that may be used to inform assumptions in 
models, or for summary information for the purpose of reports on the state of the 
epidemic etc, a fast-track process may be followed. The following criteria apply: 
 The request is for aggregated information, not individual-level data. 
 The requested information can be supplied easily by a member of the data 
centre and does not require substantial time spent on data cleaning or 
substantial new analytical work. 
 The IeDEA data are not the primary focus of the study, i.e. the proposed 
study could be published even without the IeDEA data (the IeDEA data are a 
‘nice to have’ rather than a necessity). 
 
If these criteria are met we will ask for the following: 
 The title of the project 
 The names of the investigators involved in the project and their affiliations 
 A very brief description of the aims of the project and the motivation for the 
project (1 paragraph) 
 A description of the summary data that are requested  
 An explanation of how these data will be used in the project 
 Expected outputs (journal publication/policy document/report) 
 
This will first be sent to the data centres, who will judge whether the fast track 
criteria have been met before circulating to the steering group, who will be given 
one week in which to raise any concerns. If the members of the data centre feel 
that the fast track criteria are not met, they will recommend that the applicants 
rather go through the full concept sheet process. 
 
We will ask that IeDEA-SA is acknowledged for any information provided through 
this fast track process. While we will not require that IeDEA-SA members be 
included as co-authors, co-authorship can be explored where this is appropriate. 

















The evolution of IeDEA-SA and the selection of 
cohorts for inclusion in analyses 
 
The inclusion of cohorts in the analyses in this dissertation reflects the evolution of 
the IeDEA-SA collaboration over the past few years. With the intention of being as 
inclusive as possible, new cohorts were included as they joined. However each 
analysis had different data requirements and raised different challenges. As a result, 
it was not possible to work with the same cohorts for all the analyses.  
 
At the start of this thesis, there were eleven South African cohorts participating in 
IeDEA-SA: eight sites offering services to adults exclusively or to adults and children 
combined and three pediatric sites. The adult cohorts were: Gugulethu, 
Masiphumelele, Khayelitsha, McCord, Themba Lethu, Tygerberg, Perinatal HIV 
Research (PHRU) and the Free State Province. The pediatric cohorts were: Harriet 
Shezi, Red Cross and Rahima Moosa. Chapters 3 and 4 were based on data from all 
adult sites. Data from the pediatric sites were included in Chapter 3 as the children 
in these cohorts had not yet been characterized. Since then there has been 
extensive research published on the pediatric patients, which is outside the scope 
of the thesis.  
 
Community-based and rural cohorts from Aurum and Hlabisa subsequently joined 
the IeDEA-SA collaboration and their data were included in the gender analysis 
(Chapter 7), from which the Free State province and PHRU were excluded due to 
data problems. The aging analysis in Chapter 6 included the same patients except 
for the Aurum cohort, which was excluded as outcomes were poorly recorded. 
Chapter 5 aimed to ascertain mortality after TFO/LTF and thus only included cohorts 
which collect South African civil identification numbers (Hlabisa, Themba Lethu, 
Khayelitsha and McCord).  
  
